Equity · KR / JP Market · Single-Stock Deep Dive · InsurersEquity · KR / JP Market · Single-Stock Deep Dive · Insurers株式 · 韓国/日本市場 · 個別銘柄の深掘り · 保険

손보 3사 + 도쿄해상 — 배당은 국채를 이기는가, 매출·이익은 자라는가, 돈은 어디에 묶여 있는가Three Korean P&C insurers + Tokio Marine — do dividends beat government bonds, are revenue and profit growing, and where is the money tied up?韓国損保3社 + Tokio Marine — 配当は国債に勝つか、売上・利益は伸びているか、資金はどこに縛られているか

삼성화재·현대해상·DB손해보험의 DART 정기보고서(2019Q1~, 원문 표·주석 포함)와 도쿄해상홀딩스의 EDINET 有価証券報告書·四半期·半期報告書(FY2018~FY2025, 재무제표와 주석)를 Raw Data 로 삼아 배당·이익수익률을 KTB/JGB/UST 10Y 옆에 놓고, 보험료·보험수익·순이익의 성장, 지분 구조(최대주주·상호보유·Berkshire), 유가증권·운용자산 포트폴리오, 정책보유주식이 이익으로 바뀌는 경로, 지급여력·솔벤시·ESR 을 같은 틀로 편다. 숫자 표가 '-' 인 자리는 원문 문장을 그대로 옮겼다.Using as Raw Data the DART periodic reports of Samsung F&M, Hyundai M&F and DB Insurance (from 2019Q1, including original tables and notes) and Tokio Marine's EDINET annual, quarterly and half-year securities reports (FY2018–FY2025, financial statements and notes), this page sets dividend and earnings yields next to the KTB/JGB/UST 10Y and lays out, in one frame, the growth of premiums, insurance revenue and net income; ownership (largest shareholders, cross-shareholdings, Berkshire); securities and invested-asset portfolios; the path by which policy shareholdings turn into profit; and solvency (K-ICS, solvency margin, ESR). Where a numeric table shows '-', the original sentence is quoted as is.Samsung F&M・Hyundai M&F・DB InsuranceのDART定期報告書(2019Q1〜、原文の表・注記を含む)とTokio MarineのEDINET有価証券報告書・四半期報告書・半期報告書(FY2018〜FY2025、財務諸表と注記)をRaw Dataとし、配当利回り・益回りをKTB/JGB/UST 10年と並べ、保険料・保険収益・純利益の成長、株主構成(筆頭株主・相互保有・Berkshire)、有価証券・運用資産ポートフォリオ、政策保有株式が利益に変わる経路、支払余力・ソルベンシー・ESRを同じ枠組みで示す。数値の表が「-」の箇所は原文をそのまま引いた。

기준일 2026-08-14As of 2026-08-14基準日 2026-08-14DART 정기보고서(원문·재무제표·주요정보)DART periodic reports (original text, financial statements, key information)DART定期報告書(原文・財務諸表・主要情報)EDINET 有報·半期 ·注記 (PDL1.0)EDINET annual & half-year reports · notes (PDL1.0)EDINET 有報・半期報告書・注記(PDL1.0)IFRS 4→17 (KR 2023) · J-GAAP→IFRS (TM FY2025)IFRS 4→17 (KR 2023) · J-GAAP→IFRS (TM FY2025)IFRS 4→17(韓国 2023)· 日本基準→IFRS(TM FY2025)
먼저 보는 세 줄 · 2026-08-14Three lines first · 2026-08-14まず見る三行 · 2026-08-14
  1. 배당 vs 국채 삼성화재 FY2025 3.9% vs KTB 3.38% · 현대해상 FY2023 5.8% vs KTB 3.18% · DB손보 FY2025 5.4% vs KTB 3.38% — 현대해상은 FY2024·FY2025 결산배당 미실시(원문: 법정적립금으로 배당가능이익 소진).Dividends vs. government bonds Samsung F&M FY2025 3.9% vs KTB 3.38% · Hyundai M&F FY2023 5.8% vs KTB 3.18% · DB Insurance FY2025 5.4% vs KTB 3.38% — Hyundai M&F skipped the year-end dividend for FY2024·FY2025 (company's wording: distributable profit exhausted by statutory reserves).配当 vs 国債 Samsung F&M FY2025 3.9% vs KTB 3.38% · Hyundai M&F FY2023 5.8% vs KTB 3.18% · DB Insurance FY2025 5.4% vs KTB 3.38% — Hyundai M&FはFY2024·FY2025の期末配当を見送った(原文:法定積立金で配当可能利益が消失)。
  2. 도쿄해상: FY2025 배당수익률 2.98% vs JGB10Y 2.37% · UST10Y 4.30%.Tokio Marine: FY2025 dividend yield 2.98% vs JGB10Y 2.37% · UST10Y 4.30%.Tokio Marine:FY2025 配当利回り2.98% vs JGB10Y 2.37% · UST10Y 4.30%。
  3. 자본 K-ICS 삼성화재 282.8% · 현대해상 209.0% · DB손보 204.4% · 도쿄해상 ESR 268% (99.5% VaR 새 정의 · 목표 ≥190%) — 체계가 달라 수준을 나란히 비교하지 않는다.Capital K-ICS Samsung F&M 282.8% · Hyundai M&F 209.0% · DB Insurance 204.4% · Tokio Marine ESR 268% (99.5% VaR, new definition · target ≥190%) — different regimes, so the levels are not compared side by side.資本 K-ICS Samsung F&M 282.8% · Hyundai M&F 209.0% · DB Insurance 204.4% · Tokio Marine ESR 268%(99.5% VaR・新定義 · 目標≥190%) — 制度が異なるため水準を並べて比較しない。
삼성화재 DY FY2025Samsung F&M DY FY2025Samsung F&M DY FY2025
3.9%
KTB10Y 3.38% · EY 9.5%
현대해상 DY FY2023Hyundai M&F DY FY2023Hyundai M&F DY FY2023
5.8%
KTB10Y 3.18% · EY 20.2%
DB손보 DY FY2025DB Insurance DY FY2025DB Insurance DY FY2025
5.4%
KTB10Y 3.38% · EY 21.0%
삼성화재 ROE FY2025Samsung F&M ROE FY2025Samsung F&M ROE FY2025
11%
순이익 2.02조 · 보험손익 마진 8.0%Net income KRW 2.02trn · insurance margin 8.0%純利益2.02兆ウォン · 保険損益マージン8.0%
현대해상 ROE FY2025Hyundai M&F ROE FY2025Hyundai M&F ROE FY2025
21%
순이익 1.02조 · 보험손익 마진 5.7%Net income KRW 1.02trn · insurance margin 5.7%純利益1.02兆ウォン · 保険損益マージン5.7%
DB손보 ROE FY2025DB Insurance ROE FY2025DB Insurance ROE FY2025
18%
순이익 1.79조 · 보험손익 마진 7.0%Net income KRW 1.79trn · insurance margin 7.0%純利益1.79兆ウォン · 保険損益マージン7.0%
K-ICS latestK-ICS latestK-ICS 最新
283/209/204%
Samsung / Hyundai / DB
도쿄해상 DY FY2025Tokio Marine DY FY2025Tokio Marine DY FY2025
2.98%
JGB10Y 2.37% · UST10Y 4.30%
도쿄해상 EY FY2025Tokio Marine EY FY2025Tokio Marine EY FY2025
7.1/3.8%
일본기준 / IFRS — 정책주식 매각익 차이J-GAAP / IFRS — the gap is gains on selling policy stocks日本基準 / IFRS — 差は政策株式の売却益
정책보유(상장) FY2025Policy holdings (listed) FY2025政策保有株式(上場)FY2025
1.92조엔JPY trn兆円
2029년도 말 0 목표 · 상호보유 50종목target: zero by end-FY2029 · 50 cross-held names2029年度末にゼロ目標 · 相互保有50銘柄
ESR 2026-03
268%
99.5% VaR 새 정의 · 목표 ≥190%99.5% VaR, new definition · target ≥190%99.5% VaR・新定義 · 目標≥190%
회계연도(FY)는 회사 결산 기준 — 한국 3사는 12월, 도쿄해상은 3월(FY2025 = 2025-04~2026-03). 같은 기간이 여러 보고서에 실리면 최신 제출분을 쓰고 최초 값은 Raw Data 에 남긴다. 주가는 시세 Raw Data 가 아니다: 한국 = 회사 기재 배당수익률과 DPS 로 역산(배당 없는 해는 없음), 도쿄해상 = 有報의 EPS×PER 역산(3월말). 금액은 원·엔이 섞이므로 회사 간 비교는 비율로만 한다.Fiscal years (FY) follow each company's year-end — December for the three Korean insurers, March for Tokio Marine (FY2025 = 2025-04 to 2026-03). When the same period appears in several reports, the most recent filing is used and the first-reported value is kept in the Raw Data. Share prices are not market-price Raw Data: Korea = backed out from the company-reported dividend yield and DPS (none for years without a dividend); Tokio Marine = backed out from EPS × PER in the annual securities report (March-end). Amounts mix won and yen, so companies are compared only through ratios.会計年度(FY)は各社の決算期 — 韓国3社は12月、Tokio Marineは3月(FY2025 = 2025年4月〜2026年3月)。同じ期間が複数の報告書に載る場合は最新の提出分を使い、当初の値はRaw Dataに残す。株価は株価のRaw Dataではない:韓国 = 会社開示の配当利回りとDPSから逆算(配当のない年はなし)、Tokio Marine = 有報のEPS×PERから逆算(3月末)。金額はウォンと円が混在するため、会社間の比較は比率でのみ行う。
00

한 줄In one line一行で

관측: 삼성화재 FY2025 배당수익률 3.9% vs KTB10Y 3.38% (이익수익률 9.5%) · 현대해상 FY2023 배당수익률 5.8% vs KTB10Y 3.18% (이익수익률 20.2%) · DB손보 FY2025 배당수익률 5.4% vs KTB10Y 3.38% (이익수익률 21.0%). 현대해상은 FY2024·25 배당 미실시(원문: 법정적립금 증가로 배당가능이익 소진). 지급여력(K-ICS) 삼성화재 282.8% · 현대해상 209.0% · DB손보 204.4%. 도쿄해상: FY2025 배당수익률 2.98% vs JGB10Y 2.37% · UST10Y 4.30%. 이익수익률은 일본기준 7.1% / IFRS 3.8% — 차이는 정책주식 매각익(FY2025 처분이익 0.66조엔)이 IFRS 에선 손익을 건너뛰기 때문. 상장 정책보유 1.92조엔 → 2029년도 말 0 목표, 상호보유 101→50종목. Berkshire(NICO) 2.5% 배정.
Observation: Samsung F&M FY2025 dividend yield 3.9% vs KTB10Y 3.38% (earnings yield 9.5%) · Hyundai M&F FY2023 dividend yield 5.8% vs KTB10Y 3.18% (earnings yield 20.2%) · DB Insurance FY2025 dividend yield 5.4% vs KTB10Y 3.38% (earnings yield 21.0%). Hyundai M&F paid no dividend for FY2024·25 (company's wording: distributable profit exhausted by the increase in statutory reserves). Solvency ratio (K-ICS) Samsung F&M 282.8% · Hyundai M&F 209.0% · DB Insurance 204.4%. Tokio Marine: FY2025 dividend yield 2.98% vs JGB10Y 2.37% · UST10Y 4.30%. Earnings yield J-GAAP 7.1% / IFRS 3.8% — the gap is because gains on selling policy stocks (FY2025 disposal gain JPY 0.66trn) bypass profit and loss under IFRS. Listed policy holdings JPY 1.92trn → target zero by end-FY2029; cross-holdings 101 → 50 names. 2.5% allotted to Berkshire (NICO).
観測:Samsung F&M FY2025 配当利回り3.9% vs KTB10Y 3.38%(益回り9.5%) · Hyundai M&F FY2023 配当利回り5.8% vs KTB10Y 3.18%(益回り20.2%) · DB Insurance FY2025 配当利回り5.4% vs KTB10Y 3.38%(益回り21.0%)。Hyundai M&FはFY2024・25が無配(原文:法定積立金の増加で配当可能利益が消失)。支払余力比率(K-ICS)Samsung F&M 282.8% · Hyundai M&F 209.0% · DB Insurance 204.4%。Tokio Marine:FY2025 配当利回り2.98% vs JGB10Y 2.37% · UST10Y 4.30%。益回りは日本基準7.1% / IFRS 3.8% — 差は政策株式の売却益(FY2025の処分益0.66兆円)がIFRSでは損益を通らないため。上場の政策保有1.92兆円 → 2029年度末にゼロ目標、相互保有101→50銘柄。Berkshire(NICO)に2.5%を割当。
01

한 표 — 배당·이익수익률을 국채 10Y 옆에One table — dividend and earnings yields next to the 10Y government bond一覧表 — 配当利回り・益回りを10年国債と並べる

한 표One table一覧表Three insurers: dividend yield and earnings yield next to KTB/UST 10Y (company fiscal year-end)Three insurers: dividend yield and earnings yield next to KTB/UST 10Y (company fiscal year-end)3社:配当利回りと益回りをKTB/UST 10年と並べる(各社の決算期末)

회사FYDPS(원)배당수익률KTB10Y(연말)UST10Y배당−KTBEPS(연결)이익수익률*이익수익률−KTB배당성향순이익K-ICS
삼성화재FY202519,5003.9%3.38%4.18%+0.52%p47,4789.5%+6.11%p41.1%2.02조262.9%
현대해상FY20232,0635.8%3.18%3.88%+2.62%p7,18520.2%+17.02%p28.2%0.57조173.2%
DB손보FY20257,6005.4%3.38%4.18%+2.02%p29,59721.0%+17.64%p25.7%1.79조217.8%
CompanyFYDPS (KRW)Dividend yieldKTB10Y (year-end)UST10YDY − KTBEPS (consol.)Earnings yield*EY − KTBPayout ratioNet incomeK-ICS
Samsung F&MFY202519,5003.9%3.38%4.18%+0.52pp47,4789.5%+6.11pp41.1%KRW 2.02trn262.9%
Hyundai M&FFY20232,0635.8%3.18%3.88%+2.62pp7,18520.2%+17.02pp28.2%KRW 0.57trn173.2%
DB InsuranceFY20257,6005.4%3.38%4.18%+2.02pp29,59721.0%+17.64pp25.7%KRW 1.79trn217.8%
会社FYDPS(ウォン)配当利回りKTB10Y(年末)UST10Y配当−KTBEPS(連結)益回り*益回り−KTB配当性向純利益K-ICS
Samsung F&MFY202519,5003.9%3.38%4.18%+0.52pt47,4789.5%+6.11pt41.1%2.02兆ウォン262.9%
Hyundai M&FFY20232,0635.8%3.18%3.88%+2.62pt7,18520.2%+17.02pt28.2%0.57兆ウォン173.2%
DB InsuranceFY20257,6005.4%3.38%4.18%+2.02pt29,59721.0%+17.64pt25.7%1.79兆ウォン217.8%

배당수익률은 DART '배당에 관한 사항'의 회사 기재값(배당기준일 전 1주일 평균 종가 기준), 이익수익률*은 그 수익률과 DPS 로 역산한 주가에 연결 EPS 를 나눈 값(시세 Raw Data 없이 같은 날짜 기준). 국채는 레포의 3국 커브 Raw Data(ECOS·FRED) 연말값. 현대해상 원문(FY2025 사업보고서): “배당가능이익이 소진됨에 따라 배당이 불가한 상황입니다.”

Dividend yield is the company-reported value in DART's 'matters concerning dividends' (based on the average close over the week before the record date); earnings yield* is consolidated EPS divided by the price backed out from that yield and the DPS (same date, without market-price Raw Data). Government bond yields are year-end values from the site's three-country yield-curve Raw Data (ECOS · FRED). Hyundai M&F original text (FY2025 annual report): “배당가능이익이 소진됨에 따라 배당이 불가한 상황입니다.”

配当利回りはDART「配当に関する事項」の会社開示値(配当基準日前1週間の平均終値ベース)、益回り*はその利回りとDPSから逆算した株価で連結EPSを割った値(株価のRaw Dataを使わず同じ日付ベース)。国債は当サイトの3カ国イールドカーブのRaw Data(ECOS・FRED)の年末値。 Hyundai M&Fの原文(FY2025事業報告書): “배당가능이익이 소진됨에 따라 배당이 불가한 상황입니다.”

⚠ 규율: 현대해상은 FY2024·FY2025 결산배당을 하지 않았다 — 표의 '미실시'. 이유는 회사 문장 그대로(법정적립금 증가로 배당가능이익 소진). FY2025 순이익 1.02조·ROE 20.6% 라도 배당은 0 — 숫자만 보면 놓친다.

⚠ Discipline: Hyundai M&F paid no year-end dividend for FY2024·FY2025 — 'not paid' in the table. The reason is the company's own wording (distributable profit exhausted by the increase in statutory reserves). Even with FY2025 net income of KRW 1.02trn and ROE of 20.6%, the dividend is zero — easy to miss from the numbers alone.

⚠ 規律:Hyundai M&FはFY2024·FY2025の期末配当を実施しなかった — 表の「無配」。理由は会社の文言どおり(法定積立金の増加で配当可能利益が消失)。FY2025の純利益1.02兆ウォン・ROE 20.6%でも配当は0 — 数字だけ見ると見落とす。

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 배당수익률은 회사 기재값(기준가 = 배당기준일 전 1주일 평균 종가) · 이익수익률은 그 수익률과 DPS 로 역산한 주가 기준이라 배당 없는 해는 빈다 · 국채는 회계연도 말 값 · K-ICS 경과조치 적용은 회사마다 다르다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Dividend yield is the company-reported value (reference price = average close over the week before the record date) · earnings yield uses the price backed out from that yield and the DPS, so years without a dividend are blank · government bond yields are fiscal year-end values · whether K-ICS transitional measures apply differs by company.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 配当利回りは会社開示値(基準株価 = 配当基準日前1週間の平均終値)· 益回りはその利回りとDPSから逆算した株価が基準のため、配当のない年は空欄 · 国債は会計年度末の値 · K-ICSの経過措置の適用は会社ごとに異なる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

02

배당 — 수익률·성향·국채 스프레드Dividends — yield, payout and spread over government bonds配当 — 利回り・配当性向・国債とのスプレッド

수익률Yield利回りDividend yield vs. KTB 10Y and UST 10YDividend yield vs. KTB 10Y and UST 10Y配当利回り vs KTB 10年・UST 10年

Dividend yield vs. 10Y sovereign yieldspercent · Data as of 2025-12-31 · Created 2026-11-130%2%4%6%8%FY18FY19FY20FY21FY22FY23FY24FY25%Samsung F&MHyundai M&FDB InsuranceKTB 10Y (year-end)UST 10Y (year-end)+5.8%+5.4%+4.2%+3.9%+3.4%

삼성화재 FY2025 3.9% · 현대해상 FY2023 5.8% · DB손보 FY2025 5.4% (배당 있는 마지막 해). 선이 끊긴 곳이 배당 미실시.

Samsung F&M FY2025 3.9% · Hyundai M&F FY2023 5.8% · DB Insurance FY2025 5.4% (last year with a dividend). Where a line breaks, no dividend was paid.

Samsung F&M FY2025 3.9% · Hyundai M&F FY2023 5.8% · DB Insurance FY2025 5.4%(配当のあった最後の年)。線が途切れた所は無配。

⚠ 규율: 회사 기재 수익률의 기준가는 배당기준일 전 1주일 평균 — 연말 종가와 조금 다르다.

⚠ Discipline: The reference price for the company-reported yield is the average over the week before the dividend record date — slightly different from the year-end close.

⚠ 規律:会社開示の利回りの基準株価は配当基準日前1週間の平均 — 年末終値とは少し異なる。

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 배당수익률 기준가는 배당기준일 전 1주일 평균 종가라 연말 종가와 다르다 · 선이 끊긴 곳 = 배당 미실시. Definitions: company-reported cash dividend yield (DART); sovereign = last trading day of the fiscal year.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: The reference price for the dividend yield is the average close over the week before the record date, so it differs from the year-end close · a break in a line = no dividend paid. Definitions: company-reported cash dividend yield (DART); sovereign = last trading day of the fiscal year.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 配当利回りの基準株価は配当基準日前1週間の平均終値で、年末終値とは異なる · 線が途切れた所 = 無配。 Definitions: company-reported cash dividend yield (DART); sovereign = last trading day of the fiscal year.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

스프레드SpreadスプレッドDividend yield minus KTB 10Y (percentage points)Dividend yield minus KTB 10Y (percentage points)配当利回り − KTB 10年(%ポイント)

Dividend yield − KTB 10Ypercentage points · Data as of 2025-12-31 · Created 2026-11-130%1%2%3%4%5%FY18FY19FY20FY21FY22FY23FY24FY25%pSamsung F&MHyundai M&FDB Insurance

삼성화재: FY18 +2.2, FY19 +1.7, FY20 +2.8, FY21 +3.2, FY22 +2.7, FY23 +3.3, FY24 +2.1, FY25 +0.5 · 현대해상: FY18 +0.7, FY19 +1.5, FY20 +2.6, FY21 +3.8, FY22 +2.7, FY23 +2.6 · DB손보: FY18 +0.8, FY19 +1.0, FY20 +3.2, FY21 +3.8, FY22 +3.1, FY23 +2.4, FY24 +4.1, FY25 +2.0.

Samsung F&M: FY18 +2.2, FY19 +1.7, FY20 +2.8, FY21 +3.2, FY22 +2.7, FY23 +3.3, FY24 +2.1, FY25 +0.5 · Hyundai M&F: FY18 +0.7, FY19 +1.5, FY20 +2.6, FY21 +3.8, FY22 +2.7, FY23 +2.6 · DB Insurance: FY18 +0.8, FY19 +1.0, FY20 +3.2, FY21 +3.8, FY22 +3.1, FY23 +2.4, FY24 +4.1, FY25 +2.0.

Samsung F&M:FY18 +2.2, FY19 +1.7, FY20 +2.8, FY21 +3.2, FY22 +2.7, FY23 +3.3, FY24 +2.1, FY25 +0.5 · Hyundai M&F:FY18 +0.7, FY19 +1.5, FY20 +2.6, FY21 +3.8, FY22 +2.7, FY23 +2.6 · DB Insurance:FY18 +0.8, FY19 +1.0, FY20 +3.2, FY21 +3.8, FY22 +3.1, FY23 +2.4, FY24 +4.1, FY25 +2.0。

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: 배당수익률은 회사 기재값 · KTB10Y 는 회계연도 마지막 영업일 값 · 배당 미실시 해는 빈칸. Definitions: negative = the bond pays more than the stock's cash dividend.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: Dividend yield is the company-reported value · KTB10Y is the value on the last business day of the fiscal year · years without a dividend are blank. Definitions: negative = the bond pays more than the stock's cash dividend.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: 配当利回りは会社開示値 · KTB10Yは会計年度最終営業日の値 · 無配の年は空欄。 Definitions: negative = the bond pays more than the stock's cash dividend.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

이익수익률Earnings yield益回りEarnings yield (EPS ÷ implied price) vs. KTB 10YEarnings yield (EPS ÷ implied price) vs. KTB 10Y益回り(EPS ÷ 逆算株価)vs KTB 10年

Earnings yield vs. KTB 10Ypercent · Data as of 2025-12-31 · Created 2026-11-130%10%20%30%40%FY18FY19FY20FY21FY22FY23FY24FY25%Samsung F&MHyundai M&FDB InsuranceKTB 10Y+21.0%+20.2%+9.5%+3.4%

삼성화재 FY2025 EY 9.5% (KTB 3.38%) · 현대해상 FY2023 EY 20.2% (KTB 3.18%) · DB손보 FY2025 EY 21.0% (KTB 3.38%).

Samsung F&M FY2025 EY 9.5% (KTB 3.38%) · Hyundai M&F FY2023 EY 20.2% (KTB 3.18%) · DB Insurance FY2025 EY 21.0% (KTB 3.38%).

Samsung F&M FY2025 EY 9.5%(KTB 3.38%) · Hyundai M&F FY2023 EY 20.2%(KTB 3.18%) · DB Insurance FY2025 EY 21.0%(KTB 3.38%)。

⚠ 규율: 배당이 없는 해는 주가를 역산할 수 없어 빈다(현대해상 FY2024~25).

⚠ Discipline: Years without a dividend are blank because the price cannot be backed out (Hyundai M&F FY2024–25).

⚠ 規律:配当のない年は株価を逆算できないため空欄(Hyundai M&F FY2024〜25)。

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: 주가는 시세 Raw Data 가 아니라 DPS ÷ 배당수익률로 역산했다 — 배당 없는 해는 계산하지 못한다 · EPS 는 연결. Definitions: EPS ÷ (DPS ÷ reported dividend yield); needs a dividend to back out the price.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: The price is not taken from market-price Raw Data; it is backed out as DPS ÷ dividend yield — it cannot be computed for years without a dividend · EPS is consolidated. Definitions: EPS ÷ (DPS ÷ reported dividend yield); needs a dividend to back out the price.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: 株価は株価のRaw Dataではなく、DPS ÷ 配当利回りで逆算した — 配当のない年は計算できない · EPSは連結。 Definitions: EPS ÷ (DPS ÷ reported dividend yield); needs a dividend to back out the price.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

배당Dividend配当Dividend per share and payout ratioDividend per share and payout ratio1株当たり配当と配当性向

Dividend per shareKRW · Data as of 2025-12-31 · Created 2026-11-1305,00010,00015,00020,00025,000FY18FY19FY20FY21FY22FY23FY24FY25KRWSamsung F&MHyundai M&FDB Insurance
회사FY18FY19FY20FY21FY22FY23FY24FY25
삼성화재45.8%56.2%49.6%45.5%45.8%37.4%39.0%41.1%
현대해상24.1%26.1%23.9%26.8%26.8%28.2%n/an/a
DB손보23.8%25.4%23.9%24.2%28.1%18.3%22.0%25.7%

연결 현금배당성향(%) — DART 기재값.

CompanyFY18FY19FY20FY21FY22FY23FY24FY25
Samsung F&M45.8%56.2%49.6%45.5%45.8%37.4%39.0%41.1%
Hyundai M&F24.1%26.1%23.9%26.8%26.8%28.2%n/an/a
DB Insurance23.8%25.4%23.9%24.2%28.1%18.3%22.0%25.7%

Consolidated cash payout ratio (%) — as reported to DART.

会社FY18FY19FY20FY21FY22FY23FY24FY25
Samsung F&M45.8%56.2%49.6%45.5%45.8%37.4%39.0%41.1%
Hyundai M&F24.1%26.1%23.9%26.8%26.8%28.2%n/an/a
DB Insurance23.8%25.4%23.9%24.2%28.1%18.3%22.0%25.7%

連結配当性向(%)— DART開示値。

삼성화재: FY18 11,500 → FY19 8,500 → FY20 8,800 → FY21 12,000 → FY22 13,800 → FY23 16,000 → FY24 19,000 → FY25 19,500 · 현대해상: FY18 1,130 → FY19 880 → FY20 1,000 → FY21 1,480 → FY22 1,965 → FY23 2,063 · DB손보: FY18 2,000 → FY19 1,500 → FY20 2,200 → FY21 3,500 → FY22 4,600 → FY23 5,300 → FY24 6,800 → FY25 7,600.

Samsung F&M: FY18 11,500 → FY19 8,500 → FY20 8,800 → FY21 12,000 → FY22 13,800 → FY23 16,000 → FY24 19,000 → FY25 19,500 · Hyundai M&F: FY18 1,130 → FY19 880 → FY20 1,000 → FY21 1,480 → FY22 1,965 → FY23 2,063 · DB Insurance: FY18 2,000 → FY19 1,500 → FY20 2,200 → FY21 3,500 → FY22 4,600 → FY23 5,300 → FY24 6,800 → FY25 7,600.

Samsung F&M:FY18 11,500 → FY19 8,500 → FY20 8,800 → FY21 12,000 → FY22 13,800 → FY23 16,000 → FY24 19,000 → FY25 19,500 · Hyundai M&F:FY18 1,130 → FY19 880 → FY20 1,000 → FY21 1,480 → FY22 1,965 → FY23 2,063 · DB Insurance:FY18 2,000 → FY19 1,500 → FY20 2,200 → FY21 3,500 → FY22 4,600 → FY23 5,300 → FY24 6,800 → FY25 7,600。

Source: DART, Financial Supervisory Service.
Limitations: 보통주 DPS · 배당성향은 연결 기준 회사 기재값 · 최신 사업보고서가 이전 연도를 덮는다(정정 반영). Definitions: common shares; blank = no dividend.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Common-share DPS · the payout ratio is the company-reported consolidated value · the latest annual report overrides earlier years (corrections reflected). Definitions: common shares; blank = no dividend.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 普通株のDPS · 配当性向は連結ベースの会社開示値 · 最新の事業報告書が過去の年度を上書きする(訂正を反映)。 Definitions: common shares; blank = no dividend.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

여력Capacity配当余力Retained earnings vs. statutory reserves (surrender-value, catastrophe, credit-loss)Retained earnings vs. statutory reserves (surrender-value, catastrophe, credit-loss)利益剰余金 vs 法定積立金(解約返戻金・異常危険・貸倒)

Consolidated retained earnings vs. statutory reservesKRW trillions · Data as of 2025-12-31 · Created 2026-11-1305.010.015.020.0Samsung F&MHyundai M&FDB InsuranceKRW tnRetained earningsStatutory reserves incl. to-be-addedof which surrender-value reserve14.68.213.37.05.38.44.13.96.5

삼성화재 FY2025: 이익잉여금 14.64조 vs 법정적립금 6.96조 (해약환급금준비금 4.13조) · 현대해상 FY2025: 이익잉여금 8.16조 vs 법정적립금 5.34조 (해약환급금준비금 3.92조) · DB손보 FY2025: 이익잉여금 13.31조 vs 법정적립금 8.41조 (해약환급금준비금 6.55조).

Samsung F&M FY2025: retained earnings KRW 14.64trn vs statutory reserves KRW 6.96trn (surrender-value reserve KRW 4.13trn) · Hyundai M&F FY2025: retained earnings KRW 8.16trn vs statutory reserves KRW 5.34trn (surrender-value reserve KRW 3.92trn) · DB Insurance FY2025: retained earnings KRW 13.31trn vs statutory reserves KRW 8.41trn (surrender-value reserve KRW 6.55trn).

Samsung F&M FY2025:利益剰余金14.64兆ウォン vs 法定積立金6.96兆ウォン(解約返戻金準備金4.13兆ウォン) · Hyundai M&F FY2025:利益剰余金8.16兆ウォン vs 法定積立金5.34兆ウォン(解約返戻金準備金3.92兆ウォン) · DB Insurance FY2025:利益剰余金13.31兆ウォン vs 法定積立金8.41兆ウォン(解約返戻金準備金6.55兆ウォン)。

⚠ 규율: 상법 배당가능이익은 **별도** 기준이고 여기 값은 연결 재무상태표 주기(기적립+적립예정)라 근사치다. 현대해상이 '배당 불가' 라고 적은 메커니즘이 이 열이다.

⚠ Discipline: Distributable profit under the Commercial Act is on a **separate** basis, and the values here come from the notes to the consolidated balance sheet (already reserved + to be reserved), so they are approximations. This column is the mechanism Hyundai M&F described when it wrote 'no dividend possible'.

⚠ 規律:商法上の配当可能利益は**単体**基準で、ここの値は連結貸借対照表の注記(積立済み+積立予定)のため近似値である。Hyundai M&Fが「配当不可」と記した仕組みがこの列だ。

Source: DART, Financial Supervisory Service.
Limitations: 연결 재무상태표 주기(기적립 + 적립예정)라 상법 배당가능이익(별도 기준)과 다르다 — 근사치. Definitions: latest fiscal year; reserves are carved out of retained earnings before dividends can be paid.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Taken from the notes to the consolidated balance sheet (already reserved + to be reserved), so it differs from distributable profit under the Commercial Act (separate basis) — an approximation. Definitions: latest fiscal year; reserves are carved out of retained earnings before dividends can be paid.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 連結貸借対照表の注記(積立済み + 積立予定)のため、商法上の配当可能利益(単体基準)とは異なる — 近似値。 Definitions: latest fiscal year; reserves are carved out of retained earnings before dividends can be paid.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

03

성장 — 수입보험료·보험수익과 순이익Growth — premium income, insurance revenue and net income成長 — 収入保険料・保険収益と純利益

매출Top line売上Premium income by fiscal year (regulatory basis, spans IFRS 4 → 17)Premium income by fiscal year (regulatory basis, spans IFRS 4 → 17)年度別収入保険料(監督基準、IFRS 4→17をまたぐ)

Premium income (regulatory basis)KRW trillions · Data as of 2025-12-31 · Created 2026-11-13010.020.030.040.0FY18FY19FY20FY21FY22FY23FY24FY25KRW tnSamsung F&MHyundai M&FDB Insurance30.417.516.9

삼성화재: FY2018 18.51조 → FY2025 30.39조 · 현대해상: FY2018 12.97조 → FY2025 17.52조 · DB손보: FY2018 12.33조 → FY2023 16.86조.

Samsung F&M: FY2018 KRW 18.51trn → FY2025 KRW 30.39trn · Hyundai M&F: FY2018 KRW 12.97trn → FY2025 KRW 17.52trn · DB Insurance: FY2018 KRW 12.33trn → FY2023 KRW 16.86trn.

Samsung F&M:FY2018 18.51兆ウォン → FY2025 30.39兆ウォン · Hyundai M&F:FY2018 12.97兆ウォン → FY2025 17.52兆ウォン · DB Insurance:FY2018 12.33兆ウォン → FY2023 16.86兆ウォン。

⚠ 규율: 회사마다 표의 정의가 다르다(삼성화재 FY2023 부터 퇴직연금 포함 보험료수익으로 점프). 원문에 종속회사 표만 남아 비운 해: 삼성화재 FY2022 0.29조. 시대를 넘는 성장률은 같은 회사 안에서만.

⚠ Discipline: Table definitions differ by company (Samsung F&M jumps from FY2023 to premium revenue including retirement pensions). Years blanked because only a subsidiary's table remained in the filing: Samsung F&M FY2022 KRW 0.29trn. Growth across the two accounting eras only within the same company.

⚠ 規律:表の定義は会社ごとに異なる(Samsung F&MはFY2023から退職年金を含む保険料収益へ跳ね上がる)。原文に子会社の表しか残らず空欄にした年:Samsung F&M FY2022 0.29兆ウォン。会計の時代をまたぐ成長率は同じ会社の中でのみ。

Source: DART, Financial Supervisory Service.
Limitations: 회사마다 표의 정의가 다르다(삼성화재 FY2023 부터 퇴직연금 포함) · 본사 표 없이 종속회사 표만 남은 해는 비웠다 · 회계기준을 건너는 업무보고서 기준. Definitions: Samsung = premium revenue incl. retirement pensions; Hyundai, DB = gross premiums written (DB table dropped from FY2024).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Table definitions differ by company (Samsung F&M includes retirement pensions from FY2023) · years where only a subsidiary's table remained, without the parent's, are left blank · business-report basis, which spans the change of accounting standard. Definitions: Samsung = premium revenue incl. retirement pensions; Hyundai, DB = gross premiums written (DB table dropped from FY2024).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 表の定義は会社ごとに異なる(Samsung F&MはFY2023から退職年金を含む)· 親会社の表がなく子会社の表だけが残った年は空欄 · 会計基準の変更をまたぐ業務報告書ベース。 Definitions: Samsung = premium revenue incl. retirement pensions; Hyundai, DB = gross premiums written (DB table dropped from FY2024).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

IFRS 17Insurance revenue and insurance service result (IFRS 17, FY2022 restated onward)Insurance revenue and insurance service result (IFRS 17, FY2022 restated onward)保険収益と保険サービス損益(IFRS 17、FY2022再表示以降)

Insurance revenue (IFRS 17)KRW trillions · Data as of 2025-12-31 · Created 2026-11-1305.010.015.020.025.0FY22FY23FY24FY25KRW tnSamsung F&M revenueHyundai M&F revenueDB Insurance revenue15.216.517.318.612.113.113.714.113.714.615.716.4
회사FY보험수익YoY보험손익마진투자손익순이익ROE
삼성화재FY202215.22조—1.54조10.1%0.51조1.63조—
삼성화재FY202316.49조+8.3%1.94조11.7%0.42조1.82조12.7%
삼성화재FY202417.28조+4.8%1.82조10.5%0.83조2.08조13.1%
삼성화재FY202518.64조+7.9%1.48조8.0%1.18조2.02조11.0%
현대해상FY202212.12조—1.71조14.1%0.47조1.29조—
현대해상FY202313.12조+8.3%0.91조6.9%0.29조0.61조7.8%
현대해상FY202413.71조+4.5%1.43조10.5%0.25조0.85조15.8%
현대해상FY202514.14조+3.1%0.81조5.7%0.85조1.02조20.6%
DB손보FY202213.69조—2.11조15.4%0.62조2.04조—
DB손보FY202314.57조+6.4%1.64조11.3%0.59조1.74조15.6%
DB손보FY202415.70조+7.8%1.72조10.9%0.71조1.85조19.0%
DB손보FY202516.43조+4.7%1.15조7.0%1.24조1.79조17.7%
CompanyFYInsurance revenueYoYInsurance resultMarginInvestment resultNet incomeROE
Samsung F&MFY2022KRW 15.22trn—KRW 1.54trn10.1%KRW 0.51trnKRW 1.63trn—
Samsung F&MFY2023KRW 16.49trn+8.3%KRW 1.94trn11.7%KRW 0.42trnKRW 1.82trn12.7%
Samsung F&MFY2024KRW 17.28trn+4.8%KRW 1.82trn10.5%KRW 0.83trnKRW 2.08trn13.1%
Samsung F&MFY2025KRW 18.64trn+7.9%KRW 1.48trn8.0%KRW 1.18trnKRW 2.02trn11.0%
Hyundai M&FFY2022KRW 12.12trn—KRW 1.71trn14.1%KRW 0.47trnKRW 1.29trn—
Hyundai M&FFY2023KRW 13.12trn+8.3%KRW 0.91trn6.9%KRW 0.29trnKRW 0.61trn7.8%
Hyundai M&FFY2024KRW 13.71trn+4.5%KRW 1.43trn10.5%KRW 0.25trnKRW 0.85trn15.8%
Hyundai M&FFY2025KRW 14.14trn+3.1%KRW 0.81trn5.7%KRW 0.85trnKRW 1.02trn20.6%
DB InsuranceFY2022KRW 13.69trn—KRW 2.11trn15.4%KRW 0.62trnKRW 2.04trn—
DB InsuranceFY2023KRW 14.57trn+6.4%KRW 1.64trn11.3%KRW 0.59trnKRW 1.74trn15.6%
DB InsuranceFY2024KRW 15.70trn+7.8%KRW 1.72trn10.9%KRW 0.71trnKRW 1.85trn19.0%
DB InsuranceFY2025KRW 16.43trn+4.7%KRW 1.15trn7.0%KRW 1.24trnKRW 1.79trn17.7%
会社FY保険収益前年比保険損益マージン投資損益純利益ROE
Samsung F&MFY202215.22兆ウォン—1.54兆ウォン10.1%0.51兆ウォン1.63兆ウォン—
Samsung F&MFY202316.49兆ウォン+8.3%1.94兆ウォン11.7%0.42兆ウォン1.82兆ウォン12.7%
Samsung F&MFY202417.28兆ウォン+4.8%1.82兆ウォン10.5%0.83兆ウォン2.08兆ウォン13.1%
Samsung F&MFY202518.64兆ウォン+7.9%1.48兆ウォン8.0%1.18兆ウォン2.02兆ウォン11.0%
Hyundai M&FFY202212.12兆ウォン—1.71兆ウォン14.1%0.47兆ウォン1.29兆ウォン—
Hyundai M&FFY202313.12兆ウォン+8.3%0.91兆ウォン6.9%0.29兆ウォン0.61兆ウォン7.8%
Hyundai M&FFY202413.71兆ウォン+4.5%1.43兆ウォン10.5%0.25兆ウォン0.85兆ウォン15.8%
Hyundai M&FFY202514.14兆ウォン+3.1%0.81兆ウォン5.7%0.85兆ウォン1.02兆ウォン20.6%
DB InsuranceFY202213.69兆ウォン—2.11兆ウォン15.4%0.62兆ウォン2.04兆ウォン—
DB InsuranceFY202314.57兆ウォン+6.4%1.64兆ウォン11.3%0.59兆ウォン1.74兆ウォン15.6%
DB InsuranceFY202415.70兆ウォン+7.8%1.72兆ウォン10.9%0.71兆ウォン1.85兆ウォン19.0%
DB InsuranceFY202516.43兆ウォン+4.7%1.15兆ウォン7.0%1.24兆ウォン1.79兆ウォン17.7%

삼성화재: 보험수익 15.22조 → 18.64조 · 보험손익 1.54조 → 1.48조 · 순이익 1.63조 → 2.02조 · 현대해상: 보험수익 12.12조 → 14.14조 · 보험손익 1.71조 → 0.81조 · 순이익 1.29조 → 1.02조 · DB손보: 보험수익 13.69조 → 16.43조 · 보험손익 2.11조 → 1.15조 · 순이익 2.04조 → 1.79조.

Samsung F&M: insurance revenue KRW 15.22trn → KRW 18.64trn · insurance result KRW 1.54trn → KRW 1.48trn · net income KRW 1.63trn → KRW 2.02trn · Hyundai M&F: insurance revenue KRW 12.12trn → KRW 14.14trn · insurance result KRW 1.71trn → KRW 0.81trn · net income KRW 1.29trn → KRW 1.02trn · DB Insurance: insurance revenue KRW 13.69trn → KRW 16.43trn · insurance result KRW 2.11trn → KRW 1.15trn · net income KRW 2.04trn → KRW 1.79trn.

Samsung F&M:保険収益15.22兆ウォン → 18.64兆ウォン · 保険損益1.54兆ウォン → 1.48兆ウォン · 純利益1.63兆ウォン → 2.02兆ウォン · Hyundai M&F:保険収益12.12兆ウォン → 14.14兆ウォン · 保険損益1.71兆ウォン → 0.81兆ウォン · 純利益1.29兆ウォン → 1.02兆ウォン · DB Insurance:保険収益13.69兆ウォン → 16.43兆ウォン · 保険損益2.11兆ウォン → 1.15兆ウォン · 純利益2.04兆ウォン → 1.79兆ウォン。

⚠ 규율: 보험손익 = 보험영업수익 − 보험영업비용(기타사업비용 포함). 투자손익은 따로.

⚠ Discipline: Insurance result = insurance operating revenue − insurance operating expenses (incl. other business expenses). The investment result is separate.

⚠ 規律:保険損益 = 保険営業収益 − 保険営業費用(その他事業費用を含む)。投資損益は別。

Source: DART, Financial Supervisory Service.
Limitations: IFRS 17 연결 · FY2022 는 FY2023 보고서의 재작성 비교값 · 보험손익 = 보험영업수익 − 보험영업비용(투자손익 제외). Definitions: consolidated; FY2022 is the restated comparative in the FY2023 report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: IFRS 17 consolidated · FY2022 is the restated comparative in the FY2023 report · insurance result = insurance operating revenue − insurance operating expenses (excl. investment result). Definitions: consolidated; FY2022 is the restated comparative in the FY2023 report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: IFRS 17連結 · FY2022はFY2023報告書の再表示比較値 · 保険損益 = 保険営業収益 − 保険営業費用(投資損益を除く)。 Definitions: consolidated; FY2022 is the restated comparative in the FY2023 report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

이익Earnings利益Consolidated net income by fiscal year (from the dividend table — spans both regimes)Consolidated net income by fiscal year (from the dividend table — spans both regimes)年度別の連結純利益(配当表から — 両会計基準をまたぐ)

Consolidated net incomeKRW trillions · Data as of 2025-12-31 · Created 2026-11-1300.51.01.52.02.5FY18FY19FY20FY21FY22FY23FY24FY25KRW tnSamsung F&MHyundai M&FDB Insurance2.01.80.57

삼성화재: FY2018 1.07조 → FY2025 2.02조 · 현대해상: FY2018 0.37조 → FY2023 0.57조 · DB손보: FY2018 0.53조 → FY2025 1.79조.

Samsung F&M: FY2018 KRW 1.07trn → FY2025 KRW 2.02trn · Hyundai M&F: FY2018 KRW 0.37trn → FY2023 KRW 0.57trn · DB Insurance: FY2018 KRW 0.53trn → FY2025 KRW 1.79trn.

Samsung F&M:FY2018 1.07兆ウォン → FY2025 2.02兆ウォン · Hyundai M&F:FY2018 0.37兆ウォン → FY2023 0.57兆ウォン · DB Insurance:FY2018 0.53兆ウォン → FY2025 1.79兆ウォン。

⚠ 규율: FY2022→FY2023 은 회계기준이 바뀐다 — 그 한 칸의 증감은 성장이 아니다.

⚠ Discipline: The accounting standard changes between FY2022 and FY2023 — the change across that one step is not growth.

⚠ 規律:FY2022→FY2023は会計基準が変わる — その1区間の増減は成長ではない。

Source: DART, Financial Supervisory Service.
Limitations: 배당표의 연결 순이익 — FY2022 까지 IFRS 4(최초 공시), FY2023 부터 IFRS 17 이라 한 계열이 아니다. Definitions: IFRS 4 through FY2022 as originally reported, IFRS 17 from FY2023; not one series.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Consolidated net income from the dividend table — IFRS 4 (as first reported) through FY2022 and IFRS 17 from FY2023, so it is not one series. Definitions: IFRS 4 through FY2022 as originally reported, IFRS 17 from FY2023; not one series.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 配当表の連結純利益 — FY2022まではIFRS 4(当初開示)、FY2023からはIFRS 17のため一つの系列ではない。 Definitions: IFRS 4 through FY2022 as originally reported, IFRS 17 from FY2023; not one series.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

04

지분 구조 — 최대주주·특수관계인·자기주식Ownership — largest shareholder, related parties, treasury shares株主構成 — 筆頭株主・特別関係者・自己株式

지분Ownership持分Samsung F&M: largest-shareholder group and treasury sharesSamsung F&M: largest-shareholder group and treasury sharesSamsung F&M:筆頭株主グループと自己株式

Samsung F&M — largest-shareholder group by quarterpercent of common shares · Data as of 2026-06-30 · Created 2026-11-130%5%10%15%20%25%19Q119Q420Q321Q222Q122Q423Q324Q225Q125Q426Q2%Largest holder + related (%)Largest holder alone (%)+19.6%+15.9%
주주관계기초 지분기말 지분기말 주식수
삼성생명최대주주 본인15.43%15.90%7,099,088
삼성문화재단최대주주의 계열 비영리법인3.15%3.25%1,451,241
삼성복지재단최대주주의 계열 비영리법인0.37%0.38%170,517
이재용최대주주의 특수관계인0.10%0.10%44,000
이문화최대주주의 계열회사 등기임원0.00%0.00%300
박진회최대주주의 계열회사 등기임원0.00%0.00%50
HolderRelationStake, startStake, endShares, end
삼성생명largest shareholder15.43%15.90%7,099,088
삼성문화재단non-profit affiliate of the largest shareholder3.15%3.25%1,451,241
삼성복지재단non-profit affiliate of the largest shareholder0.37%0.38%170,517
이재용related party of the largest shareholder0.10%0.10%44,000
이문화registered executive of an affiliate of the largest shareholder0.00%0.00%300
박진회registered executive of an affiliate of the largest shareholder0.00%0.00%50
株主関係期首持分期末持分期末株式数
삼성생명筆頭株主本人15.43%15.90%7,099,088
삼성문화재단筆頭株主の系列非営利法人3.15%3.25%1,451,241
삼성복지재단筆頭株主の系列非営利法人0.37%0.38%170,517
이재용筆頭株主の特別関係者0.10%0.10%44,000
이문화筆頭株主の系列会社の登記役員0.00%0.00%300
박진회筆頭株主の系列会社の登記役員0.00%0.00%50

최신(2026H1): 삼성생명(최대주주 본인) 15.9% · 삼성문화재단(최대주주의 계열 비영리법인) 3.25% · 삼성복지재단(최대주주의 계열 비영리법인) 0.38%. 자기주식 4,819,177 / 발행주식 총수 44,647,473 (10.8%, 2026H1 기준).

Latest (2026H1): 삼성생명 (largest shareholder) 15.9% · 삼성문화재단 (non-profit affiliate of the largest shareholder) 3.25% · 삼성복지재단 (non-profit affiliate of the largest shareholder) 0.38%. Treasury shares 4,819,177 / total shares issued 44,647,473 (10.8%, as of 2026H1).

最新(2026H1):삼성생명(筆頭株主本人)15.9% · 삼성문화재단(筆頭株主の系列非営利法人)3.25% · 삼성복지재단(筆頭株主の系列非営利法人)0.38%。自己株式4,819,177 / 発行済株式総数44,647,473(10.8%、2026H1時点)。

⚠ 규율: 최대주주 변동: 기록 없음.

⚠ Discipline: Changes in the largest shareholder: none recorded.

⚠ 規律:筆頭株主の異動:記録なし。

Source: DART, Financial Supervisory Service.
Limitations: DART 최대주주 현황(보통주) · 자기주식 비율 분모 = 발행주식 총수(소각 뒤) · 개인 지배주주의 간접 지분은 이 표에 없다. Definitions: DART largest-shareholder table; x = fiscal quarter.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder table (common shares) · treasury-share ratio denominator = total shares issued (after cancellation) · indirect stakes of individual controlling shareholders are not in this table. Definitions: DART largest-shareholder table; x = fiscal quarter.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DARTの最大株主現況(普通株)· 自己株式比率の分母 = 発行済株式総数(消却後)· 個人の支配株主の間接持分はこの表にない。 Definitions: DART largest-shareholder table; x = fiscal quarter.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분Ownership持分Hyundai M&F: largest-shareholder group and treasury sharesHyundai M&F: largest-shareholder group and treasury sharesHyundai M&F:筆頭株主グループと自己株式

Hyundai M&F — largest-shareholder group by quarterpercent of common shares · Data as of 2026-06-30 · Created 2026-11-130%10%20%30%19Q119Q420Q321Q222Q122Q423Q324Q225Q125Q426Q2%Largest holder + related (%)Largest holder alone (%)+24.0%+23.1%
주주관계기초 지분기말 지분기말 주식수
정몽윤최대주주 본인22.00%23.08%19,672,910
이용진계열회사 임원0.00%0.00%660
정순교계열회사 임원0.00%0.00%343
조성필계열회사 임원0.00%0.00%72
이영민계열회사 임원0.00%0.00%301
조성진계열회사 임원0.00%0.00%412
이동재계열회사 임원0.00%0.00%298
정경선최대주주 본인의 子0.45%0.48%407,756
정정이최대주주 본인의 子0.38%0.40%343,475
이석현임원0.00%0.00%1,692
황인관임원0.01%0.01%6,619
유원식계열회사 임원0.00%0.00%2,689
HolderRelationStake, startStake, endShares, end
정몽윤largest shareholder22.00%23.08%19,672,910
이용진affiliate executive0.00%0.00%660
정순교affiliate executive0.00%0.00%343
조성필affiliate executive0.00%0.00%72
이영민affiliate executive0.00%0.00%301
조성진affiliate executive0.00%0.00%412
이동재affiliate executive0.00%0.00%298
정경선child of the largest shareholder0.45%0.48%407,756
정정이child of the largest shareholder0.38%0.40%343,475
이석현executive0.00%0.00%1,692
황인관executive0.01%0.01%6,619
유원식affiliate executive0.00%0.00%2,689
株主関係期首持分期末持分期末株式数
정몽윤筆頭株主本人22.00%23.08%19,672,910
이용진系列会社役員0.00%0.00%660
정순교系列会社役員0.00%0.00%343
조성필系列会社役員0.00%0.00%72
이영민系列会社役員0.00%0.00%301
조성진系列会社役員0.00%0.00%412
이동재系列会社役員0.00%0.00%298
정경선筆頭株主本人の子0.45%0.48%407,756
정정이筆頭株主本人の子0.38%0.40%343,475
이석현役員0.00%0.00%1,692
황인관役員0.01%0.01%6,619
유원식系列会社役員0.00%0.00%2,689

최신(2026H1): 정몽윤(최대주주 본인) 23.08% · 정경선(최대주주 본인의 子) 0.48% · 정정이(최대주주 본인의 子) 0.4%. 자기주식 5,939,750 / 발행주식 총수 85,248,250 (7.0%, 2026H1 기준).

Latest (2026H1): 정몽윤 (largest shareholder) 23.08% · 정경선 (child of the largest shareholder) 0.48% · 정정이 (child of the largest shareholder) 0.4%. Treasury shares 5,939,750 / total shares issued 85,248,250 (7.0%, as of 2026H1).

最新(2026H1):정몽윤(筆頭株主本人)23.08% · 정경선(筆頭株主本人の子)0.48% · 정정이(筆頭株主本人の子)0.4%。自己株式5,939,750 / 発行済株式総数85,248,250(7.0%、2026H1時点)。

⚠ 규율: 최대주주 변동: 2025년 03월 21일 정몽윤 22.84%; 2026년 04월 03일 정몽윤 23.97%.

⚠ Discipline: Changes in the largest shareholder: 2025-03-21 정몽윤 22.84%; 2026-04-03 정몽윤 23.97%.

⚠ 規律:筆頭株主の異動:2025-03-21 정몽윤 22.84%; 2026-04-03 정몽윤 23.97%。

Source: DART, Financial Supervisory Service.
Limitations: DART 최대주주 현황(보통주) · 자기주식 비율 분모 = 발행주식 총수(소각 뒤) · 개인 지배주주의 간접 지분은 이 표에 없다. Definitions: DART largest-shareholder table; x = fiscal quarter.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder table (common shares) · treasury-share ratio denominator = total shares issued (after cancellation) · indirect stakes of individual controlling shareholders are not in this table. Definitions: DART largest-shareholder table; x = fiscal quarter.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DARTの最大株主現況(普通株)· 自己株式比率の分母 = 発行済株式総数(消却後)· 個人の支配株主の間接持分はこの表にない。 Definitions: DART largest-shareholder table; x = fiscal quarter.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분Ownership持分DB Insurance: largest-shareholder group and treasury sharesDB Insurance: largest-shareholder group and treasury sharesDB Insurance:筆頭株主グループと自己株式

DB Insurance — largest-shareholder group by quarterpercent of common shares · Data as of 2026-06-30 · Created 2026-11-130%10%20%30%19Q119Q420Q321Q222Q122Q423Q324Q225Q125Q426Q2%Largest holder + related (%)Largest holder alone (%)+27.6%+9.7%
주주관계기초 지분기말 지분기말 주식수
김남호본인9.19%9.74%6,379,520
강운식계열사임원0.00%0.00%244
DB Inc.계열사0.86%0.92%600,000
DB하이텍계열사0.50%0.65%422,500
이승주계열사임원0.00%0.00%100
디비손해보험사내근로복지기금기타0.86%0.92%600,000
안상건계열사임원0.00%0.00%2,000
김준기친인척6.07%6.43%4,208,500
김주원친인척3.21%3.40%2,229,640
DB김준기문화재단기타 단체5.10%5.40%3,539,070
김영만계열사 임원0.00%0.00%1,500
이정민계열사 임원0.00%0.00%400
HolderRelationStake, startStake, endShares, end
김남호largest shareholder9.19%9.74%6,379,520
강운식affiliate executive0.00%0.00%244
DB Inc.affiliate0.86%0.92%600,000
DB하이텍affiliate0.50%0.65%422,500
이승주affiliate executive0.00%0.00%100
디비손해보험사내근로복지기금other0.86%0.92%600,000
안상건affiliate executive0.00%0.00%2,000
김준기relative6.07%6.43%4,208,500
김주원relative3.21%3.40%2,229,640
DB김준기문화재단other organisation5.10%5.40%3,539,070
김영만affiliate executive0.00%0.00%1,500
이정민affiliate executive0.00%0.00%400
株主関係期首持分期末持分期末株式数
김남호本人(筆頭株主)9.19%9.74%6,379,520
강운식系列会社役員0.00%0.00%244
DB Inc.系列会社0.86%0.92%600,000
DB하이텍系列会社0.50%0.65%422,500
이승주系列会社役員0.00%0.00%100
디비손해보험사내근로복지기금その他0.86%0.92%600,000
안상건系列会社役員0.00%0.00%2,000
김준기親族6.07%6.43%4,208,500
김주원親族3.21%3.40%2,229,640
DB김준기문화재단その他団体5.10%5.40%3,539,070
김영만系列会社役員0.00%0.00%1,500
이정민系列会社役員0.00%0.00%400

최신(2026H1): 김남호(본인) 9.74% · DB Inc.(계열사) 0.92% · DB하이텍(계열사) 0.65% · 디비손해보험사내근로복지기금(기타) 0.92% · 김준기(친인척) 6.43% · 김주원(친인척) 3.4% · DB김준기문화재단(기타 단체) 5.4%. 자기주식 4,856,880 / 발행주식 총수 65,500,349 (7.4%, 2026H1 기준).

Latest (2026H1): 김남호 (largest shareholder) 9.74% · DB Inc. (affiliate) 0.92% · DB하이텍 (affiliate) 0.65% · 디비손해보험사내근로복지기금 (other) 0.92% · 김준기 (relative) 6.43% · 김주원 (relative) 3.4% · DB김준기문화재단 (other organisation) 5.4%. Treasury shares 4,856,880 / total shares issued 65,500,349 (7.4%, as of 2026H1).

最新(2026H1):김남호(本人(筆頭株主))9.74% · DB Inc.(系列会社)0.92% · DB하이텍(系列会社)0.65% · 디비손해보험사내근로복지기금(その他)0.92% · 김준기(親族)6.43% · 김주원(親族)3.4% · DB김준기문화재단(その他団体)5.4%。自己株式4,856,880 / 発行済株式総数65,500,349(7.4%、2026H1時点)。

⚠ 규율: 최대주주 변동: 2026년 01월 09일 김남호 25.96%; 2026년 01월 19일 김남호 25.96%; 2026년 03월 30일 김남호 27.5%; 2026년 06월 30일 김남호 27.62%.

⚠ Discipline: Changes in the largest shareholder: 2026-01-09 김남호 25.96%; 2026-01-19 김남호 25.96%; 2026-03-30 김남호 27.5%; 2026-06-30 김남호 27.62%.

⚠ 規律:筆頭株主の異動:2026-01-09 김남호 25.96%; 2026-01-19 김남호 25.96%; 2026-03-30 김남호 27.5%; 2026-06-30 김남호 27.62%。

Source: DART, Financial Supervisory Service.
Limitations: DART 최대주주 현황(보통주) · 자기주식 비율 분모 = 발행주식 총수(소각 뒤) · 개인 지배주주의 간접 지분은 이 표에 없다. Definitions: DART largest-shareholder table; x = fiscal quarter.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder table (common shares) · treasury-share ratio denominator = total shares issued (after cancellation) · indirect stakes of individual controlling shareholders are not in this table. Definitions: DART largest-shareholder table; x = fiscal quarter.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DARTの最大株主現況(普通株)· 自己株式比率の分母 = 発行済株式総数(消却後)· 個人の支配株主の間接持分はこの表にない。 Definitions: DART largest-shareholder table; x = fiscal quarter.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

출자Stakes出資DB Insurance: investments in other companies (largest by book value)DB Insurance: investments in other companies (largest by book value)DB Insurance:他法人への出資(簿価上位)

피출자회사취득목적지분%장부금액(백만)피출자 총자산(백만)피출자 순이익(백만)
Fortegra2026.06.30경영참여100.00%2,536,290,000,0009,439,059,000,000223,556,000,000
DB생명2006.03.31경영참여99.23%474,045,000,00012,156,782,000,000181,637,000,000
DB캐피탈2015.05.06경영참여94.86%143,014,000,000755,024,000,00012,459,000,000
안청재산보험주식유한회사2014.01.10일반투자15.01%135,213,000,0001,837,936,000,0005,855,000,000
DB증권2006.03.31경영참여27.34%106,307,000,00014,264,733,000,00095,459,000,000
BSH2024.02.19경영참여75.00%69,844,000,000208,401,000,000-1,222,000,000
DBV2024.01.31경영참여75.00%69,479,000,000268,516,000,0001,293,000,000
PTI2015.07.10경영참여37.32%56,777,000,000454,558,000,00015,948,000,000
IMM 인프라 제9호 사모투자합자회사2021.12.16단순투자2.93%23,620,000,000654,776,000,0003,548,000,000
DB MnS2013.02.22경영참여100.00%23,000,000,00038,943,000,0001,088,000,000
인카금융서비스2022.03.24일반투자4.48%22,191,000,0001,001,382,000,00070,953,000,000
다올투자증권2025.04.17일반투자9.73%19,845,000,00010,456,674,000,00043,857,000,000
InvesteeAcquiredPurposeStake %Book value (mn)Investee total assets (mn)Investee net income (mn)
Fortegra2026.06.30management participation100.00%2,536,290,000,0009,439,059,000,000223,556,000,000
DB생명2006.03.31management participation99.23%474,045,000,00012,156,782,000,000181,637,000,000
DB캐피탈2015.05.06management participation94.86%143,014,000,000755,024,000,00012,459,000,000
안청재산보험주식유한회사2014.01.10general investment15.01%135,213,000,0001,837,936,000,0005,855,000,000
DB증권2006.03.31management participation27.34%106,307,000,00014,264,733,000,00095,459,000,000
BSH2024.02.19management participation75.00%69,844,000,000208,401,000,000-1,222,000,000
DBV2024.01.31management participation75.00%69,479,000,000268,516,000,0001,293,000,000
PTI2015.07.10management participation37.32%56,777,000,000454,558,000,00015,948,000,000
IMM 인프라 제9호 사모투자합자회사2021.12.16simple investment2.93%23,620,000,000654,776,000,0003,548,000,000
DB MnS2013.02.22management participation100.00%23,000,000,00038,943,000,0001,088,000,000
인카금융서비스2022.03.24general investment4.48%22,191,000,0001,001,382,000,00070,953,000,000
다올투자증권2025.04.17general investment9.73%19,845,000,00010,456,674,000,00043,857,000,000
出資先取得目的持分%簿価(百万)出資先の総資産(百万)出資先の純利益(百万)
Fortegra2026.06.30経営参加100.00%2,536,290,000,0009,439,059,000,000223,556,000,000
DB생명2006.03.31経営参加99.23%474,045,000,00012,156,782,000,000181,637,000,000
DB캐피탈2015.05.06経営参加94.86%143,014,000,000755,024,000,00012,459,000,000
안청재산보험주식유한회사2014.01.10一般投資15.01%135,213,000,0001,837,936,000,0005,855,000,000
DB증권2006.03.31経営参加27.34%106,307,000,00014,264,733,000,00095,459,000,000
BSH2024.02.19経営参加75.00%69,844,000,000208,401,000,000-1,222,000,000
DBV2024.01.31経営参加75.00%69,479,000,000268,516,000,0001,293,000,000
PTI2015.07.10経営参加37.32%56,777,000,000454,558,000,00015,948,000,000
IMM 인프라 제9호 사모투자합자회사2021.12.16純投資2.93%23,620,000,000654,776,000,0003,548,000,000
DB MnS2013.02.22経営参加100.00%23,000,000,00038,943,000,0001,088,000,000
인카금융서비스2022.03.24一般投資4.48%22,191,000,0001,001,382,000,00070,953,000,000
다올투자증권2025.04.17一般投資9.73%19,845,000,00010,456,674,000,00043,857,000,000

DART 타법인출자 현황(2026H1) 상위: Fortegra 100.0% (장부 2,536,290,000,000백만) · DB생명 99.23% (장부 474,045,000,000백만) · DB캐피탈 94.86% (장부 143,014,000,000백만) · 안청재산보험주식유한회사 15.01% (장부 135,213,000,000백만) · DB증권 27.34% (장부 106,307,000,000백만) · BSH 75.0% (장부 69,844,000,000백만).

DART table of investments in other companies (2026H1), largest: Fortegra 100.0% (book 2,536,290,000,000 mn) · DB생명 99.23% (book 474,045,000,000 mn) · DB캐피탈 94.86% (book 143,014,000,000 mn) · 안청재산보험주식유한회사 15.01% (book 135,213,000,000 mn) · DB증권 27.34% (book 106,307,000,000 mn) · BSH 75.0% (book 69,844,000,000 mn).

DART他法人出資現況(2026H1)の上位:Fortegra 100.0%(簿価2,536,290,000,000百万) · DB생명 99.23%(簿価474,045,000,000百万) · DB캐피탈 94.86%(簿価143,014,000,000百万) · 안청재산보험주식유한회사 15.01%(簿価135,213,000,000百万) · DB증권 27.34%(簿価106,307,000,000百万) · BSH 75.0%(簿価69,844,000,000百万)。

⚠ 규율: 삼성화재·현대해상은 이 표를 '-' 로 비웠다 — 출자 내역은 주석(관계기업·지분증권)에서 따로 읽어야 한다(다음 단계).

⚠ Discipline: Samsung F&M and Hyundai M&F left this table blank ('-') — the investment details have to be read separately from the notes (associates, equity securities) (a later step).

⚠ 規律:Samsung F&MとHyundai M&Fはこの表を「-」で空欄にした — 出資の内訳は注記(関連会社・持分証券)から別途読む必要がある(次の段階)。

Source: DART, Financial Supervisory Service.
Limitations: DART 타법인출자 현황 — 삼성화재·현대해상은 이 표를 비웠다(주석에서 따로 읽어야 함).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART table of investments in other companies — Samsung F&M and Hyundai M&F left this table empty (it has to be read from the notes).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DARTの他法人出資現況 — Samsung F&MとHyundai M&Fはこの表を空欄にした(注記から別途読む必要がある)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

05

채권·운용자산 포트폴리오 — 유가증권 운용내역(업무보고서 기준)Bond and invested-asset portfolio — securities by type (business-report basis)債券・運用資産ポートフォリオ — 有価証券の運用内訳(業務報告書ベース)

포트폴리오PortfolioポートフォリオSamsung F&M: securities by type, fiscal year-ends + latest quarterSamsung F&M: securities by type, fiscal year-ends + latest quarterSamsung F&M:種類別の有価証券(各会計年度末 + 直近四半期)

Samsung F&M — securities portfolioKRW trillions · Data as of 2026-06-30 · Created 2026-11-13020.040.060.080.0100FY18FY19FY20FY21FY22FY23FY24FY2526H1KRW tnGovt & municipal bondsSpecial bondsFinancial bondsCorporate bondsForeign securitiesFunds (beneficiary certificates)StocksEquity stakes (contributions)Other10.912.46.541.811.011.87.145.911.311.17.37.449.210.311.06.57.248.48.28.78.042.27.810.17.96.67.351.48.19.58.07.87.052.27.78.67.89.36.811.359.38.08.07.311.129.978.8
종류FY23FY24FY2526H1
Govt & municipal bonds7.81조 (0.7%)8.10조 (1.3%)7.72조 (1.4%)7.96조 (2.4%)
Special bonds10.12조 (2.0%)9.45조 (1.4%)8.61조 (2.0%)7.97조 (2.2%)
Financial bonds1.79조 (2.6%)1.67조 (2.9%)1.91조 (3.4%)2.19조 (3.2%)
Corporate bonds7.86조 (1.8%)7.98조 (2.2%)7.75조 (2.7%)7.25조 (2.5%)
Foreign securities5.91조 (2.9%)7.79조 (4.1%)9.31조 (-0.1%)11.05조 (4.3%)
Funds (beneficiary certificates)6.59조 (4.1%)6.98조 (5.6%)6.76조 (6.7%)6.24조 (8.0%)
Stocks7.34조 (1.6%)5.34조 (1.8%)11.32조 (1.2%)29.90조 (0.2%)
Equity stakes (contributions)3.57조 (-0.2%)4.03조 (-0.7%)4.82조 (0.4%)5.13조 (2.3%)
Other0.39조 (2.8%)0.86조 (3.4%)1.10조 (3.0%)1.15조 (3.1%)

칸 = 기말잔액(조원) (회사 기재 수익률/이익률 %)

TypeFY23FY24FY2526H1
Govt & municipal bondsKRW 7.81trn (0.7%)KRW 8.10trn (1.3%)KRW 7.72trn (1.4%)KRW 7.96trn (2.4%)
Special bondsKRW 10.12trn (2.0%)KRW 9.45trn (1.4%)KRW 8.61trn (2.0%)KRW 7.97trn (2.2%)
Financial bondsKRW 1.79trn (2.6%)KRW 1.67trn (2.9%)KRW 1.91trn (3.4%)KRW 2.19trn (3.2%)
Corporate bondsKRW 7.86trn (1.8%)KRW 7.98trn (2.2%)KRW 7.75trn (2.7%)KRW 7.25trn (2.5%)
Foreign securitiesKRW 5.91trn (2.9%)KRW 7.79trn (4.1%)KRW 9.31trn (-0.1%)KRW 11.05trn (4.3%)
Funds (beneficiary certificates)KRW 6.59trn (4.1%)KRW 6.98trn (5.6%)KRW 6.76trn (6.7%)KRW 6.24trn (8.0%)
StocksKRW 7.34trn (1.6%)KRW 5.34trn (1.8%)KRW 11.32trn (1.2%)KRW 29.90trn (0.2%)
Equity stakes (contributions)KRW 3.57trn (-0.2%)KRW 4.03trn (-0.7%)KRW 4.82trn (0.4%)KRW 5.13trn (2.3%)
OtherKRW 0.39trn (2.8%)KRW 0.86trn (3.4%)KRW 1.10trn (3.0%)KRW 1.15trn (3.1%)

Cell = year-end balance (KRW trn) (company-reported yield / return %)

種類FY23FY24FY2526H1
国公債7.81兆ウォン(0.7%)8.10兆ウォン(1.3%)7.72兆ウォン(1.4%)7.96兆ウォン(2.4%)
特殊債10.12兆ウォン(2.0%)9.45兆ウォン(1.4%)8.61兆ウォン(2.0%)7.97兆ウォン(2.2%)
金融債1.79兆ウォン(2.6%)1.67兆ウォン(2.9%)1.91兆ウォン(3.4%)2.19兆ウォン(3.2%)
社債7.86兆ウォン(1.8%)7.98兆ウォン(2.2%)7.75兆ウォン(2.7%)7.25兆ウォン(2.5%)
外貨建有価証券5.91兆ウォン(2.9%)7.79兆ウォン(4.1%)9.31兆ウォン(-0.1%)11.05兆ウォン(4.3%)
受益証券(ファンド)6.59兆ウォン(4.1%)6.98兆ウォン(5.6%)6.76兆ウォン(6.7%)6.24兆ウォン(8.0%)
株式7.34兆ウォン(1.6%)5.34兆ウォン(1.8%)11.32兆ウォン(1.2%)29.90兆ウォン(0.2%)
出資金3.57兆ウォン(-0.2%)4.03兆ウォン(-0.7%)4.82兆ウォン(0.4%)5.13兆ウォン(2.3%)
その他0.39兆ウォン(2.8%)0.86兆ウォン(3.4%)1.10兆ウォン(3.0%)1.15兆ウォン(3.1%)

セル = 期末残高(兆ウォン)(会社開示の利回り/収益率 %)

삼성화재 26H1: 유가증권 78.85조 중 국내채권(국공채+특수채+금융채+회사채) 25.37조 (32.2%), 외화유가증권 11.05조 (14.0%), 주식 29.90조 (37.9%), 수익증권 6.24조 (7.9%).

Samsung F&M 26H1: of securities KRW 78.85trn, domestic bonds (govt & municipal + special + financial + corporate) KRW 25.37trn (32.2%), foreign-currency securities KRW 11.05trn (14.0%), stocks KRW 29.90trn (37.9%), funds (beneficiary certificates) KRW 6.24trn (7.9%).

Samsung F&M 26H1:有価証券78.85兆ウォンのうち国内債券(国公債+特殊債+金融債+社債)25.37兆ウォン(32.2%)、外貨建有価証券11.05兆ウォン(14.0%)、株式29.90兆ウォン(37.9%)、受益証券6.24兆ウォン(7.9%)。

⚠ 규율: 외화유가증권은 채권·주식이 섞인 회사 정의(현대해상은 해외 주식·출자금·펀드 제외). 신용등급·잔존만기는 주석 표에서 다음 단계.

⚠ Discipline: Foreign-currency securities follow each company's own definition and mix bonds and stocks (Hyundai M&F excludes overseas stocks, contributions and funds). Credit ratings and residual maturities come from the note tables in a later step.

⚠ 規律:外貨建有価証券は債券・株式が混じる各社の定義(Hyundai M&Fは海外株式・出資金・ファンドを除く)。信用格付・残存期間は注記の表で次の段階。

Source: DART, Financial Supervisory Service.
Limitations: 업무보고서 기준 유가증권 운용내역 · 외화유가증권 정의는 회사마다 다르다 · 마지막 열은 최신 분기보고서. Definitions: securities portfolio table (regulatory basis); latest column = most recent quarterly report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Securities portfolio on the business-report basis · the definition of foreign-currency securities differs by company · the last column is the latest quarterly report. Definitions: securities portfolio table (regulatory basis); latest column = most recent quarterly report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 業務報告書ベースの有価証券運用内訳 · 外貨建有価証券の定義は会社ごとに異なる · 最後の列は最新の四半期報告書。 Definitions: securities portfolio table (regulatory basis); latest column = most recent quarterly report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

포트폴리오PortfolioポートフォリオHyundai M&F: securities by type, fiscal year-ends + latest quarterHyundai M&F: securities by type, fiscal year-ends + latest quarterHyundai M&F:種類別の有価証券(各会計年度末 + 直近四半期)

Hyundai M&F — securities portfolioKRW trillions · Data as of 2026-06-30 · Created 2026-11-13010.020.030.040.0FY18FY19FY20FY21FY22FY23FY24FY2526H1KRW tnGovt & municipal bondsCorporate bondsForeign securitiesStocksOther4.86.19.123.65.77.39.325.66.97.69.827.37.88.410.128.88.07.810.128.07.36.810.828.79.37.011.832.211.56.912.334.610.27.511.433.0
종류FY23FY24FY2526H1
Govt & municipal bonds7.34조 (2.5%)9.29조 (2.3%)11.49조 (2.4%)10.25조 (2.8%)
Corporate bonds2.20조 (2.6%)2.53조 (3.0%)2.48조 (3.1%)2.34조 (2.9%)
Foreign securities6.77조 (3.3%)6.97조 (1.6%)6.93조 (-0.6%)7.50조 (1.4%)
Stocks1.59조 (27.7%)1.61조 (13.1%)1.38조 (23.1%)1.51조 (9.0%)
Other10.76조 (2.6%)11.79조 (3.3%)12.32조 (3.7%)11.37조 (3.4%)

칸 = 기말잔액(조원) (회사 기재 수익률/이익률 %)

TypeFY23FY24FY2526H1
Govt & municipal bondsKRW 7.34trn (2.5%)KRW 9.29trn (2.3%)KRW 11.49trn (2.4%)KRW 10.25trn (2.8%)
Corporate bondsKRW 2.20trn (2.6%)KRW 2.53trn (3.0%)KRW 2.48trn (3.1%)KRW 2.34trn (2.9%)
Foreign securitiesKRW 6.77trn (3.3%)KRW 6.97trn (1.6%)KRW 6.93trn (-0.6%)KRW 7.50trn (1.4%)
StocksKRW 1.59trn (27.7%)KRW 1.61trn (13.1%)KRW 1.38trn (23.1%)KRW 1.51trn (9.0%)
OtherKRW 10.76trn (2.6%)KRW 11.79trn (3.3%)KRW 12.32trn (3.7%)KRW 11.37trn (3.4%)

Cell = year-end balance (KRW trn) (company-reported yield / return %)

種類FY23FY24FY2526H1
国公債7.34兆ウォン(2.5%)9.29兆ウォン(2.3%)11.49兆ウォン(2.4%)10.25兆ウォン(2.8%)
社債2.20兆ウォン(2.6%)2.53兆ウォン(3.0%)2.48兆ウォン(3.1%)2.34兆ウォン(2.9%)
外貨建有価証券6.77兆ウォン(3.3%)6.97兆ウォン(1.6%)6.93兆ウォン(-0.6%)7.50兆ウォン(1.4%)
株式1.59兆ウォン(27.7%)1.61兆ウォン(13.1%)1.38兆ウォン(23.1%)1.51兆ウォン(9.0%)
その他10.76兆ウォン(2.6%)11.79兆ウォン(3.3%)12.32兆ウォン(3.7%)11.37兆ウォン(3.4%)

セル = 期末残高(兆ウォン)(会社開示の利回り/収益率 %)

현대해상 26H1: 유가증권 32.96조 중 국내채권(국공채+특수채+금융채+회사채) 12.59조 (38.2%), 외화유가증권 7.50조 (22.7%), 주식 1.51조 (4.6%), 수익증권 n/a (n/a).

Hyundai M&F 26H1: of securities KRW 32.96trn, domestic bonds (govt & municipal + special + financial + corporate) KRW 12.59trn (38.2%), foreign-currency securities KRW 7.50trn (22.7%), stocks KRW 1.51trn (4.6%), funds (beneficiary certificates) n/a (n/a).

Hyundai M&F 26H1:有価証券32.96兆ウォンのうち国内債券(国公債+特殊債+金融債+社債)12.59兆ウォン(38.2%)、外貨建有価証券7.50兆ウォン(22.7%)、株式1.51兆ウォン(4.6%)、受益証券n/a(n/a)。

⚠ 규율: 외화유가증권은 채권·주식이 섞인 회사 정의(현대해상은 해외 주식·출자금·펀드 제외). 신용등급·잔존만기는 주석 표에서 다음 단계.

⚠ Discipline: Foreign-currency securities follow each company's own definition and mix bonds and stocks (Hyundai M&F excludes overseas stocks, contributions and funds). Credit ratings and residual maturities come from the note tables in a later step.

⚠ 規律:外貨建有価証券は債券・株式が混じる各社の定義(Hyundai M&Fは海外株式・出資金・ファンドを除く)。信用格付・残存期間は注記の表で次の段階。

Source: DART, Financial Supervisory Service.
Limitations: 업무보고서 기준 유가증권 운용내역 · 외화유가증권 정의는 회사마다 다르다 · 마지막 열은 최신 분기보고서. Definitions: securities portfolio table (regulatory basis); latest column = most recent quarterly report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Securities portfolio on the business-report basis · the definition of foreign-currency securities differs by company · the last column is the latest quarterly report. Definitions: securities portfolio table (regulatory basis); latest column = most recent quarterly report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 業務報告書ベースの有価証券運用内訳 · 外貨建有価証券の定義は会社ごとに異なる · 最後の列は最新の四半期報告書。 Definitions: securities portfolio table (regulatory basis); latest column = most recent quarterly report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

포트폴리오PortfolioポートフォリオDB Insurance: securities by type, fiscal year-ends + latest quarterDB Insurance: securities by type, fiscal year-ends + latest quarterDB Insurance:種類別の有価証券(各会計年度末 + 直近四半期)

DB Insurance — securities portfolioKRW trillions · Data as of 2026-06-30 · Created 2026-11-13010.020.030.040.050.0FY18FY19FY20FY21FY22FY23FY24FY2526H1KRW tnGovt & municipal bondsSpecial bondsFinancial bondsCorporate bondsForeign securitiesFunds (beneficiary certificates)StocksOther4.76.45.421.74.07.96.524.43.97.47.825.54.28.48.227.54.66.78.125.86.13.77.49.231.66.34.98.49.734.75.64.610.013.438.97.63.99.010.64.039.3
종류FY23FY24FY2526H1
Govt & municipal bonds6.06조 (1.2%)6.35조 (3.1%)5.59조 (3.3%)7.64조 (2.0%)
Special bonds2.54조 (2.1%)2.09조 (2.6%)1.78조 (1.8%)1.61조 (2.1%)
Financial bonds1.02조 (3.7%)1.03조 (3.8%)0.81조 (4.5%)1.10조 (3.0%)
Corporate bonds3.74조 (3.3%)4.93조 (2.9%)4.61조 (3.1%)3.89조 (2.9%)
Foreign securities7.38조 (2.6%)8.40조 (1.1%)10.01조 (1.6%)8.96조 (2.0%)
Funds (beneficiary certificates)9.17조 (4.0%)9.67조 (4.6%)13.44조 (3.5%)10.64조 (7.7%)
Stocks1.24조 (3.2%)1.39조 (0.9%)1.47조 (4.9%)3.99조 (-1.0%)
Other0.44조 (11.4%)0.80조 (4.0%)1.22조 (4.2%)1.47조 (3.0%)

칸 = 기말잔액(조원) (회사 기재 수익률/이익률 %)

TypeFY23FY24FY2526H1
Govt & municipal bondsKRW 6.06trn (1.2%)KRW 6.35trn (3.1%)KRW 5.59trn (3.3%)KRW 7.64trn (2.0%)
Special bondsKRW 2.54trn (2.1%)KRW 2.09trn (2.6%)KRW 1.78trn (1.8%)KRW 1.61trn (2.1%)
Financial bondsKRW 1.02trn (3.7%)KRW 1.03trn (3.8%)KRW 0.81trn (4.5%)KRW 1.10trn (3.0%)
Corporate bondsKRW 3.74trn (3.3%)KRW 4.93trn (2.9%)KRW 4.61trn (3.1%)KRW 3.89trn (2.9%)
Foreign securitiesKRW 7.38trn (2.6%)KRW 8.40trn (1.1%)KRW 10.01trn (1.6%)KRW 8.96trn (2.0%)
Funds (beneficiary certificates)KRW 9.17trn (4.0%)KRW 9.67trn (4.6%)KRW 13.44trn (3.5%)KRW 10.64trn (7.7%)
StocksKRW 1.24trn (3.2%)KRW 1.39trn (0.9%)KRW 1.47trn (4.9%)KRW 3.99trn (-1.0%)
OtherKRW 0.44trn (11.4%)KRW 0.80trn (4.0%)KRW 1.22trn (4.2%)KRW 1.47trn (3.0%)

Cell = year-end balance (KRW trn) (company-reported yield / return %)

種類FY23FY24FY2526H1
国公債6.06兆ウォン(1.2%)6.35兆ウォン(3.1%)5.59兆ウォン(3.3%)7.64兆ウォン(2.0%)
特殊債2.54兆ウォン(2.1%)2.09兆ウォン(2.6%)1.78兆ウォン(1.8%)1.61兆ウォン(2.1%)
金融債1.02兆ウォン(3.7%)1.03兆ウォン(3.8%)0.81兆ウォン(4.5%)1.10兆ウォン(3.0%)
社債3.74兆ウォン(3.3%)4.93兆ウォン(2.9%)4.61兆ウォン(3.1%)3.89兆ウォン(2.9%)
外貨建有価証券7.38兆ウォン(2.6%)8.40兆ウォン(1.1%)10.01兆ウォン(1.6%)8.96兆ウォン(2.0%)
受益証券(ファンド)9.17兆ウォン(4.0%)9.67兆ウォン(4.6%)13.44兆ウォン(3.5%)10.64兆ウォン(7.7%)
株式1.24兆ウォン(3.2%)1.39兆ウォン(0.9%)1.47兆ウォン(4.9%)3.99兆ウォン(-1.0%)
その他0.44兆ウォン(11.4%)0.80兆ウォン(4.0%)1.22兆ウォン(4.2%)1.47兆ウォン(3.0%)

セル = 期末残高(兆ウォン)(会社開示の利回り/収益率 %)

DB손보 26H1: 유가증권 39.31조 중 국내채권(국공채+특수채+금융채+회사채) 14.25조 (36.2%), 외화유가증권 8.96조 (22.8%), 주식 3.99조 (10.1%), 수익증권 10.64조 (27.1%).

DB Insurance 26H1: of securities KRW 39.31trn, domestic bonds (govt & municipal + special + financial + corporate) KRW 14.25trn (36.2%), foreign-currency securities KRW 8.96trn (22.8%), stocks KRW 3.99trn (10.1%), funds (beneficiary certificates) KRW 10.64trn (27.1%).

DB Insurance 26H1:有価証券39.31兆ウォンのうち国内債券(国公債+特殊債+金融債+社債)14.25兆ウォン(36.2%)、外貨建有価証券8.96兆ウォン(22.8%)、株式3.99兆ウォン(10.1%)、受益証券10.64兆ウォン(27.1%)。

⚠ 규율: 외화유가증권은 채권·주식이 섞인 회사 정의(현대해상은 해외 주식·출자금·펀드 제외). 신용등급·잔존만기는 주석 표에서 다음 단계.

⚠ Discipline: Foreign-currency securities follow each company's own definition and mix bonds and stocks (Hyundai M&F excludes overseas stocks, contributions and funds). Credit ratings and residual maturities come from the note tables in a later step.

⚠ 規律:外貨建有価証券は債券・株式が混じる各社の定義(Hyundai M&Fは海外株式・出資金・ファンドを除く)。信用格付・残存期間は注記の表で次の段階。

Source: DART, Financial Supervisory Service.
Limitations: 업무보고서 기준 유가증권 운용내역 · 외화유가증권 정의는 회사마다 다르다 · 마지막 열은 최신 분기보고서. Definitions: securities portfolio table (regulatory basis); latest column = most recent quarterly report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Securities portfolio on the business-report basis · the definition of foreign-currency securities differs by company · the last column is the latest quarterly report. Definitions: securities portfolio table (regulatory basis); latest column = most recent quarterly report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 業務報告書ベースの有価証券運用内訳 · 外貨建有価証券の定義は会社ごとに異なる · 最後の列は最新の四半期報告書。 Definitions: securities portfolio table (regulatory basis); latest column = most recent quarterly report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

운용자산Invested assets運用資産Invested assets: loans / securities / cash and their income (latest report)Invested assets: loans / securities / cash and their income (latest report)運用資産:貸付金・有価証券・現預金とその収益(最新の報告書)

회사기간자산기말잔액구성비운용수익수익/잔액
삼성화재2026H1대출26.86조24.8%0.447조1.66%
유가증권78.85조72.7%0.872조1.11%
현예금2.05조1.9%0.008조0.39%
기타0.65조0.6%0.003조0.52%
합계108.41조100.0%1.330조1.23%
현대해상2026H1대출9.62조21.1%0.225조2.33%
유가증권32.96조72.3%0.497조1.51%
현예금1.80조3.9%0.013조0.73%
기타1.22조2.7%0.001조0.12%
합계45.59조100.0%0.736조1.61%
DB손보2026H1대출15.05조26.8%0.339조2.25%
유가증권39.31조69.9%0.712조1.81%
현예금0.57조1.0%0.010조1.74%
기타1.31조2.3%0.013조1.01%
합계56.24조100.0%1.074조1.91%
CompanyPeriodAssetYear-end balanceShareInvestment incomeIncome / balance
Samsung F&M2026H1LoansKRW 26.86trn24.8%KRW 0.447trn1.66%
SecuritiesKRW 78.85trn72.7%KRW 0.872trn1.11%
Cash & depositsKRW 2.05trn1.9%KRW 0.008trn0.39%
OtherKRW 0.65trn0.6%KRW 0.003trn0.52%
TotalKRW 108.41trn100.0%KRW 1.330trn1.23%
Hyundai M&F2026H1LoansKRW 9.62trn21.1%KRW 0.225trn2.33%
SecuritiesKRW 32.96trn72.3%KRW 0.497trn1.51%
Cash & depositsKRW 1.80trn3.9%KRW 0.013trn0.73%
OtherKRW 1.22trn2.7%KRW 0.001trn0.12%
TotalKRW 45.59trn100.0%KRW 0.736trn1.61%
DB Insurance2026H1LoansKRW 15.05trn26.8%KRW 0.339trn2.25%
SecuritiesKRW 39.31trn69.9%KRW 0.712trn1.81%
Cash & depositsKRW 0.57trn1.0%KRW 0.010trn1.74%
OtherKRW 1.31trn2.3%KRW 0.013trn1.01%
TotalKRW 56.24trn100.0%KRW 1.074trn1.91%
会社期間資産期末残高構成比運用収益収益/残高
Samsung F&M2026H1貸付金26.86兆ウォン24.8%0.447兆ウォン1.66%
有価証券78.85兆ウォン72.7%0.872兆ウォン1.11%
現預金2.05兆ウォン1.9%0.008兆ウォン0.39%
その他0.65兆ウォン0.6%0.003兆ウォン0.52%
合計108.41兆ウォン100.0%1.330兆ウォン1.23%
Hyundai M&F2026H1貸付金9.62兆ウォン21.1%0.225兆ウォン2.33%
有価証券32.96兆ウォン72.3%0.497兆ウォン1.51%
現預金1.80兆ウォン3.9%0.013兆ウォン0.73%
その他1.22兆ウォン2.7%0.001兆ウォン0.12%
合計45.59兆ウォン100.0%0.736兆ウォン1.61%
DB Insurance2026H1貸付金15.05兆ウォン26.8%0.339兆ウォン2.25%
有価証券39.31兆ウォン69.9%0.712兆ウォン1.81%
現預金0.57兆ウォン1.0%0.010兆ウォン1.74%
その他1.31兆ウォン2.3%0.013兆ウォン1.01%
合計56.24兆ウォン100.0%1.074兆ウォン1.91%

삼성화재 2026H1: 운용자산 108.41조 (자산운용률 96.4%) · 지급여력 282.8% (K-ICS) · 현대해상 2026H1: 운용자산 45.59조 (자산운용률 94.4%) · 지급여력 209.0% (K-ICS) · DB손보 2026H1: 운용자산 56.24조 (자산운용률 93.6%) · 지급여력 204.4% (K-ICS).

Samsung F&M 2026H1: invested assets KRW 108.41trn (invested-asset ratio 96.4%) · solvency ratio 282.8% (K-ICS) · Hyundai M&F 2026H1: invested assets KRW 45.59trn (invested-asset ratio 94.4%) · solvency ratio 209.0% (K-ICS) · DB Insurance 2026H1: invested assets KRW 56.24trn (invested-asset ratio 93.6%) · solvency ratio 204.4% (K-ICS).

Samsung F&M 2026H1:運用資産108.41兆ウォン(資産運用率96.4%)· 支払余力比率282.8%(K-ICS) · Hyundai M&F 2026H1:運用資産45.59兆ウォン(資産運用率94.4%)· 支払余力比率209.0%(K-ICS) · DB Insurance 2026H1:運用資産56.24兆ウォン(資産運用率93.6%)· 支払余力比率204.4%(K-ICS)。

⚠ 규율: '수익률' 열은 운용수익 ÷ 기말잔액(분기 보고서는 연환산 전 값) — 회사 기재 비율과 정의가 다르다.

⚠ Discipline: The 'Income / balance' column is investment income ÷ year-end balance (not annualised in quarterly reports) — defined differently from the company-reported ratio.

⚠ 規律:「収益/残高」列は運用収益 ÷ 期末残高(四半期報告書は年率換算前の値)— 会社開示の比率とは定義が異なる。

Source: DART, Financial Supervisory Service.
Limitations: 운용수익 ÷ 기말잔액(분기 보고서는 연환산 전) — 회사 기재 비율과 정의가 다르다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Investment income ÷ year-end balance (not annualised in quarterly reports) — the definition differs from the company-reported ratio.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 運用収益 ÷ 期末残高(四半期報告書は年率換算前)— 会社開示の比率とは定義が異なる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

06

사업 구조 — 합산비율·지급여력·CSMBusiness structure — combined ratio, solvency, CSM事業構造 — コンバインド・レシオ・支払余力・CSM

합산비율Combined ratioコンバインド・レシオLoss ratio + expense ratio = combined ratio (IFRS 4 era, company-level summary tables)Loss ratio + expense ratio = combined ratio (IFRS 4 era, company-level summary tables)損害率 + 事業費率 = コンバインド・レシオ(IFRS 4時代、会社単位の要約表)

Combined ratiopercent · Data as of 2022-12-31 · Created 2026-11-130%25%50%75%100%125%FY18FY19FY20FY21FY22%Samsung F&MHyundai M&FDB Insurance+103%+105%+104%+102%+102%+105%+108%+106%+104%+103%+103%+107%+104%+102%+101%

IFRS 17 로 넘어간 FY2023 부터는 이 표가 사라진다 — 대신 보험손익/보험수익(마진)으로 본다: 삼성화재 FY2025 8.0% · 현대해상 FY2025 5.7% · DB손보 FY2025 7.0%.

From FY2023, after the move to IFRS 17, this table disappears — the insurance result / insurance revenue (margin) is used instead: Samsung F&M FY2025 8.0% · Hyundai M&F FY2025 5.7% · DB Insurance FY2025 7.0%.

IFRS 17に移行したFY2023からこの表はなくなる — 代わりに保険損益/保険収益(マージン)で見る:Samsung F&M FY2025 8.0% · Hyundai M&F FY2025 5.7% · DB Insurance FY2025 7.0%。

⚠ 규율: 현대해상은 회사 요약표 대신 종목별 표의 합계 손해율 + 사업비율.

⚠ Discipline: For Hyundai M&F, the total loss ratio + expense ratio from the by-line tables instead of the company summary table.

⚠ 規律:Hyundai M&Fは会社の要約表の代わりに種目別表の合計損害率 + 事業費率。

Source: DART, Financial Supervisory Service.
Limitations: IFRS 4 시대(FY2022 까지) 업무보고서 요약표 · 현대해상은 종목별 표의 합계 손해율 + 사업비율 · FY2023 부터 이 표가 없다. Definitions: loss ratio + net expense ratio; regulatory business-report basis; >100 = underwriting loss before investment income.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Business-report summary tables from the IFRS 4 era (through FY2022) · for Hyundai M&F, total loss ratio + expense ratio from the by-line tables · this table no longer exists from FY2023. Definitions: loss ratio + net expense ratio; regulatory business-report basis; >100 = underwriting loss before investment income.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: IFRS 4時代(FY2022まで)の業務報告書の要約表 · Hyundai M&Fは種目別表の合計損害率 + 事業費率 · FY2023からこの表はない。 Definitions: loss ratio + net expense ratio; regulatory business-report basis; >100 = underwriting loss before investment income.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지급여력Solvency支払余力Solvency ratio: RBC through FY2022, K-ICS from 2023Solvency ratio: RBC through FY2022, K-ICS from 2023支払余力比率:FY2022まではRBC、2023年からK-ICS

Solvency ratio (RBC → K-ICS)percent · Data as of 2026-06-30 · Created 2026-11-130%100%200%300%400%18FY19Q320H121Q121FY22Q323H124Q124FY25Q326H1%Samsung F&MHyundai M&FDB Insuranceminimum 100%+283%+209%+204%

삼성화재 2026H1 282.8% (K-ICS) · 현대해상 2026H1 209.0% (K-ICS) · DB손보 2026H1 204.4% (K-ICS).

Samsung F&M 2026H1 282.8% (K-ICS) · Hyundai M&F 2026H1 209.0% (K-ICS) · DB Insurance 2026H1 204.4% (K-ICS).

Samsung F&M 2026H1 282.8%(K-ICS) · Hyundai M&F 2026H1 209.0%(K-ICS) · DB Insurance 2026H1 204.4%(K-ICS)。

⚠ 규율: K-ICS 경과조치 적용 여부는 회사·시점마다 다르다(원문 주석). 선이 끊긴 곳 = 그 분기 보고서에서 지급여력 표를 읽지 못한 기간(채우지 않음): 삼성화재 없음; 현대해상 19H1, 21H1; DB손보 19Q1, 23Q1.

⚠ Discipline: Whether K-ICS transitional measures apply differs by company and date (notes to the filings). A break in a line = a period whose quarterly report's solvency table could not be read (not filled): Samsung F&M none; Hyundai M&F 19H1, 21H1; DB Insurance 19Q1, 23Q1.

⚠ 規律:K-ICSの経過措置の適用有無は会社・時点ごとに異なる(原文注記)。線が途切れた所 = その四半期報告書で支払余力の表を読めなかった期間(補完しない):Samsung F&M なし; Hyundai M&F 19H1, 21H1; DB Insurance 19Q1, 23Q1。

Source: DART, Financial Supervisory Service.
Limitations: RBC(~FY2022)와 K-ICS(2023~)는 체계가 달라 수준을 잇지 않는다 · 경과조치 적용은 회사·시점마다 다르다 · 표를 읽지 못한 분기는 비워 뒀다(채우지 않음). Definitions: regulatory minimum 100; the regime changes at 2023 — the two levels are not comparable.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: RBC (to FY2022) and K-ICS (from 2023) are different regimes, so the levels are not joined · transitional measures differ by company and date · quarters whose table could not be read are left blank (not filled). Definitions: regulatory minimum 100; the regime changes at 2023 — the two levels are not comparable.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: RBC(〜FY2022)とK-ICS(2023〜)は制度が異なるため水準をつなげない · 経過措置の適用は会社・時点ごとに異なる · 表を読めなかった四半期は空欄のまま(補完しない)。 Definitions: regulatory minimum 100; the regime changes at 2023 — the two levels are not comparable.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

종목Lines種目Samsung F&M: insurance revenue and service expense by line (IFRS 17, 2026H1)Samsung F&M: insurance revenue and service expense by line (IFRS 17, 2026H1)Samsung F&M:種目別の保険収益と保険サービス費用(IFRS 17、2026H1)

Samsung F&M — by line of businessKRW trillions · Data as of 2026-06-30 · Created 2026-11-1302.04.06.0Long-termAutoOverseasPackageLiabilityOtherMarinePersonal acc.AnnuityEngineeringKRW tnInsurance revenueInsurance service expense

longterm 5.20조 (비용 4.27조) · auto 2.74조 (비용 2.70조) · overseas 0.44조 (비용 0.21조) · 종합 0.28조 (비용 0.16조) · 책임 0.21조 (비용 0.16조) · other 0.13조 (비용 0.09조).

Long-term KRW 5.20trn (expense KRW 4.27trn) · Auto KRW 2.74trn (expense KRW 2.70trn) · Overseas KRW 0.44trn (expense KRW 0.21trn) · Package KRW 0.28trn (expense KRW 0.16trn) · Liability KRW 0.21trn (expense KRW 0.16trn) · Other KRW 0.13trn (expense KRW 0.09trn).

長期 5.20兆ウォン(費用4.27兆ウォン) · 自動車 2.74兆ウォン(費用2.70兆ウォン) · 海外 0.44兆ウォン(費用0.21兆ウォン) · 総合 0.28兆ウォン(費用0.16兆ウォン) · 賠償責任 0.21兆ウォン(費用0.16兆ウォン) · その他 0.13兆ウォン(費用0.09兆ウォン)。

Source: DART, Financial Supervisory Service.
Limitations: IFRS 17 연결 종목별 보험수익·보험서비스비용 · 일반보험 세부 종목은 회사 분류 그대로. Definitions: IFRS 17; general-insurance sub-lines: package, liability, personal accident, engineering.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: IFRS 17 consolidated insurance revenue and insurance service expense by line · general-insurance sub-lines follow the company's own classification. Definitions: IFRS 17; general-insurance sub-lines: package, liability, personal accident, engineering.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: IFRS 17連結の種目別保険収益・保険サービス費用 · 一般保険の細目は会社の分類どおり。 Definitions: IFRS 17; general-insurance sub-lines: package, liability, personal accident, engineering.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

종목Lines種目Hyundai M&F: insurance revenue and service expense by line (IFRS 17, 2026H1)Hyundai M&F: insurance revenue and service expense by line (IFRS 17, 2026H1)Hyundai M&F:種目別の保険収益と保険サービス費用(IFRS 17、2026H1)

Hyundai M&F — by line of businessKRW trillions · Data as of 2026-06-30 · Created 2026-11-1301.02.03.04.05.0Long-termAutoOverseasMarinePackageLiabilityPersonal acc.OtherEngineeringAnnuityKRW tnInsurance revenueInsurance service expense

longterm 4.14조 (비용 3.50조) · auto 1.89조 (비용 1.88조) · overseas 0.30조 (비용 0.19조) · marine 0.20조 (비용 0.04조) · 종합 0.20조 (비용 0.07조) · 책임 0.16조 (비용 0.10조).

Long-term KRW 4.14trn (expense KRW 3.50trn) · Auto KRW 1.89trn (expense KRW 1.88trn) · Overseas KRW 0.30trn (expense KRW 0.19trn) · Marine KRW 0.20trn (expense KRW 0.04trn) · Package KRW 0.20trn (expense KRW 0.07trn) · Liability KRW 0.16trn (expense KRW 0.10trn).

長期 4.14兆ウォン(費用3.50兆ウォン) · 自動車 1.89兆ウォン(費用1.88兆ウォン) · 海外 0.30兆ウォン(費用0.19兆ウォン) · 海上 0.20兆ウォン(費用0.04兆ウォン) · 総合 0.20兆ウォン(費用0.07兆ウォン) · 賠償責任 0.16兆ウォン(費用0.10兆ウォン)。

Source: DART, Financial Supervisory Service.
Limitations: IFRS 17 연결 종목별 보험수익·보험서비스비용 · 일반보험 세부 종목은 회사 분류 그대로. Definitions: IFRS 17; general-insurance sub-lines: package, liability, personal accident, engineering.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: IFRS 17 consolidated insurance revenue and insurance service expense by line · general-insurance sub-lines follow the company's own classification. Definitions: IFRS 17; general-insurance sub-lines: package, liability, personal accident, engineering.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: IFRS 17連結の種目別保険収益・保険サービス費用 · 一般保険の細目は会社の分類どおり。 Definitions: IFRS 17; general-insurance sub-lines: package, liability, personal accident, engineering.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

종목Lines種目DB Insurance: insurance revenue and service expense by line (IFRS 17, 2026H1)DB Insurance: insurance revenue and service expense by line (IFRS 17, 2026H1)DB Insurance:種目別の保険収益と保険サービス費用(IFRS 17、2026H1)

DB Insurance — by line of businessKRW trillions · Data as of 2026-06-30 · Created 2026-11-1301.02.03.04.05.0Long-termAutoOverseasLT otherPackagePersonal acc.LiabilityMarineOtherEngineeringKRW tnInsurance revenueInsurance service expense

longterm 4.31조 (비용 3.58조) · auto 2.05조 (비용 2.02조) · overseas 0.47조 (비용 0.31조) · longterm_other 0.33조 (비용 0.24조) · 종합 0.22조 (비용 0.23조) · 상해 0.16조 (비용 0.16조).

Long-term KRW 4.31trn (expense KRW 3.58trn) · Auto KRW 2.05trn (expense KRW 2.02trn) · Overseas KRW 0.47trn (expense KRW 0.31trn) · LT other KRW 0.33trn (expense KRW 0.24trn) · Package KRW 0.22trn (expense KRW 0.23trn) · Personal acc. KRW 0.16trn (expense KRW 0.16trn).

長期 4.31兆ウォン(費用3.58兆ウォン) · 自動車 2.05兆ウォン(費用2.02兆ウォン) · 海外 0.47兆ウォン(費用0.31兆ウォン) · 長期その他 0.33兆ウォン(費用0.24兆ウォン) · 総合 0.22兆ウォン(費用0.23兆ウォン) · 傷害 0.16兆ウォン(費用0.16兆ウォン)。

Source: DART, Financial Supervisory Service.
Limitations: IFRS 17 연결 종목별 보험수익·보험서비스비용 · 일반보험 세부 종목은 회사 분류 그대로. Definitions: IFRS 17; general-insurance sub-lines: package, liability, personal accident, engineering.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: IFRS 17 consolidated insurance revenue and insurance service expense by line · general-insurance sub-lines follow the company's own classification. Definitions: IFRS 17; general-insurance sub-lines: package, liability, personal accident, engineering.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: IFRS 17連結の種目別保険収益・保険サービス費用 · 一般保険の細目は会社の分類どおり。 Definitions: IFRS 17; general-insurance sub-lines: package, liability, personal accident, engineering.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

07

도쿄해상 — 배당·이익수익률을 JGB·UST 10Y 옆에 (EDINET 有報 Raw Data)Tokio Marine — dividend and earnings yields next to JGB and UST 10Y (EDINET annual securities report Raw Data)Tokio Marine — 配当利回り・益回りをJGB・UST 10年と並べる(EDINET 有報のRaw Data)

한 표One table一覧表Tokio Marine: dividend and earnings yield next to JGB and UST 10Y (fiscal year-end, March)Tokio Marine: dividend and earnings yield next to JGB and UST 10Y (fiscal year-end, March)Tokio Marine:配当利回りと益回りをJGB・UST 10年と並べる(会計年度末、3月)

FYDPS(분할 기준, 엔)기말주가(역산)배당수익률JGB10YUST10YDY−JGBDY−USTEPS 일본기준EY 일본기준EPS IFRSEY IFRS배당성향(일본기준)TSR 5년(회사 산출)
FY201883.3 (특별 23.3)1,7874.66%-0.082%2.41%+4.74%p+2.25%p127.77.14%——65.3%118
FY201975.0 (특별 11.7)1,6504.55%0.031%0.70%+4.51%p+3.85%p123.27.47%——60.9%96
FY202078.3 (특별 11.7)1,7554.46%0.104%1.74%+4.36%p+2.72%p77.44.41%——101.2%111
FY202185.02,3763.58%0.218%2.32%+3.36%p+1.26%p204.58.61%——41.6%141
FY2022100.02,5463.93%0.389%3.48%+3.54%p+0.45%p186.47.32%——53.6%157
FY2023123.04,7042.61%0.750%4.20%+1.86%p-1.59%p351.67.47%——35.0%298
FY2024172.05,7363.00%1.497%4.23%+1.50%p-1.23%p542.29.45%231.44.03%31.7%375
FY2025218.07,3092.98%2.366%4.30%+0.62%p-1.32%p515.57.05%279.43.82%42.3%493
FYDPS (split-adjusted, JPY)Year-end price (implied)Dividend yieldJGB10YUST10YDY−JGBDY−USTEPS J-GAAPEY J-GAAPEPS IFRSEY IFRSPayout (J-GAAP)5-year TSR (company)
FY201883.3 (special 23.3)1,7874.66%-0.082%2.41%+4.74pp+2.25pp127.77.14%——65.3%118
FY201975.0 (special 11.7)1,6504.55%0.031%0.70%+4.51pp+3.85pp123.27.47%——60.9%96
FY202078.3 (special 11.7)1,7554.46%0.104%1.74%+4.36pp+2.72pp77.44.41%——101.2%111
FY202185.02,3763.58%0.218%2.32%+3.36pp+1.26pp204.58.61%——41.6%141
FY2022100.02,5463.93%0.389%3.48%+3.54pp+0.45pp186.47.32%——53.6%157
FY2023123.04,7042.61%0.750%4.20%+1.86pp-1.59pp351.67.47%——35.0%298
FY2024172.05,7363.00%1.497%4.23%+1.50pp-1.23pp542.29.45%231.44.03%31.7%375
FY2025218.07,3092.98%2.366%4.30%+0.62pp-1.32pp515.57.05%279.43.82%42.3%493
FYDPS(分割基準、円)期末株価(逆算)配当利回りJGB10YUST10YDY−JGBDY−USTEPS 日本基準益回り 日本基準EPS IFRS益回り IFRS配当性向(日本基準)5年TSR(会社算出)
FY201883.3(特別23.3)1,7874.66%-0.082%2.41%+4.74pt+2.25pt127.77.14%——65.3%118
FY201975.0(特別11.7)1,6504.55%0.031%0.70%+4.51pt+3.85pt123.27.47%——60.9%96
FY202078.3(特別11.7)1,7554.46%0.104%1.74%+4.36pt+2.72pt77.44.41%——101.2%111
FY202185.02,3763.58%0.218%2.32%+3.36pt+1.26pt204.58.61%——41.6%141
FY2022100.02,5463.93%0.389%3.48%+3.54pt+0.45pt186.47.32%——53.6%157
FY2023123.04,7042.61%0.750%4.20%+1.86pt-1.59pt351.67.47%——35.0%298
FY2024172.05,7363.00%1.497%4.23%+1.50pt-1.23pt542.29.45%231.44.03%31.7%375
FY2025218.07,3092.98%2.366%4.30%+0.62pt-1.32pt515.57.05%279.43.82%42.3%493

주가는 회사가 有報에 적은 EPS × PER로 역산한 회계연도말(3월말) 주가입니다. 연결 일본기준·提出会社(지주 단체)·연결 IFRS 세 경로로 각각 계산했고 서로 1% 안에서 맞습니다(FY2025 7,309엔). DPS는 2022-10-01 1:3 분할 기준으로 맞췄습니다(원문 DPS는 분할 전 연도를 소급하지 않음 — 각주). 국채는 같은 날 10년물(재무성·FRED Raw Data).

The price is the fiscal year-end (March-end) price backed out from the EPS × PER the company reports in its annual securities report. It was calculated three ways — consolidated J-GAAP, the filing company (holding company, single entity) and consolidated IFRS — and they agree within 1% (FY2025 JPY 7,309). DPS is adjusted to the 1:3 split of 2022-10-01 (the reported DPS does not restate pre-split years — footnote). Government bonds are 10-year yields on the same day (MOF · FRED Raw Data).

株価は会社が有報に記載したEPS × PERから逆算した会計年度末(3月末)の株価である。連結日本基準・提出会社(持株会社単体)・連結IFRSの3経路でそれぞれ計算し、互いに1%以内で一致する(FY2025 7,309円)。DPSは2022年10月1日の1:3分割基準に合わせた(原文のDPSは分割前の年度を遡及しない — 脚注)。国債は同じ日の10年物(財務省・FREDのRaw Data)。

⚠ 규율: FY2025 일본기준 EPS·순이익은 有報 5년 표의 '참고' 값으로 감사를 받지 않았습니다(원문 각주5). FY2022 원문 DPS 200엔은 분할 전 중간 150엔 + 분할 후 기말 50엔의 단순합 → 분할 기준 100엔. FY2018~20의 특별배당(資本水準調整のための一時的な配当)은 괄호.

⚠ Discipline: FY2025 J-GAAP EPS and net income are 'reference' values in the annual report's five-year table and are unaudited (original footnote 5). The FY2022 reported DPS of JPY 200 is a simple sum of a pre-split interim JPY 150 and a post-split year-end JPY 50 → JPY 100 on a post-split basis. The FY2018–20 special dividends (one-off dividends for capital-level adjustment) are in brackets.

⚠ 規律:FY2025の日本基準のEPS・純利益は有報の5年表の「参考」値で、監査を受けていない(原文の脚注5)。FY2022の原文DPS 200円は分割前の中間150円 + 分割後の期末50円の単純合計 → 分割基準で100円。FY2018〜20の特別配当(資本水準調整のための一時的な配当)は括弧内。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 주가 = 有報의 EPS × PER 역산(3월말) · DPS 는 2022-10 주식분할 기준으로 소급(우리 계산) · FY2025 일본기준 EPS 는 미감사 참고치 · 5년 TSR 은 회사 산출(배당 재투자).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Price = backed out from EPS × PER in the annual securities report (March-end) · DPS restated to the 2022-10 share split (our calculation) · FY2025 J-GAAP EPS is an unaudited reference value · the 5-year TSR is company-calculated (dividends reinvested).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 株価 = 有報のEPS × PERから逆算(3月末)· DPSは2022年10月の株式分割基準に遡及(当サイト計算)· FY2025の日本基準EPSは未監査の参考値 · 5年TSRは会社算出(配当再投資)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

수익률Yield利回りDividend yield and earnings yield vs. JGB 10Y and UST 10YDividend yield and earnings yield vs. JGB 10Y and UST 10Y配当利回りと益回り vs JGB 10年・UST 10年

Tokio Marine — yields at fiscal year-endpercent · Data as of 2026-03-31 · Created 2026-11-13-2.5%0.0%2.5%5.0%7.5%10.0%12.5%FY18FY19FY20FY21FY22FY23FY24FY25%Dividend yieldEarnings yield (J-GAAP EPS)Earnings yield (IFRS EPS)JGB 10YUST 10Y+7.1%+4.3%+3.8%+3.0%+2.4%

FY2025: 배당수익률 2.98% · JGB10Y 2.37% · UST10Y 4.30% — 배당이 JGB 보다 +0.62%p 높고 UST 보다 +1.32%p 낮습니다. 이익수익률은 일본기준 7.05% vs IFRS 3.82% — 같은 해, 같은 주가인데 회계기준만 바꿔도 이익수익률이 3.2p 벌어집니다.

FY2025: dividend yield 2.98% · JGB10Y 2.37% · UST10Y 4.30% — the dividend is +0.62pp above JGBs and +1.32pp below USTs. Earnings yield J-GAAP 7.05% vs IFRS 3.82% — same year, same share price, yet switching the accounting standard alone moves the earnings yield by 3.2pp.

FY2025:配当利回り2.98% · JGB10Y 2.37% · UST10Y 4.30% — 配当はJGBより+0.62pt高く、USTより+1.32pt低い。益回りは日本基準7.05% vs IFRS 3.82% — 同じ年・同じ株価でも会計基準を変えるだけで益回りが3.2pt開く。

⚠ 규율: IFRS 선은 FY2024(비교 재작성)·FY2025 두 점뿐입니다. 일본기준 순이익에는 정책주식 매각익이 들어가고 IFRS 순이익에는 안 들어갑니다(아래 '정책보유주식' 절).

⚠ Discipline: The IFRS line has only two points, FY2024 (restated comparative) and FY2025. J-GAAP net income includes gains on selling policy stocks; IFRS net income does not (see the 'policy shareholdings' section below).

⚠ 規律:IFRSの線はFY2024(比較の再表示)とFY2025の2点のみ。日本基準の純利益には政策株式の売却益が入り、IFRSの純利益には入らない(下の「政策保有株式」の節)。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 주가는 역산값 · IFRS 선은 FY2024(재작성)·FY2025 두 점뿐 · 국채는 3월 마지막 영업일 10년물. Definitions: price = EPS x PER from the annual report; sovereign = 10Y yield on the last business day of March.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: The price is a backed-out value · the IFRS line has only two points, FY2024 (restated) and FY2025 · government bonds are 10-year yields on the last business day of March. Definitions: price = EPS x PER from the annual report; sovereign = 10Y yield on the last business day of March.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 株価は逆算値 · IFRSの線はFY2024(再表示)とFY2025の2点のみ · 国債は3月最終営業日の10年物。 Definitions: price = EPS x PER from the annual report; sovereign = 10Y yield on the last business day of March.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

스프레드SpreadスプレッドDividend yield minus 10Y sovereign yieldDividend yield minus 10Y sovereign yield配当利回り − 10年国債利回り

Tokio Marine — dividend yield spread over sovereignspercentage points · Data as of 2026-03-31 · Created 2026-11-13-2%0%2%4%6%FY18FY19FY20FY21FY22FY23FY24FY25%pDY − JGB 10YDY − UST 10Y+4.7%+4.5%+4.4%+3.4%+3.5%+1.9%+1.5%+0.6%+2.3%+3.8%+2.7%+1.3%+0.4%-1.6%-1.2%-1.3%

DY−JGB: FY18 +4.74, FY19 +4.51, FY20 +4.36, FY21 +3.36, FY22 +3.54, FY23 +1.86, FY24 +1.50, FY25 +0.62. DY−UST: FY18 +2.25, FY19 +3.85, FY20 +2.72, FY21 +1.26, FY22 +0.45, FY23 -1.59, FY24 -1.23, FY25 -1.32.

DY−JGB: FY18 +4.74, FY19 +4.51, FY20 +4.36, FY21 +3.36, FY22 +3.54, FY23 +1.86, FY24 +1.50, FY25 +0.62. DY−UST: FY18 +2.25, FY19 +3.85, FY20 +2.72, FY21 +1.26, FY22 +0.45, FY23 -1.59, FY24 -1.23, FY25 -1.32.

DY−JGB:FY18 +4.74, FY19 +4.51, FY20 +4.36, FY21 +3.36, FY22 +3.54, FY23 +1.86, FY24 +1.50, FY25 +0.62。DY−UST:FY18 +2.25, FY19 +3.85, FY20 +2.72, FY21 +1.26, FY22 +0.45, FY23 -1.59, FY24 -1.23, FY25 -1.32。

⚠ 규율: JGB 10년물은 FY2018 말 −0.08%에서 FY2025 말 2.37%로 올랐습니다. 배당수익률의 JGB 대비 우위는 +4.74%p에서 +0.62%p로 줄었습니다.

⚠ Discipline: The 10-year JGB yield rose from −0.08% at end-FY2018 to 2.37% at end-FY2025. The dividend yield's lead over JGBs narrowed from +4.74pp to +0.62pp.

⚠ 規律:JGB10年物はFY2018末の−0.08%からFY2025末の2.37%に上昇した。配当利回りのJGBに対する優位は+4.74ptから+0.62ptに縮小した。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 주가는 역산값 · 국채는 3월 마지막 영업일 10년물. Definitions: positive = the stock's cash yield beats the bond.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: The price is a backed-out value · government bonds are 10-year yields on the last business day of March. Definitions: positive = the stock's cash yield beats the bond.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 株価は逆算値 · 国債は3月最終営業日の10年物。 Definitions: positive = the stock's cash yield beats the bond.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

4사Four insurers4社Four P&C insurers: dividend yield minus UST 10YFour P&C insurers: dividend yield minus UST 10Y損保4社:配当利回り − UST 10年

Dividend yield − UST 10Y: Korea three vs. Tokio Marinepercentage points · Data as of 2026-03-31 · Created 2026-11-13-2%0%2%4%6%FY18FY19FY20FY21FY22FY23FY24FY25%pSamsung F&MHyundai M&FDB InsuranceTokio Marine

삼성화재 FY2025 -0.28%p · 현대해상 FY2023 +1.92%p · DB손보 FY2025 +1.22%p · 도쿄해상 FY2025 -1.32%p. 사용자 틀(UST 대비 배당수익률)로 보면 네 회사 모두 같은 질문에 답해야 합니다.

Samsung F&M FY2025 -0.28pp · Hyundai M&F FY2023 +1.92pp · DB Insurance FY2025 +1.22pp · Tokio Marine FY2025 -1.32pp. In the user's frame (dividend yield vs USTs), all four companies have to answer the same question.

Samsung F&M FY2025 -0.28pt · Hyundai M&F FY2023 +1.92pt · DB Insurance FY2025 +1.22pt · Tokio Marine FY2025 -1.32pt。利用者の枠組み(UST対比の配当利回り)で見ると、4社とも同じ問いに答える必要がある。

⚠ 규율: 기준일이 다릅니다: 한국 3사는 12월말(회사 기재 배당수익률, 기준가 = 배당기준일 전 1주일 평균), 도쿄해상은 3월말(DPS ÷ EPS×PER 역산 주가). 같은 FY 라벨이라도 3개월 어긋납니다. 현대해상 FY2024~25 는 배당 미실시로 빈칸.

⚠ Discipline: Reference dates differ: the three Korean insurers at end-December (company-reported dividend yield, reference price = one-week average before the record date), Tokio Marine at end-March (DPS ÷ price backed out from EPS × PER). Even with the same FY label they are three months apart. Hyundai M&F FY2024–25 are blank because no dividend was paid.

⚠ 規律:基準日が異なる:韓国3社は12月末(会社開示の配当利回り、基準株価 = 配当基準日前1週間の平均)、Tokio Marineは3月末(DPS ÷ EPS×PERから逆算した株価)。同じFYラベルでも3カ月ずれる。Hyundai M&FのFY2024〜25は無配のため空欄。

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 기준일이 다르다 — 한국 3사 12월말(회사 기재 수익률), 도쿄해상 3월말(DPS ÷ 역산 주가) · 현대해상 FY2024~25 무배당은 빈칸. Definitions: Korea = December year-end, company-reported yield; Tokio Marine = March year-end, DPS ÷ implied price.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Reference dates differ — the three Korean insurers at end-December (company-reported yield), Tokio Marine at end-March (DPS ÷ implied price) · Hyundai M&F's no-dividend FY2024–25 are blank. Definitions: Korea = December year-end, company-reported yield; Tokio Marine = March year-end, DPS ÷ implied price.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 基準日が異なる — 韓国3社は12月末(会社開示の利回り)、Tokio Marineは3月末(DPS ÷ 逆算株価)· Hyundai M&FのFY2024〜25の無配は空欄。 Definitions: Korea = December year-end, company-reported yield; Tokio Marine = March year-end, DPS ÷ implied price.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

배당Dividend配当Dividend per share (split-adjusted): ordinary vs. one-off capital-level dividendDividend per share (split-adjusted): ordinary vs. one-off capital-level dividend1株当たり配当(分割調整後):普通配当 vs 資本水準調整の一時的な配当

Tokio Marine — DPS on a post-split basisJPY per share · Data as of 2026-03-31 · Created 2026-11-13050.0100150200250FY18FY19FY20FY21FY22FY23FY24FY25JPYOrdinaryOne-off (capital-level adjustment)60.023.383.363.375.066.778.385.085.0100100123123172172218218

분할 기준 DPS: FY18 83.3 → FY19 75.0 → FY20 78.3 → FY21 85.0 → FY22 100.0 → FY23 123.0 → FY24 172.0 → FY25 218.0. 각주의 '분할이 없었다면' DPS(분할 전 기준)는 FY2025 654엔 = 218×3 으로 검증했습니다.

Split-adjusted DPS: FY18 83.3 → FY19 75.0 → FY20 78.3 → FY21 85.0 → FY22 100.0 → FY23 123.0 → FY24 172.0 → FY25 218.0. The footnote's 'had there been no split' DPS (pre-split basis) was checked as FY2025 JPY 654 = 218 × 3.

分割基準のDPS:FY18 83.3 → FY19 75.0 → FY20 78.3 → FY21 85.0 → FY22 100.0 → FY23 123.0 → FY24 172.0 → FY25 218.0。脚注の「分割がなかった場合」のDPS(分割前基準)はFY2025で654円 = 218×3として検証した。

⚠ 규율: FY2018~20 특별배당은 원문이 '資本水準調整のための一時的な配当'(자본 수준 조정용 일시 배당)이라 적은 금액(분할 전 70·35·35엔). 배당정책 원문: 「配当を基本として株主還元の充実に努める」.

⚠ Discipline: The FY2018–20 special dividends are the amounts the filing calls 'one-off dividends for capital-level adjustment' (pre-split JPY 70 · 35 · 35). Dividend policy, in the company's words: to enhance shareholder returns with dividends as the basis.

⚠ 規律:FY2018〜20の特別配当は原文が「資本水準調整のための一時的な配当」と記した金額(分割前70・35・35円)。配当政策の原文:「配当を基本として株主還元の充実に努める」。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 분할 기준 소급은 우리 계산(원문 DPS 는 분할 전 연도를 소급하지 않음) · 특별배당 = 원문 '資本水準調整のための一時的な配当'. Definitions: 1:3 split on 2022-10-01 applied to earlier years; source footnotes give the pre-split basis.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: The split restatement is our calculation (the reported DPS does not restate pre-split years) · special dividend = what the filing calls a one-off dividend for capital-level adjustment. Definitions: 1:3 split on 2022-10-01 applied to earlier years; source footnotes give the pre-split basis.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 分割基準への遡及は当サイト計算(原文のDPSは分割前の年度を遡及しない)· 特別配当 = 原文「資本水準調整のための一時的な配当」。 Definitions: 1:3 split on 2022-10-01 applied to earlier years; source footnotes give the pre-split basis.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

환원Returns還元Cash returned to shareholders vs. net incomeCash returned to shareholders vs. net income株主への現金還元 vs 純利益

Tokio Marine — dividends and buybacks (cash flow) vs. net incomeJPY trillions · Data as of 2026-03-31 · Created 2026-11-1300.250.50.751.01.2FY18FY19FY20FY21FY22FY23FY24FY25JPY tnDividends paidShare buybacksNet income, J-GAAPNet income, IFRS

FY18 배당 0.17조엔 + 자사주 0.10조엔 = 0.27조엔 (일본기준 순이익 0.27조엔) · FY22 배당 0.19조엔 + 자사주 0.11조엔 = 0.30조엔 (일본기준 순이익 0.37조엔) · FY24 배당 0.28조엔 + 자사주 0.27조엔 = 0.55조엔 (일본기준 순이익 1.06조엔) · FY25 배당 0.38조엔 + 자사주 0.25조엔 = 0.63조엔 (일본기준 순이익 0.98조엔).

FY18 dividends JPY 0.17trn + buybacks JPY 0.10trn = JPY 0.27trn (J-GAAP net income JPY 0.27trn) · FY22 dividends JPY 0.19trn + buybacks JPY 0.11trn = JPY 0.30trn (J-GAAP net income JPY 0.37trn) · FY24 dividends JPY 0.28trn + buybacks JPY 0.27trn = JPY 0.55trn (J-GAAP net income JPY 1.06trn) · FY25 dividends JPY 0.38trn + buybacks JPY 0.25trn = JPY 0.63trn (J-GAAP net income JPY 0.98trn).

FY18 配当0.17兆円 + 自己株式取得0.10兆円 = 0.27兆円(日本基準の純利益0.27兆円) · FY22 配当0.19兆円 + 自己株式取得0.11兆円 = 0.30兆円(日本基準の純利益0.37兆円) · FY24 配当0.28兆円 + 自己株式取得0.27兆円 = 0.55兆円(日本基準の純利益1.06兆円) · FY25 配当0.38兆円 + 自己株式取得0.25兆円 = 0.63兆円(日本基準の純利益0.98兆円)。

⚠ 규율: FY2026 은 후발사건·ESR 문단에서 자사주 매입 연 4,000억엔 방침(Berkshire 몫 2,874억엔 별도)을 밝혔습니다 — 아래 '지분 구조'.

⚠ Discipline: For FY2026, the subsequent-event note and the ESR paragraph set out a buyback policy of JPY 400.0bn a year (JPY 287.4bn for Berkshire's portion separately) — see 'Ownership' below.

⚠ 規律:FY2026は後発事象・ESRの段落で、自己株式取得を年4,000億円とする方針(Berkshire分の2,874億円は別)を示した — 下の「株主構成」。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 현금흐름표 기준(지급 시점) · FY2025 는 IFRS 재무제표 · FY2025 일본기준 순이익은 미감사. Definitions: cash-flow statement; FY2025 = IFRS statements; FY2025 J-GAAP net income unaudited.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Cash-flow statement basis (when paid) · FY2025 uses the IFRS statements · FY2025 J-GAAP net income is unaudited. Definitions: cash-flow statement; FY2025 = IFRS statements; FY2025 J-GAAP net income unaudited.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: キャッシュ・フロー計算書ベース(支払時点)· FY2025はIFRS財務諸表 · FY2025の日本基準純利益は未監査。 Definitions: cash-flow statement; FY2025 = IFRS statements; FY2025 J-GAAP net income unaudited.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

TSRFive-year total shareholder return vs. the Nikkei 225 (price) over the same five yearsFive-year total shareholder return vs. the Nikkei 225 (price) over the same five years5年TSR vs 同じ5年間の日経225(価格)

Tokio Marine — 5-year TSR vs. Nikkei 225index, five fiscal years earlier = 100 · Data as of 2026-03-31 · Created 2026-11-130200400600FY18FY19FY20FY21FY22FY23FY24FY25indexTokio Marine TSR (dividends reinvested)Nikkei 225, price (dividends excluded)11896.011114115729837549314398.5174147131190188175

有報의 '株主総利回り'(배당 재투자, 5년 전=100) vs 닛케이225 가격지수의 같은 5년 변화(회계연도 말 종가). FY2025 493 vs 175.

The annual report's total shareholder return (dividends reinvested, five years earlier = 100) vs the Nikkei 225 price index's change over the same five years (fiscal year-end closes). FY2025 493 vs 175.

有報の「株主総利回り」(配当再投資、5年前=100)vs 日経225価格指数の同じ5年間の変化(会計年度末の終値)。FY2025 493 vs 175。

⚠ 규율: 각 연도 값은 그해 有報 표의 마지막 칸 — 5년 누적이라 연도끼리 더하면 안 됩니다. 有報 표의 비교 지수(TOPIX)는 JPX 라이선스를 확인하지 못해 싣지 않았고, 닛케이225 는 배당이 빠진 가격지수라 같은 조건의 비교가 아닙니다.

⚠ Discipline: Each year's value is the last column of that year's annual-report table — five-year cumulative, so years must not be added together. The table's comparison index (TOPIX) is not shown because the JPX licence could not be confirmed, and the Nikkei 225 is a price index without dividends, so this is not a like-for-like comparison.

⚠ 規律:各年の値はその年の有報の表の最後の欄 — 5年累積なので年どうしを足してはいけない。有報の表の比較指数(TOPIX)はJPXのライセンスを確認できず載せておらず、日経225は配当の抜けた価格指数なので同条件の比較ではない。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: brokerage HTS export (Nikkei 225).
Limitations: 도쿄해상 TSR = 有報 표(배당 재투자, 5년 전 = 100) · 닛케이225 는 가격지수(배당 제외)라 같은 기간 총수익보다 낮게 나온다 · 닛케이225 5년 변화는 회계연도 말(3월 마지막 거래일) 종가로 우리가 계산. Definitions: Tokio Marine as printed in each annual report; Nikkei 225 from fiscal year-end closes.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: brokerage HTS export (Nikkei 225).
Limitations: Tokio Marine TSR = table in the annual securities report (dividends reinvested, five years earlier = 100) · the Nikkei 225 is a price index (dividends excluded), so it comes out below total return over the same period · the Nikkei 225 five-year change is our calculation from fiscal year-end closes (last trading day of March). Definitions: Tokio Marine as printed in each annual report; Nikkei 225 from fiscal year-end closes.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: brokerage HTS export (Nikkei 225).
Limitations: Tokio MarineのTSR = 有報の表(配当再投資、5年前 = 100)· 日経225は価格指数(配当除く)のため同期間のトータルリターンより低く出る · 日経225の5年変化は会計年度末(3月最終取引日)の終値から当サイトが計算。 Definitions: Tokio Marine as printed in each annual report; Nikkei 225 from fiscal year-end closes.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

08

도쿄해상 — 성장: 보험료·보험수익·이익(회사 KPI 수정순이익 포함)Tokio Marine — growth: premiums, insurance revenue and profit (incl. the company KPI, adjusted net income)Tokio Marine — 成長:保険料・保険収益・利益(会社KPIの修正純利益を含む)

매출Top line売上Net premiums written (J-GAAP) and insurance revenue (IFRS)Net premiums written (J-GAAP) and insurance revenue (IFRS)正味収入保険料(日本基準)と保険収益(IFRS)

Tokio Marine — top lineJPY trillions · Data as of 2026-03-31 · Created 2026-11-132.04.06.08.010.0FY18FY19FY20FY21FY22FY23FY24FY25JPY tnNet premiums written, J-GAAPInsurance revenue, IFRS7.75.6

正味収入保険料 FY2018 3.59조엔 → FY2025 5.57조엔 (연평균 +6.5%). IFRS 보험수익 FY2024 7.40조엔 → FY2025 7.69조엔 (+4.0%).

Net premiums written FY2018 JPY 3.59trn → FY2025 JPY 5.57trn (+6.5% a year). IFRS insurance revenue FY2024 JPY 7.40trn → FY2025 JPY 7.69trn (+4.0%).

正味収入保険料 FY2018 3.59兆円 → FY2025 5.57兆円(年平均+6.5%)。IFRSの保険収益 FY2024 7.40兆円 → FY2025 7.69兆円(+4.0%)。

⚠ 규율: 엔화 약세가 해외 보험료를 엔으로 부풀립니다(해외 비중이 절반) — 현지통화 성장률은 有報에 없습니다.

⚠ Discipline: Yen weakness inflates overseas premiums in yen terms (overseas is about half) — local-currency growth is not in the annual securities report.

⚠ 規律:円安が海外保険料を円建てで膨らませる(海外の比率は半分)— 現地通貨ベースの成長率は有報にない。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 엔화 약세가 해외 보험료를 엔으로 부풀린다 — 현지통화 성장률은 有報에 없다 · FY2025 일본기준 값은 참고표(미감사). Definitions: consolidated; FY2025 J-GAAP figure from the annual report's reference table (unaudited).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Yen weakness inflates overseas premiums in yen terms — local-currency growth is not in the annual securities report · FY2025 J-GAAP figures come from a reference table (unaudited). Definitions: consolidated; FY2025 J-GAAP figure from the annual report's reference table (unaudited).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 円安が海外保険料を円建てで膨らませる — 現地通貨ベースの成長率は有報にない · FY2025の日本基準の値は参考表(未監査)。 Definitions: consolidated; FY2025 J-GAAP figure from the annual report's reference table (unaudited).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

이익Earnings利益Net income: J-GAAP vs. IFRS vs. the company's adjusted net incomeNet income: J-GAAP vs. IFRS vs. the company's adjusted net income純利益:日本基準 vs IFRS vs 会社の修正純利益

Tokio Marine — three earnings linesJPY trillions · Data as of 2026-03-31 · Created 2026-11-1300.51.01.5FY18FY19FY20FY21FY22FY23FY24FY25JPY tnNet income, J-GAAPAdjusted net income (company KPI)Net income, IFRS

修正純利益(회사 KPI): FY18 2,809억엔, FY19 2,867억엔, FY20 3,996억엔, FY21 5,783억엔, FY22 4,440억엔, FY23 7,116억엔, FY24 12,150억엔, FY25 12,048억엔. FY2025 실적 원문: 「政策株式売却益の増加等により、実績はそれぞれ12,048億円、22.0%となりました」.

Adjusted net income (company KPI): FY18 JPY 280.9bn, FY19 JPY 286.7bn, FY20 JPY 399.6bn, FY21 JPY 578.3bn, FY22 JPY 444.0bn, FY23 JPY 711.6bn, FY24 JPY 1,215.0bn, FY25 JPY 1,204.8bn. FY2025 result, original: 「政策株式売却益の増加等により、実績はそれぞれ12,048億円、22.0%となりました」.

修正純利益(会社KPI):FY18 2,809億円, FY19 2,867億円, FY20 3,996億円, FY21 5,783億円, FY22 4,440億円, FY23 7,116億円, FY24 12,150億円, FY25 12,048億円。FY2025実績の原文:「政策株式売却益の増加等により、実績はそれぞれ12,048億円、22.0%となりました」。

⚠ 규율: 수정순이익은 비GAAP 입니다. 일본기준 정의 = 순이익 + 이상위험준비금·가격변동준비금 등 적립액 − ALM 채권 손익 − 사업투자 손익 …(有報 経営方針). FY2021 정의 변경(FY2020 은 옛 정의 3,361억 / 새 정의 3,996억). FY2026 부터 IFRS 정의 — 계획 9,500억엔·수정ROE 13.0%.

⚠ Discipline: Adjusted net income is non-GAAP. J-GAAP definition = net income + provisions to catastrophe reserves, price-fluctuation reserves etc. − ALM bond gains/losses − business-investment gains/losses … (annual report, management policy). Definition revised in FY2021 (FY2020 on the old definition JPY 336.1bn / on the new definition JPY 399.6bn). IFRS definition from FY2026 — plan JPY 950.0bn · adjusted ROE 13.0%.

⚠ 規律:修正純利益は非GAAP。日本基準の定義 = 純利益 + 異常危険準備金・価格変動準備金等の積立額 − ALM債券損益 − 事業投資損益 …(有報の経営方針)。FY2021に定義変更(FY2020は旧定義3,361億円 / 新定義3,996億円)。FY2026からIFRS定義 — 計画9,500億円・修正ROE 13.0%。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 수정순이익은 회사 KPI(비GAAP) · FY2021 정의 변경 · FY2026 부터 IFRS 정의. Definitions: adjusted = company definition (J-GAAP based through FY2025; definition revised from FY2021).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Adjusted net income is a company KPI (non-GAAP) · definition revised in FY2021 · IFRS definition from FY2026. Definitions: adjusted = company definition (J-GAAP based through FY2025; definition revised from FY2021).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 修正純利益は会社KPI(非GAAP)· FY2021に定義変更 · FY2026からIFRS定義。 Definitions: adjusted = company definition (J-GAAP based through FY2025; definition revised from FY2021).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

ROEReturn on equity: J-GAAP vs. IFRS vs. company-adjustedReturn on equity: J-GAAP vs. IFRS vs. company-adjustedROE:日本基準 vs IFRS vs 会社の修正

Tokio Marine — three ROEspercent · Data as of 2026-03-31 · Created 2026-11-130%5%10%15%20%25%FY18FY19FY20FY21FY22FY23FY24FY25%ROE, J-GAAPAdjusted ROE (company KPI)ROE, IFRS+22.0%+18.7%+7.1%

FY2025: 일본기준 ROE 18.7% · 수정ROE 22.0% · IFRS ROE 7.1%. 분자: 순이익 일본기준 0.98조엔 vs IFRS 0.53조엔 (정책주식 처분익이 IFRS 손익을 건너뜀). 분모: 일본기준 순자산 5.46조엔 vs IFRS 자본 7.96조엔 (이상위험준비금 등이 IFRS 에선 자본). 회사 계획 FY2026 수정ROE 13.0%(IFRS 정의).

FY2025: J-GAAP ROE 18.7% · adjusted ROE 22.0% · IFRS ROE 7.1%. Numerator: net income J-GAAP JPY 0.98trn vs IFRS JPY 0.53trn (gains on disposing of policy stocks bypass IFRS profit and loss). Denominator: J-GAAP net assets JPY 5.46trn vs IFRS equity JPY 7.96trn (catastrophe reserves etc. are equity under IFRS). Company plan for FY2026: adjusted ROE 13.0% (IFRS definition).

FY2025:日本基準ROE 18.7% · 修正ROE 22.0% · IFRS ROE 7.1%。分子:純利益 日本基準0.98兆円 vs IFRS 0.53兆円(政策株式の処分益はIFRSの損益を通らない)。分母:日本基準の純資産5.46兆円 vs IFRS資本7.96兆円(異常危険準備金などはIFRSでは資本)。会社計画 FY2026の修正ROE 13.0%(IFRS定義)。

⚠ 규율: FY2025 일본기준 ROE 는 미감사 참고치. FY2020 수정ROE 는 새 정의 11.3%(옛 정의 9.7%). 회사 문장(IFRS 주석 10): 「ROEをグローバルピア水準まで引き上げる」.

⚠ Discipline: FY2025 J-GAAP ROE is an unaudited reference value. FY2020 adjusted ROE is 11.3% on the new definition (9.7% on the old). The company's wording (IFRS note 10): to raise ROE to the level of global peers.

⚠ 規律:FY2025の日本基準ROEは未監査の参考値。FY2020の修正ROEは新定義で11.3%(旧定義9.7%)。会社の文言(IFRS注記10):「ROEをグローバルピア水準まで引き上げる」。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 세 ROE 는 분자(정책주식 처분익)와 분모(준비금의 자본 인식)가 다르다 · 수정ROE 는 회사 KPI. Definitions: J-GAAP and IFRS as printed in the annual report; adjusted = company KPI (definition revised FY2021).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: The three ROEs differ in the numerator (gains on disposing of policy stocks) and in the denominator (reserves recognised as equity) · adjusted ROE is a company KPI. Definitions: J-GAAP and IFRS as printed in the annual report; adjusted = company KPI (definition revised FY2021).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 3つのROEは分子(政策株式の処分益)と分母(準備金の資本認識)が異なる · 修正ROEは会社KPI。 Definitions: J-GAAP and IFRS as printed in the annual report; adjusted = company KPI (definition revised FY2021).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

세그먼트SegmentsセグメントOrdinary profit by segment, J-GAAP (FY2017–FY2024)Ordinary profit by segment, J-GAAP (FY2017–FY2024)セグメント別経常利益、日本基準(FY2017〜FY2024)

Tokio Marine — ordinary profit by segment (J-GAAP)JPY trillions · Data as of 2025-03-31 · Created 2026-11-1300.51.01.52.0FY17FY18FY19FY20FY21FY22FY23FY24JPY tnDomestic P&CDomestic lifeInternationalFinancial & other0.240.340.230.140.420.180.360.140.270.30.190.570.280.160.50.320.450.840.890.491.5

FY2024: Domestic P&C 0.89조엔 · Domestic life 0.07조엔 · International 0.49조엔 · Financial & other 0.01조엔. 국내손보 경상이익의 급증(FY2024)은 원문 MD&A 「政策株式売却益が増加したことを主因として」.

FY2024: Domestic P&C JPY 0.89trn · Domestic life JPY 0.07trn · International JPY 0.49trn · Financial & other JPY 0.01trn. The jump in domestic P&C ordinary profit (FY2024) was, per the MD&A, mainly due to higher gains on sales of policy stocks.

FY2024:国内損保 0.89兆円 · 国内生保 0.07兆円 · 海外保険 0.49兆円 · 金融・その他 0.01兆円。国内損保の経常利益の急増(FY2024)は原文MD&A「政策株式売却益が増加したことを主因として」。

⚠ 규율: 세그먼트 경상이익 = 経常利益(일본기준). 네 칸 합과 합계는 백만엔 미만 절사로 최대 4백만엔 어긋납니다(검증에서 허용).

⚠ Discipline: Segment ordinary profit = ordinary profit (J-GAAP). The sum of the four columns and the total differ by up to JPY 4mn because amounts under JPY 1mn are truncated (allowed in the checks).

⚠ 規律:セグメント経常利益 = 経常利益(日本基準)。4欄の合計と総計は百万円未満の切り捨てで最大4百万円ずれる(検証で許容)。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 일본기준 세그먼트 경상이익(세그먼트 간 조정 전) · FY2025 부터 IFRS 라 이 표가 없다. Definitions: segment ordinary profit before inter-segment adjustments.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: J-GAAP segment ordinary profit (before inter-segment adjustments) · this table does not exist from FY2025 because of the switch to IFRS. Definitions: segment ordinary profit before inter-segment adjustments.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 日本基準のセグメント経常利益(セグメント間調整前)· FY2025からIFRSのためこの表はない。 Definitions: segment ordinary profit before inter-segment adjustments.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

IFRS 세그먼트IFRS segmentsIFRSセグメントIFRS segments: insurance revenue and insurance service result (FY2024 restated, FY2025)IFRS segments: insurance revenue and insurance service result (FY2024 restated, FY2025)IFRSセグメント:保険収益と保険サービス損益(FY2024再表示、FY2025)

Tokio Marine — IFRS 17 by segmentJPY trillions · Data as of 2026-03-31 · Created 2026-11-1301.02.03.04.05.0Domestic P&CDomestic lifeInternationalJPY tnRevenue FY24Revenue FY25Service result FY24Service result FY252.90.274.23.00.274.40.160.10.70.260.110.78

Domestic P&C: 보험수익 3.04조엔 · 보험서비스손익 0.26조엔 · 금융손익 0.08조엔 · Domestic life: 보험수익 0.27조엔 · 보험서비스손익 0.11조엔 · 금융손익 -0.39조엔 · International: 보험수익 4.45조엔 · 보험서비스손익 0.78조엔 · 금융손익 0.34조엔 (FY2025).

Domestic P&C: insurance revenue JPY 3.04trn · insurance service result JPY 0.26trn · finance result JPY 0.08trn · Domestic life: insurance revenue JPY 0.27trn · insurance service result JPY 0.11trn · finance result JPY -0.39trn · International: insurance revenue JPY 4.45trn · insurance service result JPY 0.78trn · finance result JPY 0.34trn (FY2025).

国内損保:保険収益3.04兆円 · 保険サービス損益0.26兆円 · 金融損益0.08兆円 · 国内生保:保険収益0.27兆円 · 保険サービス損益0.11兆円 · 金融損益-0.39兆円 · 海外保険:保険収益4.45兆円 · 保険サービス損益0.78兆円 · 金融損益0.34兆円(FY2025)。

⚠ 규율: 국내생보 금융손익이 음수(-0.39조엔)인 건 보험금융비용(할인율 부리)이 투자손익보다 큰 구조 — 일본기준엔 없던 줄입니다.

⚠ Discipline: The domestic life finance result is negative (JPY -0.39trn) because insurance finance expense (interest accreted at the discount rate) exceeds the investment result — a line that did not exist under J-GAAP.

⚠ 規律:国内生保の金融損益がマイナス(-0.39兆円)なのは、保険金融費用(割引率による利息付与)が投資損益より大きい構造のため — 日本基準にはなかった項目である。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRS 두 해(FY2024 재작성 · FY2025)뿐. Definitions: insurance service result = revenue − service expenses + reinsurance result.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Only two IFRS years (FY2024 restated · FY2025). Definitions: insurance service result = revenue − service expenses + reinsurance result.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRSは2年(FY2024再表示・FY2025)のみ。 Definitions: insurance service result = revenue − service expenses + reinsurance result.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

종목Lines種目Net premiums written by line, FY2024: domestic P&C vs. internationalNet premiums written by line, FY2024: domestic P&C vs. international種目別の正味収入保険料(FY2024):国内損保 vs 海外

Tokio Marine — net premiums written by line (FY2024)JPY trillions · Data as of 2025-03-31 · Created 2026-11-1300.51.01.5FireMarinePersonal acc.AutoCALIOtherJPY tnDomestic P&CInternational0.480.090.211.30.20.440.640.120.040.571.2

국내손보 합계 2.71조엔 중 자동차 1.29조엔 (48%). 해외 합계 2.60조엔 중 '기타'(배상책임·전문보험 등) 1.23조엔 (47%).

Of domestic P&C's total JPY 2.71trn, auto is JPY 1.29trn (48%). Of international's total JPY 2.60trn, 'other' (liability, specialty lines, etc.) is JPY 1.23trn (47%).

国内損保の合計2.71兆円のうち自動車1.29兆円(48%)。海外の合計2.60兆円のうち「その他」(賠償責任・専門保険など)1.23兆円(47%)。

⚠ 규율: FY2025 有報(IFRS)는 이 표를 싣지 않습니다 — FY2024 가 마지막 일본기준 연도.

⚠ Discipline: The FY2025 annual securities report (IFRS) does not include this table — FY2024 is the last J-GAAP year.

⚠ 規律:FY2025の有報(IFRS)はこの表を載せない — FY2024が最後の日本基準の年度。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MD&A 표(세그먼트 간 제거 전) · FY2024 가 마지막 일본기준 연도. Definitions: MD&A tables before inter-segment elimination; CALI = compulsory auto liability (Japan only).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MD&A tables (before inter-segment elimination) · FY2024 is the last J-GAAP year. Definitions: MD&A tables before inter-segment elimination; CALI = compulsory auto liability (Japan only).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MD&Aの表(セグメント間消去前)· FY2024が最後の日本基準の年度。 Definitions: MD&A tables before inter-segment elimination; CALI = compulsory auto liability (Japan only).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

09

도쿄해상 — 지분 구조: 대주주·자기주식·Berkshire·상호보유Tokio Marine — ownership: major shareholders, treasury shares, Berkshire, cross-shareholdingsTokio Marine — 株主構成:大株主・自己株式・Berkshire・相互保有

대주주Major holders大株主Top-10 shareholders as of 2026-03-31 (annual report)Top-10 shareholders as of 2026-03-31 (annual report)上位10株主(2026-03-31時点、有報)

순위주주(원문)구분주식수지분
1日本マスタートラスト信託銀行株式会社信託口신탁(국내 기관 수탁)321,356,00017.09%
2株式会社日本カストディ銀行信託口신탁(국내 기관 수탁)142,631,0007.59%
3STATE STREET BANK AND TRUST COMPANY 505001 (常任代理人株式会社みずほ銀行決済営業部)해외 수탁·증권66,592,0003.54%
4MOXLEY AND CO LLC (常任代理人株式会社三菱UFJ銀行)해외 수탁·증권34,270,0001.82%
5THE CHASE MANHATTAN BANK,N.A. LONDONSECS LENDING OMNIBUS ACCOUNT (常任代理人株式会社みずほ銀行決済営業部)해외 수탁·증권28,856,0001.53%
6東海日動従業員持株会종업원 지주회27,790,0001.48%
7明治安田生命保険相互会社(常任代理人株式会社日本カストディ銀行)신탁(국내 기관 수탁)26,973,0001.43%
8JP MORGAN CHASE BANK 385781 (常任代理人株式会社みずほ銀行決済営業部)해외 수탁·증권26,773,0001.42%
9ゴールドマン・サックス証券株式会社 BNYM (常任代理人株式会社三菱UFJ銀行)해외 수탁·증권22,249,0001.18%
10JP MORGAN CHASE BANK 385642 (常任代理人株式会社みずほ銀行決済営業部)해외 수탁·증권21,538,0001.15%
RankShareholder (as filed)TypeSharesStake
1日本マスタートラスト信託銀行株式会社信託口Trust (domestic custodian)321,356,00017.09%
2株式会社日本カストディ銀行信託口Trust (domestic custodian)142,631,0007.59%
3STATE STREET BANK AND TRUST COMPANY 505001 (常任代理人株式会社みずほ銀行決済営業部)Overseas custodian / broker66,592,0003.54%
4MOXLEY AND CO LLC (常任代理人株式会社三菱UFJ銀行)Overseas custodian / broker34,270,0001.82%
5THE CHASE MANHATTAN BANK,N.A. LONDONSECS LENDING OMNIBUS ACCOUNT (常任代理人株式会社みずほ銀行決済営業部)Overseas custodian / broker28,856,0001.53%
6東海日動従業員持株会Employee shareholding association27,790,0001.48%
7明治安田生命保険相互会社(常任代理人株式会社日本カストディ銀行)Trust (domestic custodian)26,973,0001.43%
8JP MORGAN CHASE BANK 385781 (常任代理人株式会社みずほ銀行決済営業部)Overseas custodian / broker26,773,0001.42%
9ゴールドマン・サックス証券株式会社 BNYM (常任代理人株式会社三菱UFJ銀行)Overseas custodian / broker22,249,0001.18%
10JP MORGAN CHASE BANK 385642 (常任代理人株式会社みずほ銀行決済営業部)Overseas custodian / broker21,538,0001.15%
順位株主(原文)区分株式数持分
1日本マスタートラスト信託銀行株式会社信託口信託(国内機関の受託)321,356,00017.09%
2株式会社日本カストディ銀行信託口信託(国内機関の受託)142,631,0007.59%
3STATE STREET BANK AND TRUST COMPANY 505001 (常任代理人株式会社みずほ銀行決済営業部)海外カストディ・証券66,592,0003.54%
4MOXLEY AND CO LLC (常任代理人株式会社三菱UFJ銀行)海外カストディ・証券34,270,0001.82%
5THE CHASE MANHATTAN BANK,N.A. LONDONSECS LENDING OMNIBUS ACCOUNT (常任代理人株式会社みずほ銀行決済営業部)海外カストディ・証券28,856,0001.53%
6東海日動従業員持株会従業員持株会27,790,0001.48%
7明治安田生命保険相互会社(常任代理人株式会社日本カストディ銀行)信託(国内機関の受託)26,973,0001.43%
8JP MORGAN CHASE BANK 385781 (常任代理人株式会社みずほ銀行決済営業部)海外カストディ・証券26,773,0001.42%
9ゴールドマン・サックス証券株式会社 BNYM (常任代理人株式会社三菱UFJ銀行)海外カストディ・証券22,249,0001.18%
10JP MORGAN CHASE BANK 385642 (常任代理人株式会社みずほ銀行決済営業部)海外カストディ・証券21,538,0001.15%

상위 10 합계 38.2% — 1위는 日本マスタートラスト信託銀行(신탁구좌, 17.09%). 이름이 보이는 실질 주주는 종업원지주회(東海日動従業員持株会 1.48%)와 明治安田生命(1.43%) 정도입니다. 자기주식 53,937,600주 (2.79%).

Top-10 total 38.2% — the largest is 日本マスタートラスト信託銀行 (a trust account, 17.09%). The only named beneficial holders are roughly the employee shareholding association (東海日動従業員持株会, 1.48%) and 明治安田生命 (1.43%). Treasury shares 53,937,600 (2.79%).

上位10の合計38.2% — 筆頭は日本マスタートラスト信託銀行(信託口、17.09%)。名前の見える実質株主は従業員持株会(東海日動従業員持株会 1.48%)と明治安田生命(1.43%)程度である。自己株式53,937,600株(2.79%)。

⚠ 규율: 신탁구좌·해외 수탁은 명의일 뿐 실질 주주가 아닙니다. 한국 3사처럼 '최대주주 + 특수관계인' 지배 구조가 없습니다 — 그래서 지배력 대신 상호보유(아래)를 봐야 합니다.

⚠ Discipline: Trust accounts and overseas custodians are only holders of record, not beneficial owners. There is no 'largest shareholder + related parties' control structure as at the three Korean insurers — so look at cross-shareholdings (below) instead of control.

⚠ 規律:信託口・海外カストディは名義にすぎず実質株主ではない。韓国3社のような「筆頭株主 + 特別関係者」の支配構造がない — そのため支配力の代わりに相互保有(下記)を見る必要がある。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 명의 주주(신탁구좌·해외 수탁) — 실질 주주가 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Holders of record (trust accounts, overseas custodians) — not beneficial owners.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 名義株主(信託口・海外カストディ)— 実質株主ではない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분 추이Ownership trend持分の推移Largest nominee holder, top-10 total and treasury shares by periodLargest nominee holder, top-10 total and treasury shares by period期間別の筆頭名義株主・上位10合計・自己株式

Tokio Marine — shareholder concentrationpercent of shares outstanding · Data as of 2026-03-31 · Created 2026-11-130%10%20%30%40%50%FY18FY19FY20FY21FY22FY23FY24FY25%Top-10 total (%)No.1 holder (%)Treasury (%)+38.2%+17.1%+2.8%

상위 10 합계 28.5% (2019-03-31) → 38.2% (2026-03-31). 1위 신탁구좌 7.9% → 17.1%.

Top-10 total 28.5% (2019-03-31) → 38.2% (2026-03-31). Largest holder, a trust account, 7.9% → 17.1%.

上位10の合計28.5%(2019-03-31)→ 38.2%(2026-03-31)。筆頭の信託口7.9% → 17.1%。

⚠ 규율: 자기주식 비율은 매입·소각 타이밍에 따라 반기마다 출렁입니다(매입 후 소각).

⚠ Discipline: The treasury-share ratio swings each half-year with the timing of buybacks and cancellations (bought, then cancelled).

⚠ 規律:自己株式比率は取得・消却のタイミングで半期ごとに振れる(取得後に消却)。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 有報·半期報告書 대주주 표 · 자기주식 비율은 매입·소각 시점에 따라 반기마다 출렁인다. Definitions: annual (FY) and half-year (H1) reports; x = fiscal period.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Major-shareholder tables in the annual and half-year securities reports · the treasury-share ratio swings each half-year with the timing of buybacks and cancellations. Definitions: annual (FY) and half-year (H1) reports; x = fiscal period.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 有報・半期報告書の大株主の表 · 自己株式比率は取得・消却の時期によって半期ごとに振れる。 Definitions: annual (FY) and half-year (H1) reports; x = fiscal period.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

BerkshireBerkshire Hathaway's National Indemnity: treasury-share allotment (subsequent event)Berkshire Hathaway's National Indemnity: treasury-share allotment (subsequent event)Berkshire HathawayのNational Indemnity:自己株式の第三者割当(後発事象)

後発事象(FY2025 有報): 2026-03-23 이사회가 Berkshire Hathaway 완전자회사 National Indemnity Company 와 전략적 제휴(전략적 출자·재보험 협업·M&A 공동투자)를 결의, 자기주식 48,207,200주를 1주 5,962엔(총 2,874억엔)에 제3자 배정 — 2026-04-13 납입 완료. 발행주식 1,934,000,000주 대비 2.49%. 희석을 막으려 같은 금액(2,874억엔 한도)의 자사주를 2026-04~09 에 사들이고, 별도로 2,000억엔(1억 3천만주 한도, 2026-05-21~12-23) 매입을 결의했습니다.

Subsequent event (FY2025 annual securities report): on 2026-03-23 the board resolved a strategic alliance (strategic investment, reinsurance cooperation, joint M&A investment) with National Indemnity Company, a wholly owned subsidiary of Berkshire Hathaway, and a third-party allotment of 48,207,200 treasury shares at JPY 5,962 per share (JPY 287.4bn in total) — paid in on 2026-04-13. That is 2.49% of the 1,934,000,000 shares issued. To offset the dilution it will buy back the same amount (up to JPY 287.4bn) of its own shares in 2026-04 to 09, and it separately resolved a buyback of JPY 200.0bn (up to 130 million shares, 2026-05-21 to 12-23).

後発事象(FY2025の有報):2026年3月23日の取締役会が、Berkshire Hathawayの完全子会社National Indemnity Companyとの戦略的提携(戦略的出資・再保険分野の協働・M&Aの共同投資)を決議し、自己株式48,207,200株を1株5,962円(総額2,874億円)で第三者割当 — 2026年4月13日に払込完了。発行済株式1,934,000,000株に対し2.49%。希薄化を防ぐため同額(2,874億円を上限)の自己株式を2026年4〜9月に取得し、別途2,000億円(1億3千万株を上限、2026年5月21日〜12月23日)の取得を決議した。

⚠ 규율: 지분율은 有報의 발행주식수(2026-03말 1,934,000,000주)로 나눈 값입니다. 2026-09 반기보고서(11월 제출 예정)의 대주주 표에서 실제 순위를 확인해야 합니다. 5% 미만이라 대량보유보고서 의무는 없습니다.

⚠ Discipline: The stake is divided by the shares issued per the annual securities report (1,934,000,000 at end-March 2026). The actual ranking has to be checked in the major-shareholder table of the 2026-09 half-year report (due in November). Below 5%, so no large-shareholding report is required.

⚠ 規律:持分比率は有報の発行済株式数(2026年3月末 1,934,000,000株)で割った値。実際の順位は2026-09の半期報告書(11月提出予定)の大株主の表で確認する必要がある。5%未満のため大量保有報告書の義務はない。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 後発事象 원문 · 지분율은 2026-03말 발행주식 기준 우리 계산 · 실제 순위는 다음 반기보고서에서 확인해야 한다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Subsequent-event note in the filing · the stake is our calculation on shares issued at end-March 2026 · the actual ranking has to be checked in the next half-year report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 後発事象の原文 · 持分比率は2026年3月末の発行済株式数を基準に当サイトが計算 · 実際の順位は次の半期報告書で確認する必要がある。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

NICO 가격NICO priceNICO価格Yields at National Indemnity's price (5,962 yen) vs. 10Y sovereignsYields at National Indemnity's price (5,962 yen) vs. 10Y sovereignsNational Indemnityの取得価格(5,962円)での利回り vs 10年国債

Tokio Marine — what the Berkshire entry price buyspercent · Data as of 2026-03-31 · Created 2026-11-130%2%4%6%8%10%DYEY J-GAAPEY IFRSAdj. ROE/PBJGB 10YUST 10Y%+3.7%+8.6%+4.7%+8.3%+2.4%+4.3%

매입가 기준 배당수익률 3.66% — UST10Y 4.30%보다 낮습니다. 이익수익률 일본기준 8.65% / IFRS 4.69% (IFRS P/B 1.41배). 회사 수정순자산 7.18조엔 ÷ 유통주식 1,880,062,400주 = 주당 3,821엔 → P/B 1.56배, 계획 수정ROE 13.0% ÷ P/B = 8.33%.

Dividend yield at the purchase price 3.66% — below UST10Y at 4.30%. Earnings yield J-GAAP 8.65% / IFRS 4.69% (IFRS P/B 1.41x). Company adjusted net assets JPY 7.18trn ÷ 1,880,062,400 shares outstanding = JPY 3,821 per share → P/B 1.56x; planned adjusted ROE 13.0% ÷ P/B = 8.33%.

取得価格ベースの配当利回り3.66% — UST10Y 4.30%より低い。益回り 日本基準8.65% / IFRS 4.69%(IFRS PBR 1.41倍)。会社の修正純資産7.18兆円 ÷ 流通株式1,880,062,400株 = 1株当たり3,821円 → PBR 1.56倍、計画修正ROE 13.0% ÷ PBR = 8.33%。

⚠ 규율: 제 계산(수익률 = ROE ÷ P/B). 수정ROE 는 회사 계획치·비GAAP. 처분가 5,962엔은 3월말 역산 주가 7,309엔보다 18% 낮습니다 — 결의일(3/23) 전후 시세는 Raw Data 에 없어 원인은 확인하지 못했습니다. 동기에 대한 판단은 사용자 몫.

⚠ Discipline: Our calculation (yield = ROE ÷ P/B). Adjusted ROE is a company plan figure and non-GAAP. The allotment price of JPY 5,962 is 18% below the backed-out March-end price of JPY 7,309 — prices around the resolution date (3/23) are not in the Raw Data, so the cause could not be confirmed. The judgement on motives is the reader's.

⚠ 規律:当サイトの計算(利回り = ROE ÷ PBR)。修正ROEは会社計画値・非GAAP。処分価格5,962円は3月末の逆算株価7,309円より18%低い — 決議日(3/23)前後の株価はRaw Dataになく、原因は確認できなかった。動機についての判断は利用者に委ねる。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 수정ROE 는 회사 계획치·비GAAP · 수익률 = ROE ÷ P/B 는 우리 계산 · 결의일 전후 시세는 Raw Data 에 없다. Definitions: FY2025 per-share figures ÷ 5,962 yen; Adj. ROE/PB = FY2026 plan adjusted ROE ÷ (price ÷ adjusted BVPS); sovereigns at 2026-03-31.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Adjusted ROE is a company plan figure and non-GAAP · yield = ROE ÷ P/B is our calculation · prices around the resolution date are not in the Raw Data. Definitions: FY2025 per-share figures ÷ 5,962 yen; Adj. ROE/PB = FY2026 plan adjusted ROE ÷ (price ÷ adjusted BVPS); sovereigns at 2026-03-31.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 修正ROEは会社計画値・非GAAP · 利回り = ROE ÷ PBRは当サイト計算 · 決議日前後の株価はRaw Dataにない。 Definitions: FY2025 per-share figures ÷ 5,962 yen; Adj. ROE/PB = FY2026 plan adjusted ROE ÷ (price ÷ adjusted BVPS); sovereigns at 2026-03-31.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

상호보유Cross-holdings相互保有Specified policy holdings whose issuer also holds Tokio Marine shares (cross-shareholding)Specified policy holdings whose issuer also holds Tokio Marine shares (cross-shareholding)発行体もTokio Marine株を保有する特定投資株式(相互保有)

Tokio Marine & Nichido — cross-shareholding countnumber of names · Data as of 2026-03-31 · Created 2026-11-130100200300FY18FY19FY20FY21FY22FY23FY24FY25namesSpecified holdings disclosedof which issuer holds Tokio Marine shares16750.0

특정투자주식 중 상대도 도쿄해상 주식을 가진 종목(当社の株式の保有の有無 = 有): FY2018 101 → FY2025 50. FY2018 상위의 도요타·미쓰비시상사·혼다·가오·미쓰비시지소는 모두 '有'였고, FY2025 도요타는 '無'.

Specified investment shares whose issuer also holds Tokio Marine shares (the filing's 'holds the company's shares' = yes): FY2018 101 → FY2025 50. Among the top FY2018 holdings, Toyota, Mitsu Corp, Honda, Kao and Mitsu Est. were all 'yes'; in FY2025, Toyota is 'no'.

特定投資株式のうち相手もTokio Marine株を保有する銘柄(当社の株式の保有の有無 = 有):FY2018 101 → FY2025 50。FY2018上位のトヨタ自動車・三菱商事・本田技研工業・花王・三菱地所はすべて「有」で、FY2025のトヨタ自動車は「無」。

⚠ 규율: 공시는 '최대 보유회사'(東京海上日動) 기준입니다. FY2018 대주주 8위가 「退職給付信託口・三菱商事株式会社口」(1.5%)였던 것 — 미쓰비시상사가 퇴직급여신탁으로 도쿄해상 주식을 보유했고 도쿄해상도 미쓰비시상사 주식을 보유했습니다(쌍방).

⚠ Discipline: The disclosure is for the 'largest holding company' (Tokio Marine & Nichido). In FY2018 the No. 8 major shareholder was 「退職給付信託口・三菱商事株式会社口」 (1.5%) — Mitsu Corp held Tokio Marine shares through a retirement-benefit trust, and Tokio Marine also held Mitsu Corp shares (both ways).

⚠ 規律:開示は「最大保有会社」(東京海上日動)ベース。FY2018の大株主8位が「退職給付信託口・三菱商事株式会社口」(1.5%)だったこと — 三菱商事が退職給付信託でTokio Marine株を保有し、Tokio Marineも三菱商事株を保有していた(双方向)。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 최대 보유회사(東京海上日動) 공시 기준 · 상호보유 = 원문 '当社の株式の保有の有無' 가 有. Definitions: specified investment shares of the largest holding company; issuer holds Tokio Marine shares = yes.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Based on the disclosure of the largest holding company (Tokio Marine & Nichido) · cross-shareholding = 'yes' in the filing's column on whether the issuer holds the company's shares. Definitions: specified investment shares of the largest holding company; issuer holds Tokio Marine shares = yes.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 最大保有会社(東京海上日動)の開示ベース · 相互保有 = 原文「当社の株式の保有の有無」が有。 Definitions: specified investment shares of the largest holding company; issuer holds Tokio Marine shares = yes.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

상위 보유Top holdings上位保有Largest specified policy holdings, FY2025 (book value)Largest specified policy holdings, FY2025 (book value)特定投資株式の上位(FY2025、簿価)

Tokio Marine & Nichido — top 12 policy holdings (FY2025)JPY billions · Data as of 2026-03-31 · Created 2026-11-130100200300400500ToyotaITOCHUMarubeniSamsung F&MAEONMitsu Est.Shin-EtsuMUFGMitsu ElecFUJIFILMToyota TsuK LineJPY bn40411770.068.756.952.649.437.834.331.828.924.8

トヨタ自動車株式会社 4,037억엔 · 伊藤忠商事株式会社 1,175억엔 · 丸紅株式会社 700억엔 · Samsung Fire & Marine Insurance Co., Ltd. 687억엔 · イオン株式会社 569억엔 · 三菱地所株式会社 526억엔(상호) · 信越化学工業株式会社 494억엔 · 株式会社三菱UFJフィナンシャル・グループ 378억엔.

Toyota JPY 403.7bn · ITOCHU JPY 117.5bn · Marubeni JPY 70.0bn · Samsung F&M JPY 68.7bn · AEON JPY 56.9bn · Mitsu Est. JPY 52.6bn (cross) · Shin-Etsu JPY 49.4bn · MUFG JPY 37.8bn.

トヨタ自動車株式会社 4,037億円 · 伊藤忠商事株式会社 1,175億円 · 丸紅株式会社 700億円 · Samsung Fire & Marine Insurance Co., Ltd. 687億円 · イオン株式会社 569億円 · 三菱地所株式会社 526億円(相互) · 信越化学工業株式会社 494億円 · 株式会社三菱UFJフィナンシャル・グループ 378億円。

⚠ 규율: 상호보유 상위: 三菱地所株式会社 526억엔 · 三菱電機株式会社 343억엔 · 川崎重工業株式会社 242억엔 · 東海旅客鉄道株式会社 214억엔 · 日本郵船株式会社 210억엔 · 日本製鉄株式会社 145억엔 · 花王株式会社 130억엔 · 第一三共株式会社 108억엔.

⚠ Discipline: Largest cross-holdings: Mitsu Est. JPY 52.6bn · Mitsu Elec JPY 34.3bn · Kawasaki HI JPY 24.2bn · JR Central JPY 21.4bn · NYK JPY 21.0bn · Nippon Stl JPY 14.5bn · Kao JPY 13.0bn · Daiichi S. JPY 10.8bn.

⚠ 規律:相互保有の上位:三菱地所株式会社 526億円 · 三菱電機株式会社 343億円 · 川崎重工業株式会社 242億円 · 東海旅客鉄道株式会社 214億円 · 日本郵船株式会社 210億円 · 日本製鉄株式会社 145億円 · 花王株式会社 130億円 · 第一三共株式会社 108億円。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 최대 보유회사(東京海上日動) 공시 기준 · 장부가 = 기말 공정가치. Definitions: book value = fair value at year-end; red = issuer also holds Tokio Marine shares.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Based on the disclosure of the largest holding company (Tokio Marine & Nichido) · book value = year-end fair value. Definitions: book value = fair value at year-end; red = issuer also holds Tokio Marine shares.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 最大保有会社(東京海上日動)の開示ベース · 簿価 = 期末の公正価値。 Definitions: book value = fair value at year-end; red = issuer also holds Tokio Marine shares.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

삼성화재Samsung F&MSamsung F&MCross-border link: Tokio Marine & Nichido's stake in Samsung Fire & MarineCross-border link: Tokio Marine & Nichido's stake in Samsung Fire & Marine国境を越えたつながり:東京海上日動によるSamsung F&M株式の保有

도쿄해상일동은 삼성화재 보통주 1,488,150주(장부 687억엔, FY2025 말)를 보유합니다. 삼성화재 발행주식(소각 후) 44,647,473주(2026H1 기준, DART Raw Data) 대비 3.33%. 보유 목적 원문: 「海外保険事業における投資先とのパートナーシップ構築・強化を目的として、保有しているものです。 同社、The People's Insurance Company (Group) of China Limitedおよび当社の3社提携に基づき、」. 상대는 도쿄해상 주식을 보유하지 않습니다('無').

Tokio Marine & Nichido holds 1,488,150 common shares of Samsung F&M (book value JPY 68.7bn, end-FY2025). That is 3.33% of Samsung F&M's 44,647,473 shares issued (after cancellations; as of 2026H1, DART Raw Data). Purpose of holding, original: 「海外保険事業における投資先とのパートナーシップ構築・強化を目的として、保有しているものです。 同社、The People's Insurance Company (Group) of China Limitedおよび当社の3社提携に基づき、」. The issuer does not hold Tokio Marine shares ('no').

東京海上日動はSamsung F&Mの普通株式1,488,150株(簿価687億円、FY2025末)を保有する。Samsung F&Mの発行済株式(消却後)44,647,473株(2026H1時点、DARTのRaw Data)に対し3.33%。保有目的の原文:「海外保険事業における投資先とのパートナーシップ構築・強化を目的として、保有しているものです。 同社、The People's Insurance Company (Group) of China Limitedおよび当社の3社提携に基づき、」。相手はTokio Marine株を保有していない(「無」)。

⚠ 규율: 기준일이 다릅니다(도쿄해상 2026-03말 주식수 · 삼성화재 주식수는 DART 주식총수 표의 최신 기간). 5% 미만이라 삼성화재 최대주주 표에는 나오지 않습니다.

⚠ Discipline: Reference dates differ (Tokio Marine share count at end-March 2026 · Samsung F&M share count from the latest period of the DART total-shares table). Below 5%, so it does not appear in Samsung F&M's largest-shareholder table.

⚠ 規律:基準日が異なる(Tokio Marineは2026年3月末の株式数 · Samsung F&Mの株式数はDART株式総数表の最新期間)。5%未満のためSamsung F&Mの最大株主の表には出てこない。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: DART, Financial Supervisory Service.
Limitations: 기준일이 다르다(도쿄해상 2026-03말 주식수 · 삼성화재 주식수는 DART 주식총수 표의 최신 기간).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: DART, Financial Supervisory Service.
Limitations: Reference dates differ (Tokio Marine share count at end-March 2026 · Samsung F&M share count from the latest period of the DART total-shares table).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: DART, Financial Supervisory Service.
Limitations: 基準日が異なる(Tokio Marineは2026年3月末の株式数 · Samsung F&Mの株式数はDART株式総数表の最新期間)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

10

도쿄해상 — 정책보유주식: 유보된 돈이 굴러가는 구조Tokio Marine — policy shareholdings: how retained money is put to workTokio Marine — 政策保有株式:内部留保が回る仕組み

잔고·매각Book & sales残高・売却Listed policy holdings: book value and sale proceeds of reduced names (largest holding company)Listed policy holdings: book value and sale proceeds of reduced names (largest holding company)上場の政策保有株式:簿価と減少銘柄の売却額(最大保有会社)

Tokio Marine & Nichido — listed policy holdingsJPY trillions · Data as of 2026-03-31 · Created 2026-11-1301.02.03.04.0FY18FY19FY20FY21FY22FY23FY24FY25JPY tnBook value, listed (year-end)Sale proceeds, names reduced2.42.02.52.52.43.62.21.90.110.140.110.120.130.220.920.74

상장 정책보유 장부가: FY18 2.42조엔 → FY19 1.95조엔 → FY20 2.49조엔 → FY21 2.54조엔 → FY22 2.42조엔 → FY23 3.56조엔 → FY24 2.17조엔 → FY25 1.92조엔. 감소 종목 매각액 FY2024 0.92조엔 · FY2025 0.74조엔.

Book value of listed policy holdings: FY18 JPY 2.42trn → FY19 JPY 1.95trn → FY20 JPY 2.49trn → FY21 JPY 2.54trn → FY22 JPY 2.42trn → FY23 JPY 3.56trn → FY24 JPY 2.17trn → FY25 JPY 1.92trn. Sale proceeds of reduced names FY2024 JPY 0.92trn · FY2025 JPY 0.74trn.

上場の政策保有の簿価:FY18 2.42兆円 → FY19 1.95兆円 → FY20 2.49兆円 → FY21 2.54兆円 → FY22 2.42兆円 → FY23 3.56兆円 → FY24 2.17兆円 → FY25 1.92兆円。減少銘柄の売却額 FY2024 0.92兆円 · FY2025 0.74兆円。

⚠ 규율: 원문 방침(2024-05 이사회 결정): 「2029年度末までにゼロにします」 — 비상장·자본업무제휴 출자는 제외. FY2025 는 「年間で7,456億円と計画を上回る水準で削減」, 잔고는 IFRS 연결 순자산의 24.5%(2026년도 말 20% 내외 목표).

⚠ Discipline: Policy in the company's words (board decision, 2024-05): reduce them to zero by the end of FY2029 — excluding unlisted holdings and capital and business-alliance investments. In FY2025 they were cut by JPY 745.6bn in the year, more than planned, and the balance is 24.5% of IFRS consolidated net assets (target around 20% by the end of FY2026).

⚠ 規律:原文の方針(2024年5月の取締役会決定):「2029年度末までにゼロにします」— 非上場・資本業務提携による出資は除く。FY2025は「年間で7,456億円と計画を上回る水準で削減」、残高はIFRS連結純資産の24.5%(2026年度末に20%程度が目標)。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 최대 보유회사 기준 · 감소 종목의 매각 대가는 회사 기재값. Definitions: shareholdings held for purposes other than pure investment.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Largest-holding-company basis · sale proceeds of reduced names are company-reported values. Definitions: shareholdings held for purposes other than pure investment.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 最大保有会社ベース · 減少銘柄の売却額は会社開示値。 Definitions: shareholdings held for purposes other than pure investment.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

종목 수Names銘柄数Number of listed policy-holding namesNumber of listed policy-holding names上場の政策保有銘柄数

Tokio Marine & Nichido — listed policy-holding namescount · Data as of 2026-03-31 · Created 2026-11-1302505007501,0001,250FY18FY19FY20FY21FY22FY23FY24FY25names1,1201,1021,0961,0591,003901691563

상장 정책보유 종목 수 FY2018 1,120 → FY2025 563. 비상장 681종목(장부 0.04조엔)은 축소 대상에서 빠집니다.

Number of listed policy-holding names FY2018 1,120 → FY2025 563. The 681 unlisted names (book value JPY 0.04trn) are outside the reduction target.

上場の政策保有銘柄数 FY2018 1,120 → FY2025 563。非上場の681銘柄(簿価0.04兆円)は縮減の対象外。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 최대 보유회사 기준 · 상장 정책보유 종목 수(기말). Definitions: year-end.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Largest-holding-company basis · number of listed policy-holding names (year-end). Definitions: year-end.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 最大保有会社ベース · 上場の政策保有銘柄数(期末)。 Definitions: year-end.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

평가차익Unrealised gains評価差益Available-for-sale stocks: book value vs. acquisition cost (consolidated, J-GAAP)Available-for-sale stocks: book value vs. acquisition cost (consolidated, J-GAAP)その他有価証券の株式:簿価 vs 取得原価(連結、日本基準)

Tokio Marine — stocks held as available-for-saleJPY trillions · Data as of 2025-03-31 · Created 2026-11-1301.02.03.04.0FY17FY18FY19FY20FY21FY22FY23FY24JPY tnBook valueAcquisition cost2.62.42.02.52.52.43.52.10.630.60.540.520.490.470.440.33

주식 평가차익(장부 − 취득원가): FY17 2.01조엔, FY18 1.78조엔, FY19 1.41조엔, FY20 1.94조엔, FY21 2.01조엔, FY22 1.91조엔, FY23 3.07조엔, FY24 1.78조엔. FY2024 취득원가는 장부가의 16%뿐 — 수십 년 전 원가로 들고 있던 주식입니다.

Unrealised gains on stocks (book − cost): FY17 JPY 2.01trn, FY18 JPY 1.78trn, FY19 JPY 1.41trn, FY20 JPY 1.94trn, FY21 JPY 2.01trn, FY22 JPY 1.91trn, FY23 JPY 3.07trn, FY24 JPY 1.78trn. In FY2024, acquisition cost was only 16% of book value — shares held at costs from decades ago.

株式の評価差益(簿価 − 取得原価):FY17 2.01兆円, FY18 1.78兆円, FY19 1.41兆円, FY20 1.94兆円, FY21 2.01兆円, FY22 1.91兆円, FY23 3.07兆円, FY24 1.78兆円。FY2024の取得原価は簿価の16%にすぎない — 数十年前の原価で持っていた株式である。

⚠ 규율: 백만엔 표를 조엔으로 환산. FY2022 는 FY2023 有報에서 해외 자회사 IFRS 17 소급으로 외국증권·기타가 재표시됐습니다(국내 주식은 동일).

⚠ Discipline: Tables in JPY mn converted to JPY trn. FY2022 was restated in the FY2023 annual report for foreign securities and others because of the retrospective IFRS 17 application at overseas subsidiaries (domestic stocks unchanged).

⚠ 規律:百万円の表を兆円に換算。FY2022はFY2023の有報で海外子会社のIFRS 17遡及適用により外国証券・その他が再表示された(国内株式は同じ)。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 일본기준 매도가능 주식(연결) · 차이 = 미실현 평가차익. Definitions: securities note, available-for-sale stocks; gap = unrealized gain.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: J-GAAP available-for-sale stocks (consolidated) · gap = unrealised gain. Definitions: securities note, available-for-sale stocks; gap = unrealized gain.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 日本基準のその他有価証券(株式、連結)· 差 = 未実現の評価差益。 Definitions: securities note, available-for-sale stocks; gap = unrealized gain.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

매각익Sale gains売却益Stocks sold: proceeds vs. realized gains (J-GAAP through FY2024; IFRS FY2025 = gain bypasses profit)Stocks sold: proceeds vs. realised gains (J-GAAP through FY2024; IFRS FY2025 = gain bypasses profit)株式の売却:売却額 vs 実現益(FY2024までは日本基準、FY2025のIFRSでは利益が損益を通らない)

Tokio Marine — stock sales and the gains they carriedJPY trillions · Data as of 2026-03-31 · Created 2026-11-1300.20.40.60.81.0FY17FY18FY19FY20FY21FY22FY23FY24FY25 IFRSJPY tnProceeds / fair value at saleRealized gain (cumulative at sale)0.120.110.110.110.120.130.220.920.780.090.080.080.080.090.10.190.810.66

주식 매각액·매각익(일본기준): FY2023 0.22조엔·0.19조엔 → FY2024 0.92조엔·0.81조엔 (매각액의 88%가 이익). IFRS FY2025: 처분 시 공정가치 0.78조엔 · 처분 누적이익 0.66조엔 — 이 이익은 손익계산서를 거치지 않습니다(FVOCI).

Stock sale proceeds and gains (J-GAAP): FY2023 JPY 0.22trn · JPY 0.19trn → FY2024 JPY 0.92trn · JPY 0.81trn (88% of proceeds was gain). IFRS FY2025: fair value at disposal JPY 0.78trn · cumulative gain on disposal JPY 0.66trn — this gain does not pass through the income statement (FVOCI).

株式の売却額・売却益(日本基準):FY2023 0.22兆円・0.19兆円 → FY2024 0.92兆円・0.81兆円(売却額の88%が利益)。IFRS FY2025:処分時の公正価値0.78兆円 · 処分の累積利益0.66兆円 — この利益は損益計算書を通らない(FVOCI)。

⚠ 규율: IFRS FY2024 비교치(처분 공정가치 0.94조엔 · 누적이익 0.81조엔)는 일본기준 FY2024 주식 매각(매각액 0.92조엔 · 매각익 0.81조엔)과 거의 같습니다 — 같은 거래를 두 기준으로 본 것.

⚠ Discipline: The IFRS FY2024 comparative (fair value at disposal JPY 0.94trn · cumulative gain JPY 0.81trn) is almost the same as the J-GAAP FY2024 stock sales (proceeds JPY 0.92trn · gains JPY 0.81trn) — the same transactions seen under two standards.

⚠ 規律:IFRSのFY2024比較値(処分時公正価値0.94兆円 · 累積利益0.81兆円)は日本基準のFY2024の株式売却(売却額0.92兆円 · 売却益0.81兆円)とほぼ同じ — 同じ取引を二つの基準で見たもの。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 일본기준(FY2024 까지)은 매각익이 순이익으로 · IFRS(FY2025, FVOCI)는 이익잉여금으로 바로 간다 — 같은 줄로 잇지 않는다. Definitions: J-GAAP gains flow through net income; IFRS (FVOCI) gains go straight to retained earnings.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Under J-GAAP (through FY2024) sale gains go to net income · under IFRS (FY2025, FVOCI) they go straight to retained earnings — the two are not joined into one line. Definitions: J-GAAP gains flow through net income; IFRS (FVOCI) gains go straight to retained earnings.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 日本基準(FY2024まで)では売却益が純利益へ · IFRS(FY2025、FVOCI)では利益剰余金へ直接 — 同じ線でつながない。 Definitions: J-GAAP gains flow through net income; IFRS (FVOCI) gains go straight to retained earnings.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

IFRS 다리IFRS bridgeIFRSブリッジFY2024 net income, J-GAAP → IFRS: where 0.6 trillion yen wentFY2024 net income, J-GAAP → IFRS: where 0.6 trillion yen wentFY2024の純利益、日本基準 → IFRS:0.6兆円はどこへ行ったか

Tokio Marine — FY2024 J-GAAP to IFRS profit adjustmentsJPY trillions · Data as of 2025-03-31 · Created 2026-11-13-1.5-1.0-0.500.51.0Ins. serviceInvestmentIns. financeG&ATaxOtherNI changeJPY tn-0.32-0.82-0.530.790.230.03-0.6

지배주주 순이익 일본기준 1.06조엔 → IFRS 0.45조엔 (차 -0.60조엔). 투자손익 조정 -0.82조엔(정책주식 매각익 등 FVOCI 처리), 보험서비스손익 -0.32조엔, 보험금융손익 -0.53조엔, 일반관리비 0.79조엔(사업비의 보험획득현금흐름 처리).

Net income attributable to owners of the parent: J-GAAP JPY 1.06trn → IFRS JPY 0.45trn (difference JPY -0.60trn). Investment result adjustment JPY -0.82trn (gains on selling policy stocks etc. treated as FVOCI), insurance service result JPY -0.32trn, insurance finance result JPY -0.53trn, G&A JPY 0.79trn (expenses treated as insurance acquisition cash flows).

親会社株主に帰属する当期純利益 日本基準1.06兆円 → IFRS 0.45兆円(差-0.60兆円)。投資損益の調整-0.82兆円(政策株式売却益などをFVOCI処理)、保険サービス損益-0.32兆円、保険金融損益-0.53兆円、一般管理費0.79兆円(事業費を保険獲得キャッシュ・フローとして処理)。

⚠ 규율: IFRS 初度適用 주석의 純損益に対する調整(認識及び測定の差異 열). 표시 조정(表示組替)은 빼고 그렸습니다.

⚠ Discipline: From the IFRS first-time adoption note's reconciliation of profit or loss (the recognition and measurement differences column). Presentation reclassifications are left out of the chart.

⚠ 規律:IFRS初度適用注記の純損益に対する調整(認識及び測定の差異の列)。表示組替は除いて描いた。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRS 최초 적용 주석의 인식·측정 차이만 · 세전 항목, 세금은 따로. Definitions: recognition and measurement differences only (first-time adoption note).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Only the recognition and measurement differences in the IFRS first-time adoption note · pre-tax items, tax shown separately. Definitions: recognition and measurement differences only (first-time adoption note).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRS初度適用注記の認識・測定の差異のみ · 税引前の項目、税金は別。 Definitions: recognition and measurement differences only (first-time adoption note).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

유보금Retained留保金Retained earnings at IFRS transition (2024-04-01): what J-GAAP held backRetained earnings at IFRS transition (2024-04-01): what J-GAAP held backIFRS移行日(2024-04-01)の利益剰余金:日本基準が留保していたもの

Tokio Marine — retained earnings, IFRS minus J-GAAP, at transitionJPY trillions · Data as of 2024-04-01 · Created 2026-11-13-2.002.04.0Ins. contr.FX transl.ScopeStat. resv.PeriodFin. instr.OtherTaxTotalJPY tn2.90.930.290.140.1-0.02-0.03-0.883.5

IFRS 로 옮기자 이익잉여금이 3.46조엔 늘었습니다. 가장 큰 것은 보험계약 2.92조엔 — 일본기준의 보수적 책임준비금(이상위험준비금 등)이 IFRS 17 측정에서 자본으로 넘어간 크기입니다. 가격변동준비금(特別法上の準備金) 0.14조엔도 IFRS 에선 부채가 아닙니다(원문: 「IAS第37号…負債の定義を満たさない」).

Moving to IFRS raised retained earnings by JPY 3.46trn. The largest item is insurance contracts at JPY 2.92trn — the size of J-GAAP's conservative policy reserves (catastrophe reserves etc.) that moved into equity under IFRS 17 measurement. The price-fluctuation reserve (a statutory reserve under special laws) of JPY 0.14trn is not a liability under IFRS either (original: it does not meet the definition of a liability under IAS 37).

IFRSに移ると利益剰余金が3.46兆円増えた。最大は保険契約の2.92兆円 — 日本基準の保守的な責任準備金(異常危険準備金など)がIFRS 17の測定で資本に移った大きさである。価格変動準備金(特別法上の準備金)0.14兆円もIFRSでは負債ではない(原文:「IAS第37号…負債の定義を満たさない」)。

⚠ 규율: ESR 의 실질순자산도 같은 생각입니다 — FY2019 有報 원문: 「連結純資産に、異常危険準備金、価格変動準備金等の資本性負債…を加算」. 일본기준 장부에서 부채로 잡혀 있던 '유보금'이 경제적 자본으로 계산됩니다.

⚠ Discipline: The ESR's adjusted net assets follow the same idea — FY2019 annual report, original: catastrophe reserves, price-fluctuation reserves and other equity-like liabilities are added to consolidated net assets. The 'retained money' booked as liabilities under J-GAAP counts as economic capital.

⚠ 規律:ESRの実質純資産も同じ考え方である — FY2019の有報原文:「連結純資産に、異常危険準備金、価格変動準備金等の資本性負債…を加算」。日本基準の帳簿で負債として計上されていた「留保金」が経済的な資本として計算される。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRS 이행일 조정표 · 세전 항목, 세금은 따로 · 보험계약 = 보험·재보험계약. Definitions: first-time adoption reconciliation; insurance contracts = insurance and reinsurance contracts; pre-tax items, tax separately.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRS transition-date reconciliation · pre-tax items, tax shown separately · insurance contracts = insurance and reinsurance contracts. Definitions: first-time adoption reconciliation; insurance contracts = insurance and reinsurance contracts; pre-tax items, tax separately.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRS移行日の調整表 · 税引前の項目、税金は別 · 保険契約 = 保険・再保険契約。 Definitions: first-time adoption reconciliation; insurance contracts = insurance and reinsurance contracts; pre-tax items, tax separately.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

교환 산식Swap arithmetic交換の算式Policy stocks vs. own shares: what a yen earns in each (fiscal year-end 2025)Policy stocks vs. own shares: what a yen earns in each (fiscal year-end 2025)政策株式 vs 自己株式:1円がそれぞれ生むもの(会計年度末2025)

Tokio Marine — sell policy stocks, buy back own shares?percent · Data as of 2026-03-31 · Created 2026-11-130%2%4%6%8%Policy DYJGB 10YUST 10YOwn EY IFRSOwn adj. planOwn EY J-GAAP%+1.7%+2.4%+4.3%+3.8%+6.9%+7.1%

P/B 는 IFRS 1.73배로 장부보다 비쌉니다(한국 2사는 0.78~0.94배) — '자본 대비 저평가'는 숫자로 확인되지 않습니다. Raw Data 가 보여 주는 건 교환 산식입니다: 정책주식은 시가 대비 배당 1.70%(FY2025 · FY2024 2.29%)인데, 자기 주식은 3월말 주가 대비 이익수익률 IFRS 3.82% · 회사 계획 수정순이익 기준 6.91% · 일본기준 7.05%. 회사 원문(처분 목적): 「FVOCI指定した資本性金融商品について、適正な競争を阻害する要因となりうる政策株式の削減や財務健全性の維持・向上および資本効率の向上等を目的として一部を期中に処分しています。」.

P/B is 1.73x on IFRS, above book (the two Korean insurers are at 0.78–0.94x) — 'undervalued relative to equity' is not borne out by the numbers. What the Raw Data shows is the swap arithmetic: policy stocks yield 1.70% in dividends on market value (FY2025 · FY2024 2.29%), while own shares yield, on the March-end price, 3.82% on IFRS earnings · 6.91% on the company's planned adjusted net income · 7.05% on J-GAAP. The company's wording (purpose of disposals): 「FVOCI指定した資本性金融商品について、適正な競争を阻害する要因となりうる政策株式の削減や財務健全性の維持・向上および資本効率の向上等を目的として一部を期中に処分しています。」.

PBRはIFRSで1.73倍と簿価より高い(韓国の2社は0.78〜0.94倍)— 「資本に比べて割安」は数字では確認できない。Raw Dataが示すのは交換の算式である:政策株式は時価に対する配当1.70%(FY2025 · FY2024 2.29%)だが、自己株式は3月末株価に対する益回り IFRS 3.82% · 会社計画の修正純利益ベース6.91% · 日本基準7.05%。会社の原文(処分目的):「FVOCI指定した資本性金融商品について、適正な競争を阻害する要因となりうる政策株式の削減や財務健全性の維持・向上および資本効率の向上等を目的として一部を期中に処分しています。」。

⚠ 규율: 비교 단위가 다릅니다: 정책주식은 현금 배당(시가 기준, 매각 차익 제외), 자기 주식은 회계 이익(현금 아님). 수정 기준 = FY2026 계획 수정순이익 9,500억엔 ÷ 유통주식 1,880,062,400주 = 505엔(제 계산). 매입 단가는 有報에 없습니다(총액만). 정책주식은 ESR 리스크량(주가 변동)도 씁니다 — 자본 효율 판단은 회사 문장 「修正ROEへの影響を考慮した上で事業投資や株主還元といった資本政策を決定」.

⚠ Discipline: The units differ: policy stocks give cash dividends (on market value, excluding sale gains), own shares give accounting earnings (not cash). Adjusted basis = FY2026 planned adjusted net income of JPY 950.0bn ÷ 1,880,062,400 shares outstanding = JPY 505 (our calculation). The buyback unit price is not in the annual securities report (totals only). Policy stocks also use up ESR risk capital (share-price moves) — on capital efficiency, the company's wording: capital policy, such as business investment and shareholder returns, is decided taking into account the impact on adjusted ROE.

⚠ 規律:比較の単位が異なる:政策株式は現金配当(時価ベース、売却差益を除く)、自己株式は会計上の利益(現金ではない)。修正ベース = FY2026計画の修正純利益9,500億円 ÷ 流通株式1,880,062,400株 = 505円(当サイトの計算)。取得単価は有報にない(総額のみ)。政策株式はESRのリスク量(株価変動)も使う — 資本効率の判断は会社の文言「修正ROEへの影響を考慮した上で事業投資や株主還元といった資本政策を決定」。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 정책주식 배당수익률 = FVOCI 주식 배당 ÷ 기말 공정가치 · 자기 주식 쪽은 역산 주가 기준 · 세금·거래비용·가격 영향은 따지지 않았다. Definitions: policy DY = dividends from FVOCI equities held ÷ their year-end fair value; own = earnings ÷ March-end implied price 7,309 yen.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Policy-stock dividend yield = dividends on FVOCI equities ÷ year-end fair value · the own-share side uses the backed-out price · taxes, transaction costs and price impact are not considered. Definitions: policy DY = dividends from FVOCI equities held ÷ their year-end fair value; own = earnings ÷ March-end implied price 7,309 yen.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 政策株式の配当利回り = FVOCI株式の配当 ÷ 期末公正価値 · 自己株式側は逆算株価ベース · 税金・取引コスト・価格への影響は考慮していない。 Definitions: policy DY = dividends from FVOCI equities held ÷ their year-end fair value; own = earnings ÷ March-end implied price 7,309 yen.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

FVOCI 상위FVOCI topFVOCI上位Largest equity holdings designated at FVOCI (IFRS note): transition vs. FY2024 vs. FY2025Largest equity holdings designated at FVOCI (IFRS note): transition vs. FY2024 vs. FY2025FVOCI指定の株式の上位(IFRS注記):移行日 vs FY2024 vs FY2025

Tokio Marine — top FVOCI equity holdingsJPY billions · Data as of 2026-03-31 · Created 2026-11-1302505007501,0001,250ToyotaMitsu CorpHondaSuzukiShin-EtsuITOCHUSamsung F&MDaiichi S.AEONFUJIFILMMarubeniMitsu Est.JPY bnApr 2024Mar 2025Mar 2026

도요타: 이행일 9,682억엔 → FY2025 말 4,037억엔. 미쓰비시상사는 FY2025 상위 10에서 빠졌습니다.

Toyota: JPY 968.2bn at transition → JPY 403.7bn at end-FY2025. Mitsu Corp dropped out of the FY2025 top 10.

トヨタ自動車:移行日9,682億円 → FY2025末4,037億円。三菱商事はFY2025の上位10から外れた。

⚠ 규율: 빈 칸은 그 시점 상위 10에 없다는 뜻이지 0이 아닙니다.

⚠ Discipline: A blank means the name was not in that date's top 10 — not zero.

⚠ 規律:空欄はその時点で上位10にないという意味で、0ではない。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 각 시점의 상위 10 종목만(빈칸 = 그 시점 상위 10 밖). Definitions: fair value; each date lists its own top 10 (blank = not in that date's top 10).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Only the top 10 names at each date (blank = outside that date's top 10). Definitions: fair value; each date lists its own top 10 (blank = not in that date's top 10).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 各時点の上位10銘柄のみ(空欄 = その時点の上位10外)。 Definitions: fair value; each date lists its own top 10 (blank = not in that date's top 10).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

11

도쿄해상 — 채권·운용자산 포트폴리오Tokio Marine — bond and invested-asset portfolioTokio Marine — 債券・運用資産ポートフォリオ

IFRS 투자IFRS investmentsIFRS投資Consolidated investments by type (IFRS note): transition, FY2024, FY2025Consolidated investments by type (IFRS note): transition, FY2024, FY2025種類別の連結投資(IFRS注記):移行日、FY2024、FY2025

Tokio Marine — investment securities and loansJPY trillions · Data as of 2026-03-31 · Created 2026-11-13010.020.030.0Apr 2024Mar 2025Mar 2026JPY tnJGB & Japan govtUS govtOther govtCorporate bondsSecuritizedOther debtEquitiesLoans7.82.53.03.14.62.825.66.02.63.33.53.32.823.54.22.93.64.43.42.923.8

일본 국채 등 7.77조엔 → 5.98조엔 → 4.20조엔 (-46%). 미국 국채 등 2.52조엔 → 2.85조엔 · 증권화상품 3.10조엔 → 4.39조엔 · 회사채 3.03조엔 → 3.65조엔.

Japanese government bonds etc. JPY 7.77trn → JPY 5.98trn → JPY 4.20trn (-46%). US government bonds etc. JPY 2.52trn → JPY 2.85trn · securitised products JPY 3.10trn → JPY 4.39trn · corporate bonds JPY 3.03trn → JPY 3.65trn.

日本国債等7.77兆円 → 5.98兆円 → 4.20兆円(-46%)。米国国債等2.52兆円 → 2.85兆円 · 証券化商品3.10兆円 → 4.39兆円 · 社債3.03兆円 → 3.65兆円。

⚠ 규율: FY2024 MD&A: 국내생보가 「保有契約の一部を再保険に出した」(보유계약 일부 재보험 출재) — 일본 국채 감소와 같은 해. 증권화상품은 해외(주로 미국) 자회사 보유분입니다.

⚠ Discipline: FY2024 MD&A: domestic life ceded part of its in-force business to reinsurers — the same year Japanese government bonds fell. Securitised products are held by overseas (mainly US) subsidiaries.

⚠ 規律:FY2024のMD&A:国内生保が「保有契約の一部を再保険に出した」— 日本国債が減ったのと同じ年。証券化商品は海外(主に米国)子会社の保有分である。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRS 금융상품 주석 · 이행일·FY2024·FY2025 세 시점뿐. Definitions: consolidated; IFRS financial instruments note.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRS financial-instruments note · only three dates: transition, FY2024 and FY2025. Definitions: consolidated; IFRS financial instruments note.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRSの金融商品注記 · 移行日・FY2024・FY2025の3時点のみ。 Definitions: consolidated; IFRS financial instruments note.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

채권형인가Bond-like?債券型かBond fund or insurer? IFRS profit: underwriting vs. investment spreadBond fund or insurer? IFRS profit: underwriting vs. investment spread債券ファンドか保険会社か?IFRS利益:引受 vs 投資スプレッド

Tokio Marine — where IFRS profit comes fromJPY trillions · Data as of 2026-03-31 · Created 2026-11-13-1.0-0.500.51.01.5Ins. serviceInterest inc.Other inv.Inv. expenseIns. fin. exp.Reins. fin.Finance netJPY tnFY2024 (IFRS restated)FY20250.960.81-0.19-0.06-0.60.070.031.10.79-0.06-0.06-0.680.040.03

FY2025: 보험서비스손익 1.15조엔 vs 금융손익 순액 0.03조엔 — 이자수익 0.79조엔 가운데 보험금융비용(보험부채 할인율 부리) 0.68조엔이 계약자 몫으로 나갑니다. 재무상태표의 채권(부채성)은 17.55조엔, IFRS 자본 7.96조엔의 2.2배지만 주주에게 남는 건 스프레드입니다.

FY2025: insurance service result JPY 1.15trn vs net finance result JPY 0.03trn — of interest income of JPY 0.79trn, JPY 0.68trn goes out to policyholders as insurance finance expense (interest accreted at the insurance liability discount rate). Bonds (debt securities) on the balance sheet are JPY 17.55trn, 2.2x IFRS equity of JPY 7.96trn, but what is left for shareholders is the spread.

FY2025:保険サービス損益1.15兆円 vs 金融損益(純額)0.03兆円 — 利息収益0.79兆円のうち保険金融費用(保険負債の割引率による利息付与)0.68兆円が契約者の取り分として出ていく。貸借対照表の債券(負債性)は17.55兆円でIFRS資本7.96兆円の2.2倍だが、株主に残るのはスプレッドである。

⚠ 규율: IFRS 두 해뿐입니다. 일본기준 시절엔 이 분해가 없고(책임준비금 적립·운용수익이 한 손익계산서에 섞임), 정책주식 매각익이 '투자'에 들어갔습니다.

⚠ Discipline: Only two IFRS years. Under J-GAAP this breakdown did not exist (policy-reserve provisions and investment income were mixed in one income statement), and gains on selling policy stocks went into 'investment'.

⚠ 規律:IFRSは2年のみ。日本基準の時代にはこの分解がなく(責任準備金の積立・運用収益が一つの損益計算書に混在)、政策株式の売却益が「投資」に入っていた。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRS 두 해 · 이자수익 대부분이 보험금융비용(부채 할인율 부리)으로 계약자 몫. Definitions: interest earned on the portfolio is mostly passed to policyholder liabilities as insurance finance expense.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Two IFRS years · most interest income goes to policyholders as insurance finance expense (interest accreted at the liability discount rate). Definitions: interest earned on the portfolio is mostly passed to policyholder liabilities as insurance finance expense.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRSの2年 · 利息収益の大半は保険金融費用(負債の割引率による利息付与)として契約者の取り分。 Definitions: interest earned on the portfolio is mostly passed to policyholder liabilities as insurance finance expense.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

금리 민감도Rate sensitivity金利感応度Rates up: bond losses vs. liability gains in other comprehensive incomeRates up: bond losses vs. liability gains in other comprehensive income金利上昇:その他の包括利益における債券の損失 vs 負債の利益

Tokio Marine — OCI items, net of taxJPY trillions · Data as of 2026-03-31 · Created 2026-11-13-0.4-0.200.20.40.6Debt FVOCIIns. discountReins. disc.Equity FVOCIJPY tnFY2024FY2025-0.320.35-0.01-0.33-0.120.33-0.040.45

FY2025: 채권 평가 -0.12조엔 · 보험부채 할인율 변동 0.33조엔 · 재보험 -0.04조엔 → 금리 관련 순액 0.17조엔. 같은 기간 JGB10Y 1.50% → 2.37% (3월말). JGB 가 크게 오른 해에는 부채가 채권보다 더 많이 줄어 자본이 늘었습니다. 단, 회사 민감도로는 모든 금리 +0.5%p 평행이면 자본 순 감소(아래 '질문과 답' Q12).

FY2025: bond revaluation JPY -0.12trn · change in insurance liability discount rates JPY 0.33trn · reinsurance JPY -0.04trn → rate-related net JPY 0.17trn. Over the same period JGB10Y 1.50% → 2.37% (end-March). In a year when JGB yields rose sharply, liabilities fell by more than bonds and equity rose. But on the company's sensitivity, a parallel +0.5pp move in all rates reduces equity net (see 'Questions and answers' Q12 below).

FY2025:債券評価-0.12兆円 · 保険負債の割引率の変動0.33兆円 · 再保険-0.04兆円 → 金利関連の純額0.17兆円。同じ期間のJGB10Y 1.50% → 2.37%(3月末)。JGBが大きく上昇した年には負債が債券より大きく減り資本が増えた。ただし会社の感応度では、すべての金利が+0.5%pt平行移動すると資本は純減(下の「質問と回答」Q12)。

⚠ 규율: OCI 에는 신용스프레드·환율 영향도 섞여 있어 '금리만'의 효과는 아닙니다. 주식 FVOCI 는 정책주식 평가차익(처분 시 이익잉여금으로 직행).

⚠ Discipline: OCI also contains credit-spread and FX effects, so it is not a 'rates only' effect. Equity FVOCI is the unrealised gain on policy stocks (it goes straight to retained earnings on disposal).

⚠ 規律:OCIには信用スプレッド・為替の影響も混じっており「金利だけ」の効果ではない。株式のFVOCIは政策株式の評価差益(処分時に利益剰余金へ直行)。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRS 기타포괄손익(세후) · 두 해뿐. Definitions: debt FVOCI = bond revaluation; insurance discount = liability revaluation when discount rates move.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRS other comprehensive income (after tax) · two years only. Definitions: debt FVOCI = bond revaluation; insurance discount = liability revaluation when discount rates move.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRSのその他の包括利益(税引後)· 2年のみ。 Definitions: debt FVOCI = bond revaluation; insurance discount = liability revaluation when discount rates move.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

유가증권Securities有価証券Domestic P&C (Tokio Marine & Nichido etc.): securities by typeDomestic P&C (Tokio Marine & Nichido etc.): securities by type国内損保(東京海上日動など):種類別の有価証券

Domestic P&C — securitiesJPY trillions · Data as of 2025-03-31 · Created 2026-11-1302.04.06.08.0FY17FY18FY19FY20FY21FY22FY23FY24JPY tnJGBMunicipalCorporateStocksForeign sec.Other1.80.682.70.696.01.70.682.41.06.01.40.732.00.95.21.30.662.50.955.61.30.572.61.05.61.20.522.41.05.31.10.513.61.26.51.02.21.24.9

FY2024: JGB 1.02조엔 (20.6%) · Municipal 263억엔 (0.5%) · Corporate 0.47조엔 (9.4%) · Stocks 2.16조엔 (43.8%) · Foreign sec. 1.23조엔 (25.0%) · Other 301억엔 (0.6%). 합계 FY2017 5.99조엔 → FY2024 4.94조엔.

FY2024: JGB JPY 1.02trn (20.6%) · Municipal JPY 26.3bn (0.5%) · Corporate JPY 0.47trn (9.4%) · Stocks JPY 2.16trn (43.8%) · Foreign sec. JPY 1.23trn (25.0%) · Other JPY 30.1bn (0.6%). Total FY2017 JPY 5.99trn → FY2024 JPY 4.94trn.

FY2024:国債 1.02兆円(20.6%) · 地方債 263億円(0.5%) · 社債 0.47兆円(9.4%) · 株式 2.16兆円(43.8%) · 外国証券 1.23兆円(25.0%) · その他の証券 301億円(0.6%)。合計 FY2017 5.99兆円 → FY2024 4.94兆円。

⚠ 규율: 국내손보 주식 비중 FY2023 55.2% → FY2024 43.8%: 정책주식 매각.

⚠ Discipline: Domestic P&C equity share FY2023 55.2% → FY2024 43.8%: policy-stock sales.

⚠ 規律:国内損保の株式比率 FY2023 55.2% → FY2024 43.8%:政策株式の売却。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MD&A 유가증권 표(세그먼트 간 제거 전) · 회사 분류 그대로. Definitions: MD&A securities table, before inter-segment elimination.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MD&A securities table (before inter-segment elimination) · the company's own classification. Definitions: MD&A securities table, before inter-segment elimination.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MD&Aの有価証券の表(セグメント間消去前)· 会社の分類どおり。 Definitions: MD&A securities table, before inter-segment elimination.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

유가증권Securities有価証券Domestic life (Anshin Life): securities by typeDomestic life (Anshin Life): securities by type国内生保(あんしん生命):種類別の有価証券

Domestic life — securitiesJPY trillions · Data as of 2025-03-31 · Created 2026-11-1302.04.06.08.010.0FY17FY18FY19FY20FY21FY22FY23FY24JPY tnJGBMunicipalCorporateStocksForeign sec.Other5.96.76.16.97.88.78.09.17.99.07.18.27.18.35.87.2

FY2024: JGB 5.84조엔 (81.4%) · Municipal 56억엔 (0.1%) · Corporate 0.53조엔 (7.3%) · Stocks 1억엔 (0.0%) · Foreign sec. 0.46조엔 (6.5%) · Other 0.34조엔 (4.7%). 합계 FY2017 6.71조엔 → FY2024 7.17조엔.

FY2024: JGB JPY 5.84trn (81.4%) · Municipal JPY 5.6bn (0.1%) · Corporate JPY 0.53trn (7.3%) · Stocks JPY 0.1bn (0.0%) · Foreign sec. JPY 0.46trn (6.5%) · Other JPY 0.34trn (4.7%). Total FY2017 JPY 6.71trn → FY2024 JPY 7.17trn.

FY2024:国債 5.84兆円(81.4%) · 地方債 56億円(0.1%) · 社債 0.53兆円(7.3%) · 株式 1億円(0.0%) · 外国証券 0.46兆円(6.5%) · その他の証券 0.34兆円(4.7%)。合計 FY2017 6.71兆円 → FY2024 7.17兆円。

⚠ 규율: 국내생보는 국채가 81.4% (FY2024) — 장기 부채와 듀레이션을 맞춘 ALM. FY2023 표는 원문 자체가 항목 합(83,456억엔)과 합계(83,451억엔)가 4.3억엔(428백만엔) 어긋납니다(두 해 有報 동일 — 원문 그대로 둠).

⚠ Discipline: Domestic life holds 81.4% in government bonds (FY2024) — ALM matched to the duration of long-term liabilities. The FY2023 table is itself inconsistent in the filing: the sum of items (JPY 8,345.6bn) and the total (JPY 8,345.1bn) differ by JPY 0.43bn (JPY 428mn) (the same in two years' annual reports — left as filed).

⚠ 規律:国内生保は国債が81.4%(FY2024)— 長期負債とデュレーションを合わせたALM。FY2023の表は原文自体で項目の合計(83,456億円)と合計欄(83,451億円)が4.3億円(428百万円)ずれている(2年分の有報で同じ — 原文のまま)。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MD&A 유가증권 표(세그먼트 간 제거 전) · 회사 분류 그대로. Definitions: MD&A securities table, before inter-segment elimination.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MD&A securities table (before inter-segment elimination) · the company's own classification. Definitions: MD&A securities table, before inter-segment elimination.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MD&Aの有価証券の表(セグメント間消去前)· 会社の分類どおり。 Definitions: MD&A securities table, before inter-segment elimination.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

해외 운용International assets海外運用International insurance: invested assets by typeInternational insurance: invested assets by type海外保険:種類別の運用資産

International insurance — invested assetsJPY trillions · Data as of 2025-03-31 · Created 2026-11-1305.010.015.0FY17FY18FY19FY20FY21FY22FY23FY24JPY tnSecuritiesPurchased receivablesLoansCash & depositsReal estate3.91.05.93.61.25.83.91.21.16.54.11.31.26.94.71.61.58.25.01.82.09.25.92.32.311.07.12.92.613.3

FY2024: 운용자산 13.26조엔 — 유가증권 7.14조엔 · 매입금전채권 2.92조엔 · 대출 2.61조엔. FY2017 5.91조엔 대비 +124%.

FY2024: invested assets JPY 13.26trn — securities JPY 7.14trn · purchased receivables JPY 2.92trn · loans JPY 2.61trn. +124% vs FY2017 JPY 5.91trn.

FY2024:運用資産13.26兆円 — 有価証券7.14兆円 · 買入金銭債権2.92兆円 · 貸付金2.61兆円。FY2017の5.91兆円比+124%。

⚠ 규율: FY2024 MD&A 원문: 「米国で商業用不動産担保付貸付金にかかる予想信用損失が発生」 — 대출(상업용 부동산 담보)의 신용 리스크가 여기 있습니다. IFRS FY2025 부동산담보대출 2.07조엔.

⚠ Discipline: FY2024 MD&A, original: expected credit losses arose on loans secured by US commercial real estate — this is where the credit risk of loans (backed by commercial property) sits. IFRS FY2025 real-estate-secured loans JPY 2.07trn.

⚠ 規律:FY2024のMD&A原文:「米国で商業用不動産担保付貸付金にかかる予想信用損失が発生」— 貸付金(商業用不動産担保)の信用リスクはここにある。IFRS FY2025の不動産担保付貸付金2.07兆円。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MD&A 운용자산 표 · 회사 분류 그대로. Definitions: MD&A invested-assets table.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MD&A invested-assets table · the company's own classification. Definitions: MD&A invested-assets table.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MD&Aの運用資産の表 · 会社の分類どおり。 Definitions: MD&A invested-assets table.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

이율Yields利回りIncome yield on securities by segment vs. 10Y sovereignsIncome yield on securities by segment vs. 10Y sovereignsセグメント別の有価証券インカム利回り vs 10年国債

Tokio Marine — income yield on securitiespercent · Data as of 2025-03-31 · Created 2026-11-13-2%0%2%4%6%FY17FY18FY19FY20FY21FY22FY23FY24%Domestic P&CDomestic lifeInternationalJGB 10YUST 10Y+5.1%+4.2%+3.7%+1.5%+1.4%

FY2024 유가증권 인컴 이율: 국내손보 5.13% · 국내생보 1.40% · 해외 3.72%. 국내손보 이율이 높은 건 원가가 낮은 정책주식 배당 때문입니다(분모가 취득원가).

FY2024 income yield on securities: domestic P&C 5.13% · domestic life 1.40% · international 3.72%. Domestic P&C's yield is high because of dividends on low-cost policy stocks (the denominator is acquisition cost).

FY2024の有価証券のインカム利回り:国内損保5.13% · 国内生保1.40% · 海外3.72%。国内損保の利回りが高いのは原価の低い政策株式の配当のため(分母が取得原価)。

⚠ 규율: 인컴 이율 = 이자·배당 수입 ÷ 평균 운용액(취득원가 기준) — 시가 기준 수익률이 아닙니다. 실현 이율(매각손익 포함)은 Raw Data 에 따로 있습니다.

⚠ Discipline: Income yield = interest and dividend income ÷ average invested amount (at cost) — not a market-value yield. The realised yield (incl. sale gains and losses) is kept separately in the Raw Data.

⚠ 規律:インカム利回り = 利息・配当収入 ÷ 平均運用額(取得原価ベース)— 時価ベースの利回りではない。実現利回り(売却損益を含む)はRaw Dataに別途ある。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 이자·배당 ÷ 평균잔고(취득원가 기준, MD&A) — 시가 수익률이 아니다 · 국채는 회계연도 말. Definitions: interest & dividends ÷ average balance at cost (MD&A); sovereigns at fiscal year-end.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Interest and dividends ÷ average balance (at cost, MD&A) — not a market-value yield · government bonds at fiscal year-end. Definitions: interest & dividends ÷ average balance at cost (MD&A); sovereigns at fiscal year-end.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 利息・配当 ÷ 平均残高(取得原価ベース、MD&A)— 時価ベースの利回りではない · 国債は会計年度末。 Definitions: interest & dividends ÷ average balance at cost (MD&A); sovereigns at fiscal year-end.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

12

도쿄해상 — 건전성: 솔벤시 마진 비율·ESRTokio Marine — soundness: solvency margin ratio and ESRTokio Marine — 健全性:ソルベンシー・マージン比率・ESR

SMRSolvency margin ratio: group (consolidated) and Tokio Marine & Nichido (single)Solvency margin ratio: group (consolidated) and Tokio Marine & Nichido (single)ソルベンシー・マージン比率:グループ(連結)と東京海上日動(単体)

Tokio Marine — regulatory solvency margin ratiopercent · Data as of 2025-03-31 · Created 2026-11-130%200%400%600%800%1000%FY17FY18FY19FY20FY21FY22FY23FY24%Group, consolidatedTokio Marine & Nichido, singleminimum 200%+920%+591%

연결 SMR: FY17 879.3, FY18 854.2, FY19 845.8, FY20 896.5, FY21 827.3, FY22 627.5, FY23 652.8, FY24 590.8. 원문 사유(FY2024): 「その他有価証券評価差額金の減少による連結ソルベンシー・マージン総額の減少が主因」 — 정책주식 매각이 평가차익(=마진)을 줄였습니다.

Consolidated SMR: FY17 879.3, FY18 854.2, FY19 845.8, FY20 896.5, FY21 827.3, FY22 627.5, FY23 652.8, FY24 590.8. Reason given in the filing (FY2024): mainly a fall in the consolidated solvency margin due to lower net unrealised gains on available-for-sale securities — sales of policy stocks reduced the unrealised gains (= the margin).

連結SMR:FY17 879.3, FY18 854.2, FY19 845.8, FY20 896.5, FY21 827.3, FY22 627.5, FY23 652.8, FY24 590.8。原文の理由(FY2024):「その他有価証券評価差額金の減少による連結ソルベンシー・マージン総額の減少が主因」— 政策株式の売却が評価差益(= マージン)を減らした。

⚠ 규율: SMR 은 2026-03 말부터 일본의 경제가치 기준 규제(ESR)로 바뀌었습니다. FY2025 有報는 SMR 수치를 싣지 않습니다. 검증: 모든 표에서 A ÷ (B/2) 재계산이 기재값과 0.2pt 안(백만엔 절사).

⚠ Discipline: From end-March 2026 the SMR was replaced by Japan's economic-value-based regulation (ESR). The FY2025 annual securities report does not include SMR figures. Check: in every table, recomputing A ÷ (B/2) matches the reported value within 0.2pt (JPY mn truncation).

⚠ 規律:SMRは2026年3月末から日本の経済価値ベースの規制(ESR)に変わった。FY2025の有報はSMRの数値を載せない。検証:すべての表でA ÷(B/2)の再計算が記載値と0.2pt以内(百万円未満切り捨て)。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 감독 기준 지급여력비율(회계연도 말). Definitions: regulatory minimum 200%; fiscal year-end; ratio = margin ÷ (risk ÷ 2).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Regulatory solvency margin ratio (fiscal year-end). Definitions: regulatory minimum 200%; fiscal year-end; ratio = margin ÷ (risk ÷ 2).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 監督基準のソルベンシー・マージン比率(会計年度末)。 Definitions: regulatory minimum 200%; fiscal year-end; ratio = margin ÷ (risk ÷ 2).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

ESREconomic solvency ratio (company internal, then the new regulatory basis)Economic solvency ratio (company internal, then the new regulatory basis)経済価値ベースのソルベンシー比率(会社内部、その後は新しい規制基準)

Tokio Marine — ESR at March year-endpercent · Data as of 2026-03-31 · Created 2026-11-1301002003002020202120222023202420252026 *%153127128124140149268

2020-03 153% (목표 150–210%) · 2021-03 127% (목표 100–140%) · 2022-03 128% (목표 100–140%) · 2023-03 124% (목표 100–140%) · 2024-03 140% (목표 100–140%) · 2025-03 149% (목표 100–140%) · 2026-03 268% (목표 ≥190%). 자사주 매입 반영 후(pro forma): 2025-03 143% · 2026-03 255%.

2020-03 153% (target 150–210%) · 2021-03 127% (target 100–140%) · 2022-03 128% (target 100–140%) · 2023-03 124% (target 100–140%) · 2024-03 140% (target 100–140%) · 2025-03 149% (target 100–140%) · 2026-03 268% (target ≥190%). After buybacks (pro forma): 2025-03 143% · 2026-03 255%.

2020-03 153%(目標150–210%) · 2021-03 127%(目標100–140%) · 2022-03 128%(目標100–140%) · 2023-03 124%(目標100–140%) · 2024-03 140%(目標100–140%) · 2025-03 149%(目標100–140%) · 2026-03 268%(目標≥190%)。自己株式取得反映後(プロフォーマ):2025-03 143% · 2026-03 255%。

⚠ 규율: 2026-03 의 268%는 정의가 바뀐 값입니다(신뢰수준 99.95% → 99.5%, 목표 100–140% → ≥190%) — 2025-03 의 149%와 나란히 비교하면 안 됩니다. 원문: 「2026年3月末から日本国内において新資本規制(経済価値ベースのソルベンシー規制)が導入」.

⚠ Discipline: The 2026-03 figure of 268% is on a changed definition (confidence level 99.95% → 99.5%, target 100–140% → ≥190%) — do not compare it side by side with 2025-03's 149%. Original: a new capital regulation (economic-value-based solvency regulation) was introduced in Japan from end-March 2026.

⚠ 規律:2026-03の268%は定義が変わった値である(信頼水準99.95% → 99.5%、目標100–140% → ≥190%)— 2025-03の149%と並べて比較してはならない。原文:「2026年3月末から日本国内において新資本規制(経済価値ベースのソルベンシー規制)が導入」。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 회사 산출(내부 모형) — 2026-03 부터 새 규제 정의로 바뀌어 앞뒤가 같은 기준이 아니다. Definitions: 99.95% VaR through Mar 2025; * = 99.5% VaR from Mar 2026 (new definition).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Company-calculated (internal model) — switched to the new regulatory definition from 2026-03, so before and after are not on the same basis. Definitions: 99.95% VaR through Mar 2025; * = 99.5% VaR from Mar 2026 (new definition).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 会社算出(内部モデル)— 2026年3月から新しい規制上の定義に変わり、前後は同じ基準ではない。 Definitions: 99.95% VaR through Mar 2025; * = 99.5% VaR from Mar 2026 (new definition).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

13

도쿄해상 — 출처·이용조건·검증Tokio Marine — sources, terms of use and verificationTokio Marine — データ源・利用条件・検証

출처Sources出典Sources, license terms and verificationSources, licence terms and verificationデータ源・利用条件・検証

구분건수기간
有価証券報告書82019-03-31 ~ 2026-03-31
半期報告書/四半期報告書(第2四半期)72019-09-30 ~ 2025-09-30
四半期報告書(第1四半期)52019-06-30 ~ 2023-06-30
四半期報告書(第3四半期)52019-12-31 ~ 2023-12-31
TypeCountPeriod
Annual securities report82019-03-31 ~ 2026-03-31
Half-year report / Q2 quarterly report72019-09-30 ~ 2025-09-30
Q1 quarterly report52019-06-30 ~ 2023-06-30
Q3 quarterly report52019-12-31 ~ 2023-12-31
区分件数期間
有価証券報告書82019-03-31 ~ 2026-03-31
半期報告書/四半期報告書(第2四半期)72019-09-30 ~ 2025-09-30
四半期報告書(第1四半期)52019-06-30 ~ 2023-06-30
四半期報告書(第3四半期)52019-12-31 ~ 2023-12-31

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) — 東京海上ホールディングス株式会社 提出書類 25건(有価証券報告書 第17期~第24期, 四半期報告書, 半期報告書; 2019-06-21~2026-06-26 提出).
加工:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東京海上ホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工).
国債:出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工) · Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
닛케이225:Source: brokerage HTS export (Nikkei 225). — 가격지수(배당 제외), 회계연도 말 종가. TOPIX 값은 싣지 않는다(JPX 지수 라이선스 미확인).
BEI·物価連動国債(Q15):出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。 · 「10年物価連動」入札の最高利回り(実質)と「国債金利情報」の同残存期間の名目利回り(直線補間)の差をAdrenalin Babyが計算(Q15)(그림은 옮기지 않고 수치만 사용) · Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) — 東京海上ホールディングス株式会社 提出書類 25 filings (有価証券報告書 第17期~第24期, 四半期報告書, 半期報告書; filed 2019-06-21~2026-06-26).
加工:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東京海上ホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工).
国債:出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工) · Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Nikkei 225:Source: brokerage HTS export (Nikkei 225). — price index (dividends excluded), fiscal year-end closes. TOPIX values are not shown (JPX index licence not confirmed).
BEI·物価連動国債(Q15):出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。 · 「10年物価連動」入札の最高利回り(実質)と「国債金利情報」の同残存期間の名目利回り(直線補間)の差をAdrenalin Babyが計算(Q15) (figures only; the chart itself is not reproduced) · Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) — 東京海上ホールディングス株式会社 提出書類 25件(有価証券報告書 第17期~第24期、四半期報告書、半期報告書;2019-06-21~2026-06-26 提出)。
加工:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東京海上ホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)。
国債:出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工) · Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
日経225:Source: brokerage HTS export (Nikkei 225). — 価格指数(配当除く)、会計年度末の終値。TOPIXの値は載せない(JPXの指数ライセンス未確認)。
BEI·物価連動国債(Q15):出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。 · 「10年物価連動」入札の最高利回り(実質)と「国債金利情報」の同残存期間の名目利回り(直線補間)の差をAdrenalin Babyが計算(Q15)(図は転載せず数値のみ使用)· Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).

⚠ 규율: 이용조건(EDINET 利用規約, 2026-10-01 원문 확인): 출처 기재 · 가공 시 가공 사실과 주체 기재 · 가공물을 국가 원자료처럼 보이게 하지 않음 · 단시간 대량 접근 금지 · 자동 대량 수집 금지 · 통지 의무 없음. 검증: 369건 중 원문 자체 불일치 1(국내생보 FY2023 유가증권 합계).

⚠ Discipline: Terms of use (EDINET terms, original checked 2026-10-01): cite the source · when processing, state the fact of processing and who did it · do not make processed material look like the government's original data · no heavy access in a short time · no automated bulk collection · no notification required. Verification: of 369 checks, source-internal inconsistencies 1 (domestic life FY2023 securities total).

⚠ 規律:利用条件(EDINET利用規約、2026-10-01に原文確認):出典の記載 · 加工時は加工の事実と主体を記載 · 加工物を国の原データのように見せない · 短時間の大量アクセス禁止 · 自動大量収集の禁止 · 通知義務なし。検証:369件のうち原文自体の不一致1(国内生保 FY2023の有価証券合計)。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).
Source: brokerage HTS export (Nikkei 225).
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: 원천·이용조건·검증 요약(차트 아님).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).
Source: brokerage HTS export (Nikkei 225).
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: Summary of sources, terms of use and verification (not a chart).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).
Source: brokerage HTS export (Nikkei 225).
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: データ源・利用条件・検証の要約(チャートではない)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

14

4사 비교 — 같은 IFRS 17, 다른 이익 구조 (FY2025, 비율만)Four-company comparison — same IFRS 17, different profit structures (FY2025, ratios only)4社比較 — 同じIFRS 17、異なる利益構造(FY2025、比率のみ)

이익 원천Profit source利益の源泉Where operating profit comes from: insurance result vs. net investment result (% of insurance revenue)Where operating profit comes from: insurance result vs. net investment result (% of insurance revenue)営業利益の源泉:保険損益 vs 純投資損益(保険収益比、%)

FY2025 — operating profit per 100 of insurance revenuepercent of insurance revenue · Data as of 2026-03-31 · Created 2026-11-1305.010.015.020.0Samsung F&MHyundai M&FDB InsuranceTokio Marine%Insurance resultNet investment / finance result8.06.314.35.76.011.77.07.514.514.915.3

영업이익 중 투자(순금융) 몫: 삼성화재 44% (FY2024 31%) · 현대해상 51% (FY2024 15%) · DB손보 52% (FY2024 29%) · 도쿄해상 2% (FY2024 3%). 한국 3사는 FY2025 에 보험손익 마진이 줄고(삼성 10.5→8.0% 등) 투자 몫이 절반 안팎으로 커졌습니다. 도쿄해상은 이자수익 대부분이 보험금융비용으로 계약자 몫이라 순금융손익이 보험수익의 0.3%뿐입니다.

Investment (net finance) share of operating profit: Samsung F&M 44% (FY2024 31%) · Hyundai M&F 51% (FY2024 15%) · DB Insurance 52% (FY2024 29%) · Tokio Marine 2% (FY2024 3%). In FY2025 the three Korean insurers' insurance margins fell (Samsung F&M 10.5→8.0%, etc.) and the investment share grew to around half. At Tokio Marine, most interest income goes to policyholders as insurance finance expense, so the net finance result is only 0.3% of insurance revenue.

営業利益に占める投資(純金融)の割合:Samsung F&M 44%(FY2024 31%) · Hyundai M&F 51%(FY2024 15%) · DB Insurance 52%(FY2024 29%) · Tokio Marine 2%(FY2024 3%)。韓国3社はFY2025に保険損益マージンが縮小し(Samsung F&M 10.5→8.0%など)、投資の割合が半分前後に拡大した。Tokio Marineは利息収益の大半が保険金融費用として契約者の取り分となるため、純金融損益は保険収益の0.3%にすぎない。

⚠ 규율: 정의 차이: 한국 '보험손익'은 기타사업비용(비귀속 비용)까지 뺀 값, 도쿄해상 '보험서비스손익'은 일반관리비(FY2025 0.72조엔, 솔루션사업 포함)를 빼기 전 — 일반관리비를 빼면 5.5%(하한). 한국 투자손익 = 투자영업수익 − 투자영업비용(보험금융비용 포함)으로 Raw Data 에서 확인.

⚠ Discipline: Definitions differ: the Korean 'insurance result' is after other business expenses (non-attributable costs), while Tokio Marine's 'insurance service result' is before G&A (FY2025 JPY 0.72trn, incl. the solutions business) — after G&A it is 5.5% (lower bound). Korean investment result = investment operating revenue − investment operating expenses (incl. insurance finance expense), checked in the Raw Data.

⚠ 規律:定義の違い:韓国の「保険損益」はその他事業費用(非帰属費用)まで差し引いた値、Tokio Marineの「保険サービス損益」は一般管理費(FY2025 0.72兆円、ソリューション事業を含む)の控除前 — 一般管理費を差し引くと5.5%(下限)。韓国の投資損益 = 投資営業収益 − 投資営業費用(保険金融費用を含む)で、Raw Dataで確認。

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 정의 차이 — 한국 보험손익은 비귀속 비용까지 뺀 값, 도쿄해상 보험서비스손익은 일반관리비 차감 전 · 원·엔이 섞여 비율만 비교한다 · 기준일: 한국 3사 12월말, 도쿄해상 3월말. Definitions: Korea: insurance + investment result (net of ins. finance); Tokio Marine: service + finance result.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Definitions differ — the Korean insurance result is after non-attributable expenses, Tokio Marine's insurance service result is before G&A · won and yen are mixed, so only ratios are compared · reference dates: the three Korean insurers at end-December, Tokio Marine at end-March. Definitions: Korea: insurance + investment result (net of ins. finance); Tokio Marine: service + finance result.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 定義の違い — 韓国の保険損益は非帰属費用まで差し引いた値、Tokio Marineの保険サービス損益は一般管理費控除前 · ウォンと円が混在するため比率のみ比較 · 基準日:韓国3社は12月末、Tokio Marineは3月末。 Definitions: Korea: insurance + investment result (net of ins. finance); Tokio Marine: service + finance result.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

수익성·성장Profitability & growth収益性・成長Profitability and growth: ROE, pre-tax margin, insurance revenue growthProfitability and growth: ROE, pre-tax margin, insurance revenue growth収益性と成長:ROE、税引前マージン、保険収益の伸び

FY2025 — ROE, pre-tax margin and growthpercent · Data as of 2026-03-31 · Created 2026-11-1305.010.015.020.025.0ROE (IFRS)Pre-tax / ins. revenueIns. revenue growth%Samsung F&MHyundai M&FDB InsuranceTokio Marine11.014.97.920.68.73.117.715.04.77.19.84.0

삼성화재: ROE 11.0% · 세전마진 14.9% · 보험수익 +7.9% · 현대해상: ROE 20.6% · 세전마진 8.7% · 보험수익 +3.1% · DB손보: ROE 17.7% · 세전마진 15.0% · 보험수익 +4.7% · 도쿄해상: ROE 7.1% · 세전마진 9.8% · 보험수익 +4.0%.

Samsung F&M: ROE 11.0% · pre-tax margin 14.9% · insurance revenue +7.9% · Hyundai M&F: ROE 20.6% · pre-tax margin 8.7% · insurance revenue +3.1% · DB Insurance: ROE 17.7% · pre-tax margin 15.0% · insurance revenue +4.7% · Tokio Marine: ROE 7.1% · pre-tax margin 9.8% · insurance revenue +4.0%.

Samsung F&M:ROE 11.0% · 税引前マージン14.9% · 保険収益+7.9% · Hyundai M&F:ROE 20.6% · 税引前マージン8.7% · 保険収益+3.1% · DB Insurance:ROE 17.7% · 税引前マージン15.0% · 保険収益+4.7% · Tokio Marine:ROE 7.1% · 税引前マージン9.8% · 保険収益+4.0%。

⚠ 규율: 현대해상 ROE 20.6%는 IFRS 17 자본이 얇아서(자본/보험수익 0.36배 vs 도쿄해상 1.03배)입니다. 도쿄해상 ROE 는 IFRS 기준 — 정책주식 처분익은 손익을 건너뜁니다(일본기준 18.7% · 수정 22.0%).

⚠ Discipline: Hyundai M&F's ROE of 20.6% reflects thin IFRS 17 equity (equity / insurance revenue 0.36x vs Tokio Marine 1.03x). Tokio Marine's ROE is on IFRS — gains on disposing of policy stocks bypass profit and loss (J-GAAP 18.7% · adjusted 22.0%).

⚠ 規律:Hyundai M&FのROE 20.6%はIFRS 17の資本が薄いため(資本/保険収益0.36倍 vs Tokio Marine 1.03倍)。Tokio MarineのROEはIFRSベース — 政策株式の処分益は損益を通らない(日本基準18.7% · 修正22.0%)。

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRS 17 연결 · 성장률은 현지통화(도쿄해상은 엔, 환율 효과 포함) · 기준일: 한국 3사 12월말, 도쿄해상 3월말. Definitions: IFRS 17 consolidated; growth = FY2025 vs FY2024 in local currency (Tokio Marine in yen, FX included).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRS 17 consolidated · growth in local currency (yen for Tokio Marine, FX effects included) · reference dates: the three Korean insurers at end-December, Tokio Marine at end-March. Definitions: IFRS 17 consolidated; growth = FY2025 vs FY2024 in local currency (Tokio Marine in yen, FX included).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRS 17連結 · 成長率は現地通貨(Tokio Marineは円、為替効果を含む)· 基準日:韓国3社は12月末、Tokio Marineは3月末。 Definitions: IFRS 17 consolidated; growth = FY2025 vs FY2024 in local currency (Tokio Marine in yen, FX included).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

국채 대비vs. sovereigns国債対比Shareholder yield vs. sovereigns: dividend and earnings yield spreadsShareholder yield vs. sovereigns: dividend and earnings yield spreads株主利回り vs 国債:配当利回り・益回りのスプレッド

FY2025 — yields minus 10Y sovereignpercentage points · Data as of 2026-03-31 · Created 2026-11-13-5%0%5%10%15%20%DY − home 10YDY − UST 10YEY − home 10Y%pSamsung F&MHyundai M&FDB InsuranceTokio Marine+0.5%-0.3%+6.1%-3.4%-4.2%+2.0%+1.2%+17.6%+0.6%-1.3%+1.5%

삼성화재: DY 3.90% (자국 10Y 3.38%) · EY 9.5% · P/B 0.94배 · 현대해상: DY 0.00% (자국 10Y 3.38%) · EY n/a · P/B n/a · DB손보: DY 5.40% (자국 10Y 3.38%) · EY 21.0% · P/B 0.78배 · 도쿄해상: DY 2.98% (자국 10Y 2.37%) · EY 3.8% · P/B 1.73배.

Samsung F&M: DY 3.90% (home 10Y 3.38%) · EY 9.5% · P/B 0.94x · Hyundai M&F: DY 0.00% (home 10Y 3.38%) · EY n/a · P/B n/a · DB Insurance: DY 5.40% (home 10Y 3.38%) · EY 21.0% · P/B 0.78x · Tokio Marine: DY 2.98% (home 10Y 2.37%) · EY 3.8% · P/B 1.73x.

Samsung F&M:DY 3.90%(自国10年3.38%)· EY 9.5% · PBR 0.94倍 · Hyundai M&F:DY 0.00%(自国10年3.38%)· EY n/a · PBR n/a · DB Insurance:DY 5.40%(自国10年3.38%)· EY 21.0% · PBR 0.78倍 · Tokio Marine:DY 2.98%(自国10年2.37%)· EY 3.8% · PBR 1.73倍。

⚠ 규율: 같은 '손보주'인데 시장은 도쿄해상을 IFRS 이익의 26배·장부의 1.7배, 한국 2사를 장부 이하(P/B 0.94·0.78)로 값을 매겼습니다. 주가는 역산값(한국 = 배당기준일 전 1주 평균, 도쿄해상 = 3월말 EPS×PER).

⚠ Discipline: Same kind of 'P&C stock', yet the market priced Tokio Marine at 26x IFRS earnings and 1.7x book, and two of the Korean insurers below book (P/B 0.94 · 0.78). Prices are backed-out values (Korea = one-week average before the record date, Tokio Marine = March-end EPS × PER).

⚠ 規律:同じ「損保株」でも、市場はTokio MarineをIFRS利益の26倍・簿価の1.7倍、韓国の2社を簿価以下(PBR 0.94・0.78)で評価した。株価は逆算値(韓国 = 配当基準日前1週間の平均、Tokio Marine = 3月末のEPS×PER)。

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 주가는 역산값 · 한국 12월말 · 도쿄해상 3월말 · 현대해상 무배당은 배당수익률 0, 주가 역산 불가. Definitions: home = KTB (Korea, Dec) / JGB (Tokio Marine, Mar); Hyundai paid no dividend: DY = 0, price not derivable.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Prices are backed-out values · Korea at end-December · Tokio Marine at end-March · Hyundai M&F's no-dividend year: dividend yield 0, price cannot be backed out. Definitions: home = KTB (Korea, Dec) / JGB (Tokio Marine, Mar); Hyundai paid no dividend: DY = 0, price not derivable.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 株価は逆算値 · 韓国は12月末 · Tokio Marineは3月末 · Hyundai M&Fの無配は配当利回り0、株価は逆算不可。 Definitions: home = KTB (Korea, Dec) / JGB (Tokio Marine, Mar); Hyundai paid no dividend: DY = 0, price not derivable.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

한눈에At a glance一目でScorecard: the comparison table as charts (FY2025)Scorecard: the comparison table as charts (FY2025)スコアカード:比較表をチャートで(FY2025)

P&C insurers — scorecard, FY2025 (IFRS 17)percent, percentage points and multiples · Data as of 2026-03-31 · Created 2026-11-13Samsung F&MHyundai M&FDB InsuranceTokio MarineInvestment share of operating profit44.2%51.2%52.0%2.1%Insurance marginTM before G&A8.0%5.7%7.0%14.9%ROE (IFRS)11.0%20.6%17.7%7.1%Pre-tax / insurance revenue14.9%8.7%15.0%9.8%Insurance revenue growthlocal currency7.9%3.1%4.7%4.0%Dividend yield − home 10YKTB / JGB+0.5-3.4+2.0+0.6Dividend yield − UST 10Y-0.3-4.2+1.2-1.3Earnings yieldimplied price9.5%n/a21.0%3.8%Price / bookimplied price0.94xn/a0.78x1.73xPayout ratioTM excl. buybacks41.1%0.0%25.7%78.0%Capital ratioK-ICS vs ESR: not same basis283%209%204%268%Controlling group stake19.6%24.0%27.6%none (no controlling holder)Equities / securitiesdifferent taxonomies44.4%4.6%10.1%16.2%Home govt bonds / securitiesdifferent taxonomies20.2%31.1%23.5%19.9%Statutory reserves / retainedKorea only47.5%65.5%63.2%n/a (J-GAAP sub. books)

아래 표의 숫자를 지표별 막대로 옮겼습니다. 막대 색 = 회사(남색 삼성화재 · 적색 현대해상 · 황색 DB손보 · 청색 도쿄해상). 패널마다 축이 따로라 패널 간 길이 비교는 의미가 없습니다.

The numbers in the table below, turned into bars by metric. Bar colour = company (navy Samsung F&M · red Hyundai M&F · gold DB Insurance · blue Tokio Marine). Each panel has its own axis, so comparing bar lengths across panels is meaningless.

下の表の数字を指標別の棒に置き換えた。棒の色 = 会社(紺 Samsung F&M · 赤 Hyundai M&F · 黄 DB Insurance · 青 Tokio Marine)。パネルごとに軸が別なので、パネル間で棒の長さを比べても意味がない。

⚠ 규율: 현대해상: FY2025 무배당(원문 근거) → 배당수익률 0, 주가 역산 불가 → 이익수익률·P/B 없음. 도쿄해상 법정적립금은 IFRS 연결 장부에 없는 항목(자회사 일본기준 장부에 있음).

⚠ Discipline: Hyundai M&F: no dividend for FY2025 (per the filing) → dividend yield 0, price cannot be backed out → no earnings yield or P/B. Tokio Marine's statutory reserves are not an item in the IFRS consolidated accounts (they sit in the subsidiaries' J-GAAP books).

⚠ 規律:Hyundai M&F:FY2025は無配(原文根拠)→ 配当利回り0、株価は逆算不可 → 益回り・PBRなし。Tokio Marineの法定積立金はIFRS連結の帳簿にない項目(子会社の日本基準の帳簿にある)。

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 패널마다 축이 따로 · 자본비율은 K-ICS 와 ESR 로 체계가 다르다 · 포트폴리오 분류가 회사마다 다르다. Definitions: each panel has its own scale; ratios only (KRW and JPY not mixed); n/a = not derivable from the ledgers.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Each panel has its own axis · capital ratios are on different regimes (K-ICS vs ESR) · portfolio classifications differ by company. Definitions: each panel has its own scale; ratios only (KRW and JPY not mixed); n/a = not derivable from the ledgers.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: パネルごとに軸が別 · 資本比率はK-ICSとESRで制度が異なる · ポートフォリオの分類は会社ごとに異なる。 Definitions: each panel has its own scale; ratios only (KRW and JPY not mixed); n/a = not derivable from the ledgers.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

비교표Table比較表Side by side: valuation, payout, capital, control, portfolio, locked retained earningsSide by side: valuation, payout, capital, control, portfolio, locked retained earnings並べて比較:バリュエーション・配当性向・資本・支配・ポートフォリオ・拘束された利益剰余金

회사P/B배당성향자본비율최대주주(지배)주식 비중(유가증권)자국 국공채 비중이익잉여금 중 법정적립금
삼성화재0.94배41.1%K-ICS 283% (2026H1)삼성생명 15.9% (특수관계 합 19.6%)44.4% (2026H1)20.2%47.5%
현대해상n/a0.0%K-ICS 209% (2026H1)정몽윤 23.1% (특수관계 합 24.0%)4.6% (2026H1)31.1%65.5%
DB손보0.78배25.7%K-ICS 204% (2026H1)김남호 9.7% (특수관계 합 27.6%)10.1% (2026H1)23.5%63.2%
도쿄해상1.73배78.0%ESR 268% (2026-03, 회사 산출)지배주주 없음 — 1위 신탁구좌 17.1% · NICO(Berkshire) 2.5%16.2% (FY2025 IFRS)19.9%—
CompanyP/BPayout ratioCapital ratioLargest holder (control)Equities (of securities)Home govt bonds shareStatutory reserves in retained earnings
Samsung F&M0.94x41.1%K-ICS 283% (2026H1)삼성생명 15.9% (related parties total 19.6%)44.4% (2026H1)20.2%47.5%
Hyundai M&Fn/a0.0%K-ICS 209% (2026H1)정몽윤 23.1% (related parties total 24.0%)4.6% (2026H1)31.1%65.5%
DB Insurance0.78x25.7%K-ICS 204% (2026H1)김남호 9.7% (related parties total 27.6%)10.1% (2026H1)23.5%63.2%
Tokio Marine1.73x78.0%ESR 268% (2026-03, company-calculated)No controlling shareholder — the largest, a trust account, holds 17.1% · NICO (Berkshire) 2.5%16.2% (FY2025 IFRS)19.9%—
会社PBR配当性向資本比率筆頭株主(支配)株式の比率(有価証券)自国国公債の比率利益剰余金に占める法定積立金
Samsung F&M0.94倍41.1%K-ICS 283% (2026H1)삼성생명 15.9%(特別関係者合計19.6%)44.4% (2026H1)20.2%47.5%
Hyundai M&Fn/a0.0%K-ICS 209% (2026H1)정몽윤 23.1%(特別関係者合計24.0%)4.6% (2026H1)31.1%65.5%
DB Insurance0.78倍25.7%K-ICS 204% (2026H1)김남호 9.7%(特別関係者合計27.6%)10.1% (2026H1)23.5%63.2%
Tokio Marine1.73倍78.0%ESR 268%(2026-03、会社算出)支配株主なし — 筆頭は信託口17.1% · NICO(Berkshire)2.5%16.2% (FY2025 IFRS)19.9%—

도쿄해상 배당성향 78%(IFRS EPS) + 자사주 매입 0.25조엔 → 주주환원이 IFRS 순이익의 118%. 한국은 배당성향 41.1% · 25.7% · 0.0%(현대해상 미실시), 이익잉여금 중 법정적립금(해약환급금·비상위험·대손준비금, 적립예정 포함) 비중 47.5% · 65.5% · 63.2% — 한국의 '유보'는 배당을 막고(현대해상), 일본의 '유보'(이상위험준비금 등)는 IFRS 연결 자본으로 넘어갔습니다(이행일 +2.92조엔, 세전).

Tokio Marine payout ratio 78% (IFRS EPS) + buybacks JPY 0.25trn → shareholder returns at 118% of IFRS net income. In Korea, payout ratios 41.1% · 25.7% · 0.0% (Hyundai M&F paid none), and statutory reserves (surrender-value, catastrophe and credit-loss reserves, incl. amounts to be reserved) as a share of retained earnings 47.5% · 65.5% · 63.2% — Korea's 'retention' blocks dividends (Hyundai M&F), while Japan's 'retention' (catastrophe reserves etc.) moved into IFRS consolidated equity (+JPY 2.92trn at transition, pre-tax).

Tokio Marineの配当性向78%(IFRS EPS)+ 自己株式取得0.25兆円 → 株主還元はIFRS純利益の118%。韓国は配当性向41.1% · 25.7% · 0.0%(Hyundai M&Fは無配)、利益剰余金に占める法定積立金(解約返戻金・異常危険・貸倒準備金、積立予定を含む)の比率47.5% · 65.5% · 63.2% — 韓国の「留保」は配当を妨げ(Hyundai M&F)、日本の「留保」(異常危険準備金など)はIFRS連結資本に移った(移行日+2.92兆円、税引前)。

⚠ 규율: 자본비율은 체계가 다릅니다: K-ICS(감독 표준모형, 경과조치 회사별) vs 도쿄해상 ESR(회사가 99.5% VaR 로 산출, 2026-03 일본 경제가치 규제 도입에 맞춰 정의 변경). 지주사 배당 여력은 자회사 일본기준 단체 장부(이상위험준비금 잔존)에 달려 있어 IFRS 자본 증가가 곧 배당 가능액은 아닙니다. 포트폴리오 분류도 다릅니다(한국 = 업무보고서 운용내역, 국공채+특수채 · 도쿄해상 = IFRS 금융상품 주석, 일본 국채 등).

⚠ Discipline: Capital ratios are on different regimes: K-ICS (supervisory standard model, transitional measures by company) vs Tokio Marine's ESR (calculated by the company at 99.5% VaR; definition changed with the introduction of Japan's economic-value-based regulation in 2026-03). The holding company's dividend capacity depends on the subsidiaries' J-GAAP single-entity books (where catastrophe reserves remain), so an increase in IFRS equity is not the same as distributable funds. Portfolio classifications also differ (Korea = business-report securities breakdown, govt & municipal + special bonds · Tokio Marine = IFRS financial-instruments note, Japanese government bonds etc.).

⚠ 規律:資本比率は制度が異なる:K-ICS(監督の標準モデル、経過措置は会社別)vs Tokio MarineのESR(会社が99.5% VaRで算出、2026年3月の日本の経済価値ベース規制の導入に合わせて定義変更)。持株会社の配当余力は子会社の日本基準の単体帳簿(異常危険準備金が残る)に左右されるため、IFRS資本の増加がそのまま配当可能額ではない。ポートフォリオの分類も異なる(韓国 = 業務報告書の運用内訳、国公債+特殊債 · Tokio Marine = IFRSの金融商品注記、日本国債など)。

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 자본비율 체계(K-ICS vs ESR)와 포트폴리오 분류가 다르다 · 주가는 역산값.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Capital-ratio regimes (K-ICS vs ESR) and portfolio classifications differ · prices are backed-out values.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 資本比率の制度(K-ICS vs ESR)とポートフォリオの分類が異なる · 株価は逆算値。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

15

질문과 답 — 사용자 질문을 Raw Data 숫자로 다시 계산 (2026-10-01~02)Questions and answers — the user's questions, recomputed from Raw Data figures (2026-10-01–02)質問と回答 — 利用者の質問をRaw Dataの数字で再計算(2026-10-01〜02)

Q1도쿄해상에 투자하면 채권에 우회 투자하는 것인가?Is investing in Tokio Marine an indirect bet on bonds?Tokio Marineへの投資は債券への迂回投資なのか?

Q1 — where Tokio Marine's IFRS profit comes from (FY2025)JPY trillions · Data as of 2026-03-31 · Created 2026-11-13-1.0-0.500.51.01.5Ins. serviceInterest inc.Ins. fin. exp.Finance netJPY tn1.10.79-0.680.03

답: 재무상태표는 채권형, 손익은 보험형. 채권(부채성 증권) 17.55조엔 = IFRS 자본 7.96조엔의 2.2배, 그 돈의 원천은 보험계약부채 20.22조엔. 그런데 FY2025 보험서비스손익 1.15조엔 vs 금융손익 순액 0.03조엔 — 이자수익 0.79조엔 가운데 0.68조엔이 보험금융비용(부채 할인율 부리)으로 계약자 몫입니다.

Answer: a bond-like balance sheet, an insurance-like P&L. Bonds (debt securities) of JPY 17.55trn = 2.2x IFRS equity of JPY 7.96trn, funded by insurance contract liabilities of JPY 20.22trn. Yet in FY2025 the insurance service result was JPY 1.15trn vs a net finance result of JPY 0.03trn — of interest income of JPY 0.79trn, JPY 0.68trn goes to policyholders as insurance finance expense (interest accreted at the liability discount rate).

答え:貸借対照表は債券型、損益は保険型。債券(負債性証券)17.55兆円 = IFRS資本7.96兆円の2.2倍、その資金の源泉は保険契約負債20.22兆円。しかしFY2025の保険サービス損益1.15兆円 vs 金融損益(純額)0.03兆円 — 利息収益0.79兆円のうち0.68兆円が保険金融費用(負債の割引率による利息付与)として契約者の取り分である。

⚠ 규율: IFRS 두 해(FY2024 재작성·FY2025)뿐입니다. 4사 비교: 영업이익 중 투자 몫 한국 3사 44% · 51% · 52% vs 도쿄해상 2% — '채권형'에 가까운 건 오히려 한국 쪽.

⚠ Discipline: Only two IFRS years (FY2024 restated · FY2025). Four-company comparison: investment share of operating profit, the three Korean insurers 44% · 51% · 52% vs Tokio Marine 2% — if anything, it is the Korean side that is closer to 'bond-like'.

⚠ 規律:IFRSは2年(FY2024再表示・FY2025)のみ。4社比較:営業利益に占める投資の割合 韓国3社44% · 51% · 52% vs Tokio Marine 2% — 「債券型」に近いのはむしろ韓国側。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRS 두 해뿐 · 보험금융비용 = 부채 할인율 부리. Definitions: interest earned on the bond book is mostly passed to policyholder liabilities.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Two IFRS years only · insurance finance expense = interest accreted at the liability discount rate. Definitions: interest earned on the bond book is mostly passed to policyholder liabilities.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: IFRSは2年のみ · 保険金融費用 = 負債の割引率による利息付与。 Definitions: interest earned on the bond book is mostly passed to policyholder liabilities.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q2버핏(Berkshire)은 왜 주목하나? 단순히 배당 때문인가?Why is Buffett (Berkshire) interested? Is it simply the dividend?バフェット(Berkshire)はなぜ注目するのか?単に配当のためか?

Q2 — yields at National Indemnity's price (5,962 yen)percent · Data as of 2026-03-31 · Created 2026-11-130%2%4%6%8%10%DY @NICOUST 10YJGB 10YEY IFRS @NICOAdj. ROE/PB%+3.7%+4.3%+2.4%+4.7%+8.3%

답: 배당만으로는 설명되지 않습니다. 매입가 기준 배당수익률 3.66% < UST10Y 4.30%. 공시가 밝힌 제휴 축(원문): 「当社への戦略的出資、再保険分野における協働およびM&A等における戦略的提携」. Raw Data 가 보여 주는 다른 근거: 보험서비스손익 1.15조엔 · ESR 268%(목표 ≥190%) · 상장 정책보유 1.92조엔(2029년도 말까지 0으로 — 풀리는 자본) · 자사주 매입 연 4,000억엔(Berkshire 몫 별도).

Answer: the dividend alone does not explain it. Dividend yield at the purchase price 3.66% < UST10Y 4.30%. The pillars of the alliance stated in the disclosure (original): 「当社への戦略的出資、再保険分野における協働およびM&A等における戦略的提携」. Other evidence in the Raw Data: insurance service result JPY 1.15trn · ESR 268% (target ≥190%) · listed policy holdings JPY 1.92trn (to zero by the end of FY2029 — capital to be released) · buybacks of JPY 400.0bn a year (Berkshire's portion separate).

答え:配当だけでは説明できない。取得価格ベースの配当利回り3.66% < UST10Y 4.30%。開示が示した提携の柱(原文):「当社への戦略的出資、再保険分野における協働およびM&A等における戦略的提携」。Raw Dataが示す他の根拠:保険サービス損益1.15兆円 · ESR 268%(目標≥190%)· 上場の政策保有1.92兆円(2029年度末までにゼロへ — 解放される資本)· 自己株式取得 年4,000億円(Berkshire分は別)。

⚠ 규율: 처분가 5,962엔은 3월말 역산 주가 7,309엔보다 18% 낮습니다 — 결의일 전후 시세는 Raw Data 에 없어 원인 미확인. 지분 2.49%(발행주식 대비). 동기는 Raw Data 밖 — 판단은 사용자 몫.

⚠ Discipline: The allotment price of JPY 5,962 is 18% below the backed-out March-end price of JPY 7,309 — prices around the resolution date are not in the Raw Data, so the cause is unconfirmed. Stake 2.49% (of shares issued). The motive lies outside the Raw Data — the judgement is the reader's.

⚠ 規律:処分価格5,962円は3月末の逆算株価7,309円より18%低い — 決議日前後の株価はRaw Dataになく、原因は未確認。持分2.49%(発行済株式比)。動機はRaw Dataの外 — 判断は利用者に委ねる。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 처분가 기준 수익률은 우리 계산 · 수정ROE 는 회사 계획치·비GAAP. Definitions: FY2025 DPS and EPS ÷ allotment price; sovereigns at 2026-03-31; Adj. ROE/PB = FY2026 plan ÷ (price ÷ adjusted BVPS).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Yields at the allotment price are our calculation · adjusted ROE is a company plan figure and non-GAAP. Definitions: FY2025 DPS and EPS ÷ allotment price; sovereigns at 2026-03-31; Adj. ROE/PB = FY2026 plan ÷ (price ÷ adjusted BVPS).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 処分価格基準の利回りは当サイト計算 · 修正ROEは会社計画値・非GAAP。 Definitions: FY2025 DPS and EPS ÷ allotment price; sovereigns at 2026-03-31; Adj. ROE/PB = FY2026 plan ÷ (price ÷ adjusted BVPS).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q3ROE 와 ROI 는? (같은 해인데 왜 세 배 차이가 나나)What are the ROE and ROI? (Why a threefold gap in the same year?)ROEとROIは?(同じ年なのになぜ3倍も違うのか)

Q3 — FY2025 return on equity three ways, and return at the entry pricepercent · Data as of 2026-03-31 · Created 2026-11-130%5%10%15%20%25%ROE J-GAAPAdj. ROEROE IFRSROI IFRS @NICOROI adj. @NICO%+18.7%+22.0%+7.1%+5.0%+8.3%

답: ROE 일본기준 18.7% · 수정 22.0% · IFRS 7.1%. 분자 — 순이익 일본기준 0.98조엔 vs IFRS 0.53조엔(정책주식 처분익이 IFRS 손익을 건너뜀). 분모 — 일본기준 순자산 5.46조엔 vs IFRS 자본 7.96조엔(이상위험준비금 등이 IFRS 에선 자본). NICO 매입가 기준 ROI: IFRS P/B 1.41배 → 5.01%, 수정순자산 기준 P/B 1.56배 × 계획 수정ROE 13.0% → 8.33%.

Answer: ROE J-GAAP 18.7% · adjusted 22.0% · IFRS 7.1%. Numerator — net income J-GAAP JPY 0.98trn vs IFRS JPY 0.53trn (gains on disposing of policy stocks bypass IFRS profit and loss). Denominator — J-GAAP net assets JPY 5.46trn vs IFRS equity JPY 7.96trn (catastrophe reserves etc. count as equity under IFRS). ROI at NICO's purchase price: IFRS P/B 1.41x → 5.01%; P/B on adjusted net assets 1.56x × planned adjusted ROE 13.0% → 8.33%.

答え:ROEは日本基準18.7% · 修正22.0% · IFRS 7.1%。分子 — 純利益 日本基準0.98兆円 vs IFRS 0.53兆円(政策株式の処分益はIFRSの損益を通らない)。分母 — 日本基準の純資産5.46兆円 vs IFRS資本7.96兆円(異常危険準備金などはIFRSでは資本)。NICOの取得価格ベースのROI:IFRS PBR 1.41倍 → 5.01%、修正純資産ベースのPBR 1.56倍 × 計画修正ROE 13.0% → 8.33%。

⚠ 규율: ROI = ROE ÷ P/B 는 제 계산. 일본기준 FY2025 값은 미감사. 수정ROE 는 회사 KPI(비GAAP, FY2021 정의 변경, FY2026 부터 IFRS 정의).

⚠ Discipline: ROI = ROE ÷ P/B is our calculation. J-GAAP FY2025 figures are unaudited. Adjusted ROE is a company KPI (non-GAAP; definition revised in FY2021; IFRS definition from FY2026).

⚠ 規律:ROI = ROE ÷ PBRは当サイトの計算。日本基準のFY2025の値は未監査。修正ROEは会社KPI(非GAAP、FY2021に定義変更、FY2026からIFRS定義)。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: ROI = ROE ÷ (가격 ÷ 장부) 는 우리 계산 · 수정 ROI 는 회사 계획치. Definitions: ROI = ROE ÷ (price ÷ book) at 5,962 yen; adjusted ROI uses the FY2026 plan (company KPI).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: ROI = ROE ÷ (price ÷ book) is our calculation · adjusted ROI uses the company plan figure. Definitions: ROI = ROE ÷ (price ÷ book) at 5,962 yen; adjusted ROI uses the FY2026 plan (company KPI).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: ROI = ROE ÷(株価 ÷ 簿価)は当サイト計算 · 修正ROIは会社計画値。 Definitions: ROI = ROE ÷ (price ÷ book) at 5,962 yen; adjusted ROI uses the FY2026 plan (company KPI).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q4국내 손보사와 비교하면?How does it compare with the Korean P&C insurers?韓国の損保会社と比べると?

Q4 — investment share of operating profit, FY2025percent · Data as of 2026-03-31 · Created 2026-11-130%20%40%60%Samsung F&MHyundai M&FDB InsuranceTokio Marine%+44.2%+51.2%+52.0%+2.1%

답: 같은 IFRS 17 인데 이익 구조가 반대. 영업이익 중 투자 몫 삼성화재 44% · 현대해상 51% · DB손보 52% · 도쿄해상 2%. 국채 대비로는 한국이 쌉니다 — P/B 삼성화재 0.94배 · 현대해상 산출 불가(무배당) · DB손보 0.78배 · 도쿄해상 1.73배, 이익수익률 삼성화재 9.5% · 현대해상 산출 불가 · DB손보 21.0% · 도쿄해상 3.8%. 한국 이익잉여금의 47.5%~65.5%가 법정적립금에 묶여 배당을 막고(현대해상 무배당), 도쿄해상은 IFRS 순이익의 118%를 배당·자사주로 돌려줍니다.

Answer: same IFRS 17, opposite profit structures. Investment share of operating profit Samsung F&M 44% · Hyundai M&F 51% · DB Insurance 52% · Tokio Marine 2%. Against government bonds Korea is cheaper — P/B Samsung F&M 0.94x · Hyundai M&F not derivable (no dividend) · DB Insurance 0.78x · Tokio Marine 1.73x, earnings yield Samsung F&M 9.5% · Hyundai M&F not derivable · DB Insurance 21.0% · Tokio Marine 3.8%. 47.5%–65.5% of Korean retained earnings is tied up in statutory reserves, blocking dividends (Hyundai M&F paid none), while Tokio Marine returns 118% of IFRS net income through dividends and buybacks.

答え:同じIFRS 17なのに利益構造が逆。営業利益に占める投資の割合 Samsung F&M 44% · Hyundai M&F 51% · DB Insurance 52% · Tokio Marine 2%。国債対比では韓国が割安 — PBR Samsung F&M 0.94倍 · Hyundai M&F 算出不可(無配) · DB Insurance 0.78倍 · Tokio Marine 1.73倍、益回り Samsung F&M 9.5% · Hyundai M&F 算出不可 · DB Insurance 21.0% · Tokio Marine 3.8%。韓国の利益剰余金の47.5%〜65.5%が法定積立金に拘束されて配当を妨げ(Hyundai M&Fは無配)、Tokio MarineはIFRS純利益の118%を配当・自己株式取得で還元している。

⚠ 규율: 자세한 지표 15개는 위 '4사 비교' 절의 점수판. 자본비율(K-ICS vs ESR)은 체계가 달라 직접 비교 불가, 주가는 역산값(기준일 3개월 차).

⚠ Discipline: The 15 detailed metrics are in the scorecard of the 'Four-company comparison' section above. Capital ratios (K-ICS vs ESR) are on different regimes and cannot be compared directly; prices are backed-out values (reference dates three months apart).

⚠ 規律:詳細な指標15個は上の「4社比較」の節のスコアカード。資本比率(K-ICS vs ESR)は制度が異なり直接比較できない。株価は逆算値(基準日に3カ月の差)。

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 한국 = 투자손익 ÷ (보험손익 + 투자손익) · 도쿄해상 = 금융손익 ÷ (서비스손익 + 금융손익) — 정의가 다르다. Definitions: Korea: investment result ÷ (insurance + investment result); Tokio Marine: finance result ÷ (service + finance result).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Korea = investment result ÷ (insurance result + investment result) · Tokio Marine = finance result ÷ (service result + finance result) — the definitions differ. Definitions: Korea: investment result ÷ (insurance + investment result); Tokio Marine: finance result ÷ (service + finance result).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 韓国 = 投資損益 ÷(保険損益 + 投資損益)· Tokio Marine = 金融損益 ÷(サービス損益 + 金融損益)— 定義が異なる。 Definitions: Korea: investment result ÷ (insurance + investment result); Tokio Marine: finance result ÷ (service + finance result).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q5자본 대비 저평가라서, 적은 비용(자사주 매입)으로 사내 돈을 굴리는 게 기대수익이 더 크다고 보는 건가?Is it undervalued relative to equity, so that putting the company's money into cheap buybacks promises a higher expected return?資本に比べて割安なので、少ないコスト(自己株式取得)で社内の資金を回すほうが期待リターンが大きいと見ているのか?

Q5 — a yen in policy stocks vs. a yen in own shares (FY2025)percent · Data as of 2026-03-31 · Created 2026-11-130%2%4%6%8%Policy stocks DYOwn EY IFRSOwn adj. planOwn EY J-GAAP%+1.7%+3.8%+6.9%+7.1%

답: '저평가'는 숫자로 확인되지 않지만, '더 큰 기대수익'은 교환 산식으로는 맞습니다. P/B 1.73배(IFRS)로 장부보다 비쌉니다. 그러나 정책주식은 시가 대비 배당 1.70%, 자기 주식은 3월말 주가 대비 이익수익률 IFRS 3.82% · 계획 수정 기준 6.91% · 일본기준 7.05%. 회사 원문(처분 목적): 「FVOCI指定した資本性金融商品について、適正な競争を阻害する要因となりうる政策株式の削減や財務健全性の維持・向上および資本効率の向上等を目的として一部を期中に処分しています。」.

Answer: 'undervalued' is not borne out by the numbers, but 'a higher expected return' holds on the swap arithmetic. At a P/B of 1.73x (IFRS) it trades above book. But policy stocks yield 1.70% in dividends on market value, while own shares yield, on the March-end price, 3.82% on IFRS earnings · 6.91% on the planned adjusted basis · 7.05% on J-GAAP. The company's wording (purpose of disposals): 「FVOCI指定した資本性金融商品について、適正な競争を阻害する要因となりうる政策株式の削減や財務健全性の維持・向上および資本効率の向上等を目的として一部を期中に処分しています。」.

答え:「割安」は数字では確認できないが、「より大きな期待リターン」は交換の算式では成り立つ。PBR 1.73倍(IFRS)で簿価より高い。しかし政策株式は時価に対する配当1.70%、自己株式は3月末株価に対する益回り IFRS 3.82% · 計画修正ベース6.91% · 日本基準7.05%。会社の原文(処分目的):「FVOCI指定した資本性金融商品について、適正な競争を阻害する要因となりうる政策株式の削減や財務健全性の維持・向上および資本効率の向上等を目的として一部を期中に処分しています。」。

⚠ 규율: 현금 배당(정책주식) vs 회계 이익(자기 주식)이라 단위가 다릅니다. 매입 단가는 有報에 없음. 정책주식은 ESR 리스크량도 씁니다 — 회사 원칙(원문): 「修正ROEへの影響を考慮した上で事業投資や株主還元といった資本政策を決定」.

⚠ Discipline: Cash dividends (policy stocks) vs accounting earnings (own shares) — the units differ. The buyback unit price is not in the annual securities report. Policy stocks also use up ESR risk capital — the company's principle: capital policy, such as business investment and shareholder returns, is decided taking into account the impact on adjusted ROE.

⚠ 規律:現金配当(政策株式)vs 会計上の利益(自己株式)で単位が異なる。取得単価は有報にない。政策株式はESRのリスク量も使う — 会社の原則(原文):「修正ROEへの影響を考慮した上で事業投資や株主還元といった資本政策を決定」。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 세금·거래비용·가격 영향은 따지지 않았다 · 자기 주식 쪽은 역산 주가 기준. Definitions: policy DY = dividends from FVOCI equities ÷ year-end fair value; own = earnings ÷ March-end implied price 7,309 yen.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Taxes, transaction costs and price impact are not considered · the own-share side uses the backed-out price. Definitions: policy DY = dividends from FVOCI equities ÷ year-end fair value; own = earnings ÷ March-end implied price 7,309 yen.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 税金・取引コスト・価格への影響は考慮していない · 自己株式側は逆算株価ベース。 Definitions: policy DY = dividends from FVOCI equities ÷ year-end fair value; own = earnings ÷ March-end implied price 7,309 yen.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q6버핏이 노리는 게 JGB 금리 상승인가? (지금 채권 금리가 오르는데)Is Buffett betting on rising JGB yields? (bond yields are rising now)バフェットが狙うのはJGB金利の上昇か?(今、債券金利が上がっているが)

Q6 — JGB curve at the Berkshire deal vs. nowpercent · Data as of 2026-11-12 · Created 2026-11-130%1%2%3%4%5%1Y3Y5Y7Y9Y15Y25Y40Y%JGB 2026-03-31 (NICO deal)JGB 2026-11-12 (latest)+4.0%+3.7%

답: 도쿄해상 장부는 'JGB 롱'이 아닙니다 — 금리 상승의 이득은 부채 쪽에서 나왔습니다. JGB 10년물 2.37% (2026-03-31) → 2.84% (2026-11-12), 출자 이후 +48bp. 같은 기간 회사는 일본 국채 등을 7.77조엔 → 5.98조엔 → 4.20조엔 순으로 줄였습니다. 금리가 오른 두 해의 금리 관련 기타포괄손익(채권 평가 + 보험·재보험 부채 할인율) FY2024 0.03조엔 · FY2025 0.17조엔 — 부채 가치가 채권보다 더 줄어 자본이 늘었습니다. 단, 이는 JGB 가 UST 보다 많이 오른 해의 결과 — 모든 금리가 같이 오르면 자본은 줄어듭니다(회사 민감도, Q12).

Answer: Tokio Marine's books are not 'long JGBs' — the gain from higher rates came from the liability side. JGB 10-year 2.37% (2026-03-31) → 2.84% (2026-11-12), +48bp since the investment. Over the same stretch the company cut its Japanese government bonds etc. JPY 7.77trn → JPY 5.98trn → JPY 4.20trn. In the two years when rates rose, rate-related other comprehensive income (bond revaluation + insurance and reinsurance liability discount rates) was FY2024 JPY 0.03trn · FY2025 JPY 0.17trn — liability values fell by more than bond values, so equity rose. But this is the result of years when JGB yields rose more than UST yields — if all rates rise together, equity falls (company sensitivity, Q12).

答え:Tokio Marineの帳簿は「JGBロング」ではない — 金利上昇の利益は負債側から生じた。JGB10年物2.37%(2026-03-31)→ 2.84%(2026-11-12)、出資以降+48bp。同じ期間に会社は日本国債等を7.77兆円 → 5.98兆円 → 4.20兆円と減らした。金利が上昇した2年間の金利関連のその他の包括利益(債券評価 + 保険・再保険負債の割引率)はFY2024 0.03兆円 · FY2025 0.17兆円 — 負債価値が債券より大きく減り、資本が増えた。ただし、これはJGBがUSTより大きく上昇した年の結果 — すべての金利が一緒に上がれば資本は減る(会社の感応度、Q12)。

⚠ 규율: OCI 에는 신용스프레드·환율 효과도 섞여 '금리만'의 효과는 아닙니다. 출자 이후(2026-04~09)의 효과는 2026-09 半期報告書(11월 제출 예정)에서 확인할 수 있습니다. Berkshire 의 동기·엔화 조달 같은 Raw Data 밖 이야기는 확인하지 않았습니다 — 판단은 사용자 몫.

⚠ Discipline: OCI also mixes in credit-spread and FX effects, so it is not a 'rates only' effect. The effect after the investment (2026-04~09) can be checked in the 2026-09 half-year securities report (due in November). Matters outside the Raw Data, such as Berkshire's motives or yen funding, were not checked — the judgement is the reader's.

⚠ 規律:OCIには信用スプレッド・為替の効果も混じり、「金利だけ」の効果ではない。出資以降(2026-04~09)の効果は2026-09の半期報告書(11月提出予定)で確認できる。Berkshireの動機・円資金の調達といったRaw Data外の話は確認していない — 判断は利用者に委ねる。

出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 재무성 국채금리(복리) · 처분 결의일 커브 vs 최신 커브. Definitions: Ministry of Finance JGB curve; x = maturity.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MOF JGB yields (compound) · curve on the allotment resolution date vs the latest curve. Definitions: Ministry of Finance JGB curve; x = maturity.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 財務省の国債金利(複利)· 処分決議日のカーブ vs 最新のカーブ。 Definitions: Ministry of Finance JGB curve; x = maturity.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q7도쿄해상이 가장 잘 되는 매크로 환경은? (짧은 시계열 말고 레짐으로)In which macro environment does Tokio Marine do best? (by regime, not a short time series)Tokio Marineが最も好調なマクロ環境は?(短い時系列ではなくレジームで)

Q7 — Tokio Marine total return vs. Nikkei 225, by fiscal yearpercent · Data as of 2026-03-31 · Created 2026-11-13-25%0%25%50%75%100%FY14FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25%Tokio Marine total shareholder returnNikkei 225, price change

답(관측): 금리 정상화 레짐에서 가장 좋았습니다. 경계 = 미 실질 10년 금리 저점(2021-08-03 -1.19%). 이전 FY2014~2020: 도쿄해상 연 11.7% vs 닛케이225(가격) 연 10.2% (차이 +1.6%p/년). 이후 FY2021~2025: 연 37.6% vs 11.8% (차이 +25.8%p/년) — 그동안 JGB10Y 0.10% → 2.37%, 미 실질 10년 -0.63% → 2.00%, 엔/달러 약세. 차이 상위: FY2023 +45.8%p · FY2021 +45.7%p · FY2024 +37.6%p · FY2014 +20.5%p. 최저: FY2020 -43.1%p(닛케이225 +54.2%, 미 실질 -0.63%). 차이에는 도쿄해상 배당이 들어 있다(닛케이225 는 배당 제외).

Answer (observation): best in the rate-normalisation regime. Boundary = trough of the US real 10-year yield (2021-08-03 -1.19%). Before, FY2014–2020: Tokio Marine 11.7% a year vs Nikkei 225 (price) 10.2% a year (gap +1.6pp/yr). After, FY2021–2025: 37.6% vs 11.8% a year (gap +25.8pp/yr) — meanwhile JGB10Y 0.10% → 2.37%, US real 10-year -0.63% → 2.00%, and a weaker yen against the dollar. Largest gaps: FY2023 +45.8pp · FY2021 +45.7pp · FY2024 +37.6pp · FY2014 +20.5pp. Lowest: FY2020 -43.1pp (Nikkei 225 +54.2%, US real -0.63%). The gap includes Tokio Marine's dividends (the Nikkei 225 excludes dividends).

答え(観測):金利正常化のレジームで最も良かった。境界 = 米実質10年金利の底(2021-08-03 -1.19%)。以前のFY2014〜2020:Tokio Marine 年11.7% vs 日経225(価格)年10.2%(差+1.6pt/年)。以降のFY2021〜2025:年37.6% vs 11.8%(差+25.8pt/年)— その間にJGB10Y 0.10% → 2.37%、米実質10年-0.63% → 2.00%、円安・ドル高。差の上位:FY2023 +45.8pt · FY2021 +45.7pt · FY2024 +37.6pt · FY2014 +20.5pt。最低:FY2020 -43.1pt(日経225 +54.2%、米実質-0.63%)。差にはTokio Marineの配当が含まれる(日経225は配当除く)。

⚠ 규율: 표본은 회계연도 12개 — 통계 검정이 아니라 관측입니다. 같은 시기에 회사 고유 사건(정책주식 0 계획 2024-05, 자연재해가 컸던 FY2018~19, 자사주 확대)이 겹쳐 매크로만의 효과로 분리되지 않습니다. 연간 수익률은 보고서마다 지수가 정수로 반올림돼 최대 1.3%p 차이(중앙값 사용).

⚠ Discipline: The sample is 12 fiscal years — an observation, not a statistical test. Company-specific events overlap in the same period (the plan to cut policy stocks to zero, 2024-05; heavy natural catastrophes in FY2018–19; larger buybacks), so the macro effect cannot be isolated. Annual returns differ by up to 1.3pp across reports because each report rounds the index to whole numbers (the median is used).

⚠ 規律:標本は会計年度12個 — 統計的検定ではなく観測である。同じ時期に会社固有の出来事(政策株式ゼロ計画 2024年5月、自然災害が大きかったFY2018〜19、自己株式取得の拡大)が重なり、マクロだけの効果には分離できない。年間リターンは報告書ごとに指数が整数に丸められるため最大1.3ptの差(中央値を使用)。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: brokerage HTS export (Nikkei 225).
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 도쿄해상 TSR(배당 포함) vs 닛케이225 가격 수익률(배당 제외) — 차이엔 배당이 섞인다 · 레짐 경계(미 실질 10년 금리 저점)는 데이터로 정했고 경계를 바꾸면 숫자가 달라진다 · 표본이 회계연도 몇 개뿐이라 검정이 아니라 관측. Definitions: Tokio Marine rebuilt from the 5-year TSR tables in each annual report (dividends reinvested); Nikkei 225 = price index, dividends excluded; regime boundary = US real-yield trough.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: brokerage HTS export (Nikkei 225).
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Tokio Marine TSR (incl. dividends) vs Nikkei 225 price return (excl. dividends) — the gap includes dividends · the regime boundary (US real 10-year yield trough) was set from the data, and moving it changes the numbers · only a handful of fiscal years, so this is an observation, not a test. Definitions: Tokio Marine rebuilt from the 5-year TSR tables in each annual report (dividends reinvested); Nikkei 225 = price index, dividends excluded; regime boundary = US real-yield trough.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: brokerage HTS export (Nikkei 225).
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Tokio MarineのTSR(配当込み)vs 日経225の価格リターン(配当除く)— 差には配当が混じる · レジームの境界(米実質10年金利の底)はデータで決めており、境界を変えると数字が変わる · 標本は会計年度数個のみのため検定ではなく観測。 Definitions: Tokio Marine rebuilt from the 5-year TSR tables in each annual report (dividends reinvested); Nikkei 225 = price index, dividends excluded; regime boundary = US real-yield trough.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q7 지도Q7 mapQ7 マップRegime map — the same fiscal years with rate, real-yield and yen changesRegime map — the same fiscal years with rate, real-yield and yen changesレジーム・マップ — 同じ会計年度の金利・実質利回り・円の変化

Q7 — regime map: Tokio Marine vs. macro, by fiscal year (April–March)percent and basis points · Data as of 2026-03-31 · Created 2026-11-13TM TSRNikkei 225GapJGB 10Y chgUST 10Y chgUS real 10Y chgUSD/JPY chgFY2014+50.0+29.5+20.5-24-79-42+16.5FY2015-14.0-12.7-1.3-45-16-2-6.3FY2016+27.9+12.8+15.1+12+62+27-0.9FY2017+4.0+13.5-9.5-2+34+26-4.7FY2018+18.8-1.2+20.0-12-33-16+4.2FY2019-4.0-10.8+6.8+11-171-70-2.8FY2020+11.2+54.2-43.1+7+104-46+2.9FY2021+41.0-4.7+45.7+11+58+11+9.8FY2022+11.4+0.8+10.6+17+116+168+9.3FY2023+89.8+44.0+45.8+36+72+72+13.9FY2024+25.9-11.8+37.6+75+3-3-0.9FY2025+31.5+43.4-11.9+87+7+15+6.1

도쿄해상이 닛케이225 보다 크게 앞선 해: FY2023, FY2021, FY2024 — 같은 해 미 10년 +72bp · +58bp · +3bp · JGB10Y +36bp · +11bp · +75bp · 엔/달러 +13.9% · +9.8% · -0.9%. 크게 뒤진 해: FY2020(미 실질 10년 -46bp · 닛케이225 +54.2%). Raw Data 속 연결 고리: 금리↑ → 보험부채 할인 효과(OCI +) · 운용 이율↑ / 엔 약세 → 해외 보험(보험수익의 과반)의 엔 환산 / 주가↑ → 정책주식 평가차익 → 매각 → 환원.

Years when Tokio Marine beat the Nikkei 225 by a wide margin: FY2023, FY2021, FY2024 — in the same years US 10-year +72bp · +58bp · +3bp · JGB10Y +36bp · +11bp · +75bp · USD/JPY +13.9% · +9.8% · -0.9%. Year it lagged badly: FY2020 (US real 10-year -46bp · Nikkei 225 +54.2%). Links in the Raw Data: rates↑ → insurance liability discount effect (OCI +) · higher investment yields / weaker yen → yen translation of international insurance (over half of insurance revenue) / share prices↑ → unrealised gains on policy stocks → sales → shareholder returns.

Tokio Marineが日経225を大きく上回った年:FY2023, FY2021, FY2024 — 同じ年の米10年+72bp · +58bp · +3bp · JGB10Y +36bp · +11bp · +75bp · 円/ドル+13.9% · +9.8% · -0.9%。大きく下回った年:FY2020(米実質10年-46bp · 日経225 +54.2%)。Raw Dataの中のつながり:金利↑ → 保険負債の割引効果(OCI +)· 運用利回り↑ / 円安 → 海外保険(保険収益の過半)の円換算 / 株価↑ → 政策株式の評価差益 → 売却 → 還元。

⚠ 규율: 원천: 도쿄해상 有報 '株主総利回り' 표(EDINET) · 닛케이225 = 증권사 HTS 내보내기(가격지수) · JGB 10년 = 재무성 국채금리정보 · UST 10년·실질 10년·엔/달러 = FRED. 회계연도말(3월 마지막 영업일) 값끼리 비교. 레짐 경계는 데이터로 정했지만(실질금리 저점) 경계 선택에 따라 숫자는 달라집니다.

⚠ Discipline: Sources: Tokio Marine's annual-report total shareholder return table (EDINET) · Nikkei 225 = brokerage HTS export (price index) · JGB 10-year = MOF JGB yield information · UST 10-year, real 10-year and USD/JPY = FRED. Fiscal year-end values compared (last business day of March). The regime boundary was set from the data (the real-yield trough), but the numbers change with the choice of boundary.

⚠ 規律:データ源:Tokio Marineの有報「株主総利回り」の表(EDINET)· 日経225 = 証券会社HTSのエクスポート(価格指数)· JGB10年 = 財務省の国債金利情報 · UST10年・実質10年・円/ドル = FRED。会計年度末(3月最終営業日)の値どうしを比較。レジームの境界はデータで決めた(実質金利の底)が、境界の選び方で数字は変わる。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: brokerage HTS export (Nikkei 225).
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 회계연도말(3월 마지막 영업일) 값끼리 비교 · 닛케이225 는 가격지수(배당 제외) · 색 진하기는 열 안의 상대 크기. Definitions: navy = positive, red = negative; shade = size within the column; USD/JPY chg > 0 = weaker yen; rows below the line = after the US real-yield trough; Nikkei 225 = price index.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: brokerage HTS export (Nikkei 225).
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Fiscal year-end values compared (last business day of March) · the Nikkei 225 is a price index (dividends excluded) · shade = relative size within the column. Definitions: navy = positive, red = negative; shade = size within the column; USD/JPY chg > 0 = weaker yen; rows below the line = after the US real-yield trough; Nikkei 225 = price index.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: brokerage HTS export (Nikkei 225).
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 会計年度末(3月最終営業日)の値どうしの比較 · 日経225は価格指数(配当除く)· 色の濃さは列内の相対的な大きさ。 Definitions: navy = positive, red = negative; shade = size within the column; USD/JPY chg > 0 = weaker yen; rows below the line = after the US real-yield trough; Nikkei 225 = price index.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q8보험 유보자금(float)과 영업이익을 엔화로 재투자하는 구조인가? (버핏식 구조라면 이해가 된다)Is the structure one of reinvesting the insurance float and operating profit in yen? (That would make sense if it were a Buffett-style structure)保険の留保資金(フロート)と営業利益を円で再投資する構造なのか?(バフェット流の構造なら理解できる)

Q8 — where the float is invested: invested assets by segmentJPY trillions · Data as of 2025-03-31 · Created 2026-11-13010.020.030.0FY17FY18FY19FY20FY21FY22FY23FY24JPY tnDomestic P&CDomestic lifeInternational7.37.15.920.37.07.35.820.06.39.16.521.96.69.46.922.96.79.38.224.26.58.69.224.37.68.711.027.36.57.713.327.4

답: Raw Data 는 '엔화 재투자'가 아니라 '해외 재배치 + 주주환원'을 보여 줍니다. 운용자산 중 해외 비중 FY2017 29% → FY2024 48% (해외 5.91조엔 → 13.26조엔). 국내 국채(손보+생보) 7.71조엔 → 6.85조엔(FY2020 정점 9.39조엔), IFRS 연결 일본 국채 등 7.77조엔 → 4.20조엔. 보험부채(float)는 일본기준 16.42조엔 (FY2018) → 23.18조엔 (FY2024). FY2018~FY2025 누적: 영업현금흐름 9.04조엔 · 배당+자사주 2.68조엔 · 자회사 인수 0.79조엔.

Answer: the Raw Data shows not 'reinvestment in yen' but 'redeployment overseas + shareholder returns'. Overseas share of invested assets FY2017 29% → FY2024 48% (overseas JPY 5.91trn → JPY 13.26trn). Domestic government bonds (P&C + life) JPY 7.71trn → JPY 6.85trn (peak in FY2020 at JPY 9.39trn), IFRS consolidated Japanese government bonds etc. JPY 7.77trn → JPY 4.20trn. Insurance liabilities (float), J-GAAP, JPY 16.42trn (FY2018) → JPY 23.18trn (FY2024). Cumulative FY2018–FY2025: operating cash flow JPY 9.04trn · dividends + buybacks JPY 2.68trn · acquisitions of subsidiaries JPY 0.79trn.

答え:Raw Dataが示すのは「円での再投資」ではなく「海外への再配置 + 株主還元」である。運用資産に占める海外の比率 FY2017 29% → FY2024 48%(海外5.91兆円 → 13.26兆円)。国内国債(損保+生保)7.71兆円 → 6.85兆円(FY2020がピークで9.39兆円)、IFRS連結の日本国債等7.77兆円 → 4.20兆円。保険負債(フロート)は日本基準で16.42兆円(FY2018)→ 23.18兆円(FY2024)。FY2018〜FY2025の累計:営業キャッシュ・フロー9.04兆円 · 配当+自己株式取得2.68兆円 · 子会社の取得0.79兆円。

⚠ 규율: Berkshire 제휴 축(원문)의 'M&A 공동투자'는 이 해외 재배치와 같은 방향입니다. 영업현금흐름은 FY2018~24 일본기준·FY2025 IFRS 를 이어 붙인 값(기준이 달라 합계는 근사). 해외 운용자산 증가에는 엔화 약세 환산 효과가 섞여 있습니다.

⚠ Discipline: The 'joint M&A investment' among the pillars of the Berkshire alliance (original) points the same way as this overseas redeployment. Operating cash flow joins J-GAAP for FY2018–24 and IFRS for FY2025 (different bases, so the total is approximate). The rise in overseas invested assets includes the translation effect of a weaker yen.

⚠ 規律:Berkshireとの提携の柱(原文)の「M&Aの共同投資」はこの海外再配置と同じ方向である。営業キャッシュ・フローはFY2018〜24の日本基準とFY2025のIFRSをつないだ値(基準が異なるため合計は近似)。海外運用資産の増加には円安の換算効果が混じっている。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MD&A 운용자산 표(세그먼트 간 제거 전) · 해외 운용자산의 통화 내역은 표에 없다. Definitions: MD&A invested-assets tables, before inter-segment elimination; international = mostly USD assets.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MD&A invested-assets tables (before inter-segment elimination) · the currency breakdown of overseas invested assets is not in the tables. Definitions: MD&A invested-assets tables, before inter-segment elimination; international = mostly USD assets.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: MD&Aの運用資産の表(セグメント間消去前)· 海外運用資産の通貨内訳は表にない。 Definitions: MD&A invested-assets tables, before inter-segment elimination; international = mostly USD assets.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q9일본 주식이 좋아서 반영된 것뿐 아닌가? 영업이익이 는 게 아니라Isn't it just the strong Japanese stock market showing through, rather than operating profit growing?日本株が好調だったのが反映されただけではないか?営業利益が増えたのではなく

Q9 — J-GAAP ordinary profit split: overseas, domestic core, stock sale gainsJPY trillions · Data as of 2025-03-31 · Created 2026-11-1300.51.01.52.0FY17FY18FY19FY20FY21FY22FY23FY24JPY tnInternational insuranceDomestic core (rest)Japanese stock sale gains (net)0.180.340.140.190.420.160.360.140.270.190.290.570.160.240.50.450.20.190.840.490.160.811.5

답: 일본기준 이익 증가는 상당 부분 맞습니다 — 하지만 해외 보험은 따로 컸습니다. 경상이익 FY2018 0.42조엔 → FY2024 1.46조엔 (증가 1.04조엔) 중 주식 매각익 0.08조엔 → 0.81조엔 (증가분의 70%), 국내 본업(나머지)은 0.19조엔 → 0.16조엔, 오히려 줄었습니다. 반면 해외 보험 경상이익 0.14조엔 → 0.49조엔 (3.4배) — 회계연도 평균 엔/달러(110.9 → 152.4)로 나눈 달러 환산으로도 2.5배. 주식 매각익이 없는 IFRS 보험서비스손익은 FY2024 0.96조엔 → FY2025 1.15조엔 (+19%).

Answer: for J-GAAP profit growth, largely yes — but international insurance grew on its own. Of ordinary profit FY2018 JPY 0.42trn → FY2024 JPY 1.46trn (up JPY 1.04trn), stock sale gains went JPY 0.08trn → JPY 0.81trn (70% of the increase), and the domestic core (the rest) went JPY 0.19trn → JPY 0.16trn, a decline. International insurance ordinary profit, by contrast, went JPY 0.14trn → JPY 0.49trn (3.4x) — 2.5x even in dollars at fiscal-year average USD/JPY (110.9 → 152.4). The IFRS insurance service result, which contains no stock sale gains, went FY2024 JPY 0.96trn → FY2025 JPY 1.15trn (+19%).

答え:日本基準の利益増加はかなりの部分その通り — ただし海外保険は別に伸びた。経常利益 FY2018 0.42兆円 → FY2024 1.46兆円(増加1.04兆円)のうち株式売却益は0.08兆円 → 0.81兆円(増加分の70%)、国内本業(残り)は0.19兆円 → 0.16兆円で、むしろ減った。一方、海外保険の経常利益は0.14兆円 → 0.49兆円(3.4倍)— 会計年度平均の円/ドル(110.9 → 152.4)で割ったドル換算でも2.5倍。株式売却益のないIFRSの保険サービス損益はFY2024 0.96兆円 → FY2025 1.15兆円(+19%)。

⚠ 규율: 국내 본업(나머지)에는 정책주식 배당 등 이자·배당 수입이 남아 있어 '일본 주식 몫'을 다 걷어낸 값이 아닙니다. 해외는 달러 외 통화(유로·파운드 등)도 섞여 달러 환산은 근사. 주가는 이익만큼 오르지 않았습니다 — 일본기준 PER 22.7배(FY2020) → 14.2배(FY2025). 그 이유는 Raw Data 에 없습니다.

⚠ Discipline: The domestic core (the rest) still contains interest and dividend income such as dividends on policy stocks, so it does not strip out the whole 'Japanese equity' part. International mixes in non-dollar currencies (euro, sterling, etc.), so the dollar conversion is approximate. The share price did not rise as much as profit — J-GAAP P/E 22.7x (FY2020) → 14.2x (FY2025). The reason is not in the Raw Data.

⚠ 規律:国内本業(残り)には政策株式の配当などの利息・配当収入が残っており、「日本株の分」をすべて取り除いた値ではない。海外はドル以外の通貨(ユーロ・ポンドなど)も混じるため、ドル換算は近似。株価は利益ほど上がらなかった — 日本基準PER 22.7倍(FY2020)→ 14.2倍(FY2025)。その理由はRaw Dataにない。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 주식 매각익 = 매도 이익 − 손실 · 국내 핵심 = 합계 − 해외 − 주식 매각익(우리 계산) · 일본기준. Definitions: stock gains = AFS stocks sold, gains − losses; domestic core = total − international − stock gains.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Stock sale gains = gains on sale − losses · domestic core = total − international − stock sale gains (our calculation) · J-GAAP. Definitions: stock gains = AFS stocks sold, gains − losses; domestic core = total − international − stock gains.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 株式売却益 = 売却益 − 売却損 · 国内本業 = 合計 − 海外 − 株式売却益(当サイト計算)· 日本基準。 Definitions: stock gains = AFS stocks sold, gains − losses; domestic core = total − international − stock gains.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q10해외 보험 이익이 늘어봤자 몇 % 인데? 매출로는 몇 % 인가?Even if international insurance profit is growing, what share is it? And what share of revenue?海外保険の利益が増えたところで何%なのか?売上では何%か?

Q10 — international share of revenue and profitpercent · Data as of 2026-03-31 · Created 2026-11-130%20%40%60%80%100%FY18 JFY24 JFY24 IFRSFY25 IFRS%Revenue shareProfit share+34.7%+48.2%+57.0%+57.4%+42.4%+75.0%+86.3%+91.5%

답: 매출의 절반, IFRS 이익의 90%가 해외입니다. 일본기준 매출(세그먼트 경상수익) 해외 비중 FY2018 35% → FY2024 48%, 주식 매각익을 뺀 경상이익 중 해외 42% → 75%. IFRS 보험수익 해외 57% · 세전이익 해외 92%(FY2025) — 국내생보 세전 -0.28조엔. 이자·배당 수입도 해외 69%(FY2024, 0.69조엔 / 1.01조엔).

Answer: half of revenue and 90% of IFRS profit are international. International share of J-GAAP revenue (segment ordinary income) FY2018 35% → FY2024 48%, and of ordinary profit excluding stock sale gains 42% → 75%. IFRS insurance revenue international 57% · pre-tax profit international 92% (FY2025) — domestic life pre-tax JPY -0.28trn. Interest and dividend income is also 69% international (FY2024, JPY 0.69trn / JPY 1.01trn).

答え:売上の半分、IFRS利益の90%が海外である。日本基準の売上(セグメント経常収益)に占める海外の比率 FY2018 35% → FY2024 48%、株式売却益を除いた経常利益のうち海外42% → 75%。IFRSの保険収益 海外57% · 税引前利益 海外92%(FY2025)— 国内生保の税引前-0.28兆円。利息・配当収入も海外が69%(FY2024、0.69兆円 / 1.01兆円)。

⚠ 규율: 일본기준과 IFRS 의 매출·이익 정의가 달라 막대끼리 같은 줄로 잇지 않았습니다. 일본기준 매출 비중은 세그먼트 간 거래를 지우기 전 값.

⚠ Discipline: J-GAAP and IFRS define revenue and profit differently, so the bars are not joined into one line. The J-GAAP revenue share is before eliminating inter-segment transactions.

⚠ 規律:日本基準とIFRSでは売上・利益の定義が異なるため、棒どうしを同じ線でつないでいない。日本基準の売上比率はセグメント間取引の消去前の値。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 일본기준 세그먼트(매각익 제외)와 IFRS(보험수익·세전이익)는 정의가 다르다. Definitions: J = J-GAAP segment revenue and ordinary profit excl. stock sale gains; IFRS = insurance revenue and pre-tax profit.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: J-GAAP segments (excl. sale gains) and IFRS (insurance revenue, pre-tax profit) are defined differently. Definitions: J = J-GAAP segment revenue and ordinary profit excl. stock sale gains; IFRS = insurance revenue and pre-tax profit.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 日本基準のセグメント(売却益除く)とIFRS(保険収益・税引前利益)は定義が異なる。 Definitions: J = J-GAAP segment revenue and ordinary profit excl. stock sale gains; IFRS = insurance revenue and pre-tax profit.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q11그건 계절성(일시적) 매출·이익 아닌가?Isn't that seasonal (temporary) revenue and profit?それは季節性(一時的)の売上・利益ではないのか?

Q11 — first-half share of the full year (April–September)percent · Data as of 2025-03-31 · Created 2026-11-13-100%-50%0%50%100%FY18FY19FY20FY21FY22FY23FY24%Intl revenue, H1 shareIntl profit, H1 shareDomestic P&C profit, H1 share

답: 매출엔 계절성이 없고, 이익은 사건(재해·코로나)에 출렁입니다. 상반기 매출 비중 해외 48%~51%, 국내손보 48%~53% — 매년 반반. 이익 상반기 비중은 해외 -47%~66% · 국내손보 -13%~76%. 해외 경상이익 달러 환산(회계연도 평균 엔/달러): FY17 $0.64bn · FY18 $1.28bn · FY19 $1.15bn · FY20 $0.42bn · FY21 $1.65bn · FY22 $1.18bn · FY23 $3.13bn · FY24 $3.21bn — FY2023 부터 계단식 상승.

Answer: revenue shows no seasonality; profit swings with events (catastrophes, COVID). First-half share of revenue: international 48%~51%, domestic P&C 48%~53% — half and half every year. First-half share of profit: international -47%~66% · domestic P&C -13%~76%. International ordinary profit in dollars (fiscal-year average USD/JPY): FY17 $0.64bn · FY18 $1.28bn · FY19 $1.15bn · FY20 $0.42bn · FY21 $1.65bn · FY22 $1.18bn · FY23 $3.13bn · FY24 $3.21bn — a step up from FY2023.

答え:売上に季節性はなく、利益は出来事(災害・コロナ)で振れる。上半期の売上比率 海外48%~51%、国内損保48%~53% — 毎年半々。利益の上半期比率は海外-47%~66% · 国内損保-13%~76%。海外経常利益のドル換算(会計年度平均の円/ドル):FY17 $0.64bn · FY18 $1.28bn · FY19 $1.15bn · FY20 $0.42bn · FY21 $1.65bn · FY22 $1.18bn · FY23 $3.13bn · FY24 $3.21bn — FY2023から階段状に上昇。

⚠ 규율: 국내손보 상반기(7~9월)는 태풍철이라 재해가 큰 해(FY2018·19·22) 상반기 이익이 낮습니다. FY2023~24 해외 이익의 계단 상승이 지속될지는 이 Raw Data 로 판단할 수 없습니다(미 금리 상승기의 운용수익·요율 상승기와 겹침).

⚠ Discipline: Domestic P&C's first half (July–September) is typhoon season, so first-half profit is low in heavy-catastrophe years (FY2018, FY2019, FY2022). Whether the FY2023–24 step up in international profit will last cannot be judged from this Raw Data (it overlaps with higher investment income in the US rate-rise period and a period of rising premium rates).

⚠ 規律:国内損保の上半期(7〜9月)は台風シーズンで、災害の大きい年(FY2018・19・22)は上半期の利益が低い。FY2023〜24の海外利益の階段状の上昇が続くかはこのRaw Dataでは判断できない(米金利上昇期の運用収益・料率上昇期と重なる)。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 반기 비중 50 = 계절성 없음 · 일본기준 세그먼트(반기·연간 보고서). Definitions: 50 = no seasonality; J-GAAP segments from half-year and annual reports.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: A half-year share of 50 = no seasonality · J-GAAP segments (half-year and annual reports). Definitions: 50 = no seasonality; J-GAAP segments from half-year and annual reports.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 上半期比率50 = 季節性なし · 日本基準のセグメント(半期・年次報告書)。 Definitions: 50 = no seasonality; J-GAAP segments from half-year and annual reports.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q12보유 JGB·UST 평가손(채권 NAV)은 얼마나 되나?How large are the unrealised losses on the JGBs and USTs held (bond NAV)?保有するJGB・USTの評価損(債券のNAV)はどのくらいか?

Q12 — unrealized gain/loss on amortized-cost bonds (J-GAAP, off balance sheet)JPY trillions · Data as of 2025-03-31 · Created 2026-11-13-1.0-0.500.51.0FY17FY18FY19FY20FY21FY22FY23FY24JPY tnHeld to maturityPolicy-reserve matching0.690.890.890.650.420.1-0.23-0.5900.020.01-0.11-0.24-0.39-0.58-0.72

답: 큽니다. 일본기준 원가채권(만기보유+책임준비금대응) 평가손익 FY2018 0.91조엔 → FY2024 -1.31조엔(일본기준 순자산 5.10조엔의 26%). IFRS(모든 채권 시가) 자본 내 채권 누적 평가손 -0.99조엔 → -1.31조엔 → -1.43조엔, 보험부채 할인율 누적익 0.23조엔 → 0.57조엔 → 0.86조엔 — 순 -0.57조엔. 회사 민감도(FY2025): 금리 +0.5%p 평행이면 채권 -0.47조엔, 보험부채 0.27조엔, 자본 순 -0.20조엔.

Answer: large. J-GAAP unrealised gain/loss on bonds at amortised cost (held to maturity + policy-reserve matching) FY2018 JPY 0.91trn → FY2024 JPY -1.31trn (26% of J-GAAP net assets of JPY 5.10trn). Under IFRS (all bonds at fair value), the cumulative bond revaluation loss in equity went JPY -0.99trn → JPY -1.31trn → JPY -1.43trn, and the cumulative gain from insurance liability discount rates JPY 0.23trn → JPY 0.57trn → JPY 0.86trn — net JPY -0.57trn. Company sensitivity (FY2025): a parallel +0.5pp rate shift moves bonds by JPY -0.47trn and insurance liabilities by JPY 0.27trn, equity net JPY -0.20trn.

答え:大きい。日本基準の原価評価債券(満期保有+責任準備金対応)の評価損益 FY2018 0.91兆円 → FY2024 -1.31兆円(日本基準の純資産5.10兆円の26%)。IFRS(すべての債券を時価)では資本内の債券の累積評価損-0.99兆円 → -1.31兆円 → -1.43兆円、保険負債の割引率の累積益0.23兆円 → 0.57兆円 → 0.86兆円 — 純額-0.57兆円。会社の感応度(FY2025):金利+0.5%ptの平行移動なら債券-0.47兆円、保険負債0.27兆円、資本は純額-0.20兆円。

⚠ 규율: 정정(Q1·Q6 관련): FY24·25 금리 OCI 가 플러스였던 건 JGB 가 UST 보다 크게 오른 해였기 때문 — 모든 금리가 같이 오르면 자본은 줄어듭니다(회사 공시). 2026-03-31 이후 2026-11-10: JGB10Y +38bp · UST10Y +68bp — 실제 영향은 2026-09 半期報告書에서. FY2024 생보는 만기보유 채권을 매도가능으로 바꿨습니다(원문: 「当連結会計年度において、東京海上日動あんしん生命保険株式会社では、個人保険(利差配当・利差配当一時払)資産区分に属する満期保有目的の債券を全額その他有価証券に変更しています(変更時連結貸借対照表計上額2,019,783百万円)。」). IFRS 채권 누적 평가손은 JGB·UST·회사채 합산(나라별 구분 공시 없음).

⚠ Discipline: Correction (re Q1 and Q6): rate-related OCI was positive in FY24·25 because those were years when JGB yields rose more than UST yields — if all rates rise together, equity falls (company disclosure). From 2026-03-31 to 2026-11-10: JGB10Y +38bp · UST10Y +68bp — the actual impact will show in the 2026-09 half-year securities report. In FY2024 the life insurer reclassified its held-to-maturity bonds as available-for-sale (original: 「当連結会計年度において、東京海上日動あんしん生命保険株式会社では、個人保険(利差配当・利差配当一時払)資産区分に属する満期保有目的の債券を全額その他有価証券に変更しています(変更時連結貸借対照表計上額2,019,783百万円)。」). The cumulative IFRS bond revaluation loss combines JGBs, USTs and corporate bonds (no breakdown by country is disclosed).

⚠ 規律:訂正(Q1・Q6関連):FY24・25の金利OCIがプラスだったのはJGBがUSTより大きく上昇した年だったため — すべての金利が一緒に上がれば資本は減る(会社開示)。2026-03-31以降2026-11-10まで:JGB10Y +38bp · UST10Y +68bp — 実際の影響は2026-09の半期報告書で。FY2024に生保は満期保有目的の債券をその他有価証券に変更した(原文:「当連結会計年度において、東京海上日動あんしん生命保険株式会社では、個人保険(利差配当・利差配当一時払)資産区分に属する満期保有目的の債券を全額その他有価証券に変更しています(変更時連結貸借対照表計上額2,019,783百万円)。」)。IFRSの債券の累積評価損はJGB・UST・社債の合算(国別の区分開示なし)。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 만기보유 채권 시가 − 장부(유가증권 주석 공시만) · 일본기준 · 재무상태표 밖. Definitions: fair value − carrying amount; disclosed only in the securities note.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Held-to-maturity bonds, fair value − carrying amount (disclosed only in the securities note) · J-GAAP · off balance sheet. Definitions: fair value − carrying amount; disclosed only in the securities note.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 満期保有債券の時価 − 簿価(有価証券注記の開示のみ)· 日本基準 · 貸借対照表外。 Definitions: fair value − carrying amount; disclosed only in the securities note.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q13JGB 쿠폰은 미미하고, UST 쿠폰은 엔화 환헤지 비용으로 다 날리는 것 아닌가?JGB coupons are tiny — and doesn't the yen hedging cost wipe out the UST coupon?JGBのクーポンはわずかで、USTのクーポンは円の為替ヘッジコストで消えてしまうのではないか?

Q13 — what a yen investor keeps from UST after hedgingpercent · Data as of 2026-11-10 · Created 2026-11-13-2%0%2%4%6%19-0320-0321-0322-0323-0324-0325-0326-0326-11%Hedge cost proxy (UST 3M − JGB 1Y)UST 10Y hedged into yenJGB 10Y+2.7%+2.7%+2.3%

답: 엔화 법인이 산 UST 에 대해선 맞지만, 그건 작은 부분입니다. 헤지 비용 근사 2026-11-10 기준 2.70%p → 헤지 후 UST10Y 2.28%(JGB10Y 2.75%보다 낮음), 2023~24 년엔 헤지 후 마이너스. 하지만 달러 채권 대부분은 해외 자회사가 달러 부채를 대고 들고 있어 헤지가 필요 없습니다 — 해외 운용자산 13.26조엔 vs 엔화 법인 외국증권 1.70조엔(FY2024). 이자·배당 수입 해외 69%, 국내생보(국채 중심) 이율 1.40%.

Answer: true for USTs bought by the yen-based entities, but that is a small part. Hedge-cost proxy as of 2026-11-10: 2.70pp → UST10Y after hedging 2.28% (below JGB10Y at 2.75%), and negative after hedging in 2023–24. But most dollar bonds are held by overseas subsidiaries against dollar liabilities, so no hedge is needed — overseas invested assets JPY 13.26trn vs foreign securities at the yen-based entities JPY 1.70trn (FY2024). Interest and dividend income 69% international; domestic life (mostly JGBs) income yield 1.40%.

答え:円建ての法人が買ったUSTについてはその通りだが、それは小さな部分である。ヘッジコストの近似値は2026-11-10時点で2.70pt → ヘッジ後のUST10Y 2.28%(JGB10Y 2.75%より低い)、2023〜24年はヘッジ後マイナス。しかしドル債の大半は海外子会社がドル負債の見合いで保有しており、ヘッジは不要 — 海外運用資産13.26兆円 vs 円建て法人の外国証券1.70兆円(FY2024)。利息・配当収入の海外比率69%、国内生保(国債中心)の利回り1.40%。

⚠ 규율: 헤지 비용은 미 3개월물 − JGB 1년물로 근사(실제 통화스왑·선물환 비용과 다름, 회사 공시 없음). 헤지 비율·대상도 Raw Data 에 없습니다.

⚠ Discipline: The hedge cost is approximated as US 3-month − JGB 1-year (different from actual currency-swap and forward costs; not disclosed by the company). The hedge ratio and hedged items are not in the Raw Data either.

⚠ 規律:ヘッジコストは米3カ月物 − JGB1年物で近似(実際の通貨スワップ・為替予約のコストとは異なり、会社開示なし)。ヘッジ比率・対象もRaw Dataにない。

Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Limitations: 환헤지 비용은 대용치(미 단기금리 − 일본 단기금리)이지 회사 실제 헤지 비용이 아니다 · 회계연도 말 + 최신. Definitions: proxy, not the company's actual hedge cost; fiscal year-ends plus latest.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Limitations: The FX hedge cost is a proxy (US short rate − Japanese short rate), not the company's actual hedge cost · fiscal year-ends plus the latest. Definitions: proxy, not the company's actual hedge cost; fiscal year-ends plus latest.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Limitations: 為替ヘッジコストは代用値(米短期金利 − 日本短期金利)で、会社の実際のヘッジコストではない · 会計年度末 + 最新。 Definitions: proxy, not the company's actual hedge cost; fiscal year-ends plus latest.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q14해상(손보)이라 장기보다 단·중기물(front-belly) 비중이 클 것 같은데? 10년 이상이면 만기보유해야 해서 난감할 텐데As a P&C insurer, wouldn't it hold more short and medium maturities (front to belly) than long ones? Over 10 years it would have to hold to maturity, which would be awkward損保なので長期より短・中期(フロント〜ベリー)の比率が大きそうだが?10年超なら満期保有せざるを得ず厄介だろう

Q14 — maturity of bonds held, FY2024 (face amount)JPY trillions · Data as of 2025-03-31 · Created 2026-11-1302.04.06.08.010.0<= 1y1-5y5-10y> 10yJPY tnJGB, held to maturityJGB, policy-reserve matchingJGB, available for saleCorporate bonds, AFSForeign securities, AFS0.740.951.50.871.02.52.31.70.763.18.0

답: 연결 국채는 반대로 10년 초과가 70% (FY2024) — 장기물은 만기보유·생보 대응 묶음에 있습니다. 손보 성격에 가까운 매도가능 국채는 10년 이내 67%, 회사채 10년 이내 87% — 짐작대로 단·중기. 외국증권(매도가능)은 10년 초과 58%. 국채 10년 초과 비중 FY2019 85% → FY2024 70%. '난감함'에 대한 회사의 대응(원문): 만기보유 → 매도가능 변경(FY2024), 「(ALM)を基本とした資産運用に継続的に取り組み、既に引き受けている生命保険契約の長期負債の一部を再保険会社に出再するなど、金利リスクコントロールの多様化および高度化に努めました。」.

Answer: on the contrary, 70% of consolidated government bonds are over 10 years (FY2024) — the long bonds sit in the held-to-maturity and life-matching buckets. AFS government bonds, closer to the P&C business, are 67% within 10 years, and corporate bonds 87% within 10 years — short and medium term, as guessed. Foreign securities (AFS) are 58% over 10 years. Share of government bonds over 10 years FY2019 85% → FY2024 70%. The company's response to the 'awkwardness' (original): reclassification from held-to-maturity to available-for-sale (FY2024), 「(ALM)を基本とした資産運用に継続的に取り組み、既に引き受けている生命保険契約の長期負債の一部を再保険会社に出再するなど、金利リスクコントロールの多様化および高度化に努めました。」.

答え:連結の国債は逆に10年超が70%(FY2024)— 長期債は満期保有・生保対応の区分にある。損保の性格に近いその他有価証券の国債は10年以内が67%、社債は10年以内が87% — 推測どおり短・中期。外国証券(その他有価証券)は10年超が58%。国債の10年超比率 FY2019 85% → FY2024 70%。「厄介さ」への会社の対応(原文):満期保有 → その他有価証券への変更(FY2024)、「(ALM)を基本とした資産運用に継続的に取り組み、既に引き受けている生命保険契約の長期負債の一部を再保険会社に出再するなど、金利リスクコントロールの多様化および高度化に努めました。」。

⚠ 규율: 상환 예정액은 액면·연결 기준이라 사업별(손보·생보·해외) 구분이 없습니다. FY2025 IFRS 有報엔 이 표가 없어 FY2024 가 마지막.

⚠ Discipline: Redemption amounts are at face value on a consolidated basis, with no split by business (P&C, life, international). The FY2025 IFRS annual securities report lacks this table, so FY2024 is the last.

⚠ 規律:償還予定額は額面・連結ベースで、事業別(損保・生保・海外)の区分はない。FY2025のIFRSの有報にはこの表がなく、FY2024が最後。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 상환 예정표(액면·연결) · 사업별 구분 없음 · IFRS 有報엔 이 표가 없어 FY2024 가 마지막. Definitions: redemption schedule note (consolidated); AFS = available for sale.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Redemption schedule (face value, consolidated) · no split by business · the IFRS annual securities report lacks this table, so FY2024 is the last. Definitions: redemption schedule note (consolidated); AFS = available for sale.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 償還予定表(額面・連結)· 事業別の区分なし · IFRSの有報にはこの表がなく、FY2024が最後。 Definitions: redemption schedule note (consolidated); AFS = available for sale.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q15보험료 상승률이 인플레이션보다 높나? (허들: JGB10Y 3.1%대 · 닛케이 TR · 인플레이션 · JGB10Y 실질)Are premiums rising faster than inflation? (hurdles: JGB10Y in the 3.1% range · Nikkei TR · inflation · real JGB10Y)保険料の上昇率はインフレより高いか?(ハードル:JGB10Y 3.1%台 · 日経TR · インフレ · JGB10Y実質)

Q15 — premium growth vs. the hurdles (percent per year)percent per year · Data as of 2026-09-17 · Created 2026-11-130%5%10%15%Group NPWJapan P&CIntl (JPY)Intl (USD)JGB 10YNikkei 225US CPIBEI 10YReal 10Y% per year+6.7%+2.4%+13.0%+7.2%+2.8%+9.0%+3.8%+2.1%+0.8%

답: 국내손보 보험료(연 2.4%)는 일본 기대 인플레이션(BEI 2.09%)과 비교해 빠르고, JGB10Y(2.84%)·닛케이225 가격(연 9.0%)보다 각각 낮습니다 / 낮습니다. 해외 달러 보험료(연 7.2%)는 미 CPI(연 3.8%)보다 빠릅니다. FY2018→FY2024 연평균 — 국내손보 正味収入保険料 2.4% vs 일본 BEI(10년, 재무성 공표 2026-09-17) 2.09% · 해외 달러 환산 7.2% vs 미 CPI(같은 회계연도 평균) 3.8% · 연결(엔) 6.7%, 해외 엔화 13.0%(엔 약세 포함). 허들: JGB10Y 2.84%(2026-11-12) · 닛케이225(가격, 배당 제외) 연 9.0%(FY2019~2024). JGB10Y 실질(물가연동국채 수익률, 재무성 공표)은 0.84% — 시장 기준으로 플러스입니다. IFRS 국내손보 보험수익 FY2025 +3.6%.

Answer: Domestic P&C premiums (2.4% a year) are growing faster than Japan's expected inflation (BEI 2.09%), and are lower / lower than the JGB10Y (2.84%) and the Nikkei 225 price index (9.0% a year) respectively. International premiums in dollars (7.2% a year) are growing faster than US CPI (3.8% a year). Annual average FY2018→FY2024 — domestic P&C net premiums written 2.4% vs Japan BEI (10-year, MOF-published 2026-09-17) 2.09% · international in dollars 7.2% vs US CPI (same fiscal-year average) 3.8% · consolidated (yen) 6.7%, international in yen 13.0% (incl. yen weakness). Hurdles: JGB10Y 2.84% (2026-11-12) · Nikkei 225 (price, dividends excluded) 9.0% a year (FY2019–2024). The real JGB10Y yield (inflation-indexed JGB yield, MOF-published) is 0.84% — positive on a market basis. IFRS domestic P&C insurance revenue FY2025 +3.6%.

答え:国内損保の保険料(年2.4%)は日本の期待インフレ率(BEI 2.09%)と比べて速く、JGB10Y(2.84%)・日経225価格(年9.0%)よりそれぞれ低い / 低い。海外のドル建て保険料(年7.2%)は米CPI(年3.8%)より速い。 FY2018→FY2024の年平均 — 国内損保の正味収入保険料2.4% vs 日本のBEI(10年、財務省公表2026-09-17)2.09% · 海外のドル換算7.2% vs 米CPI(同じ会計年度の平均)3.8% · 連結(円)6.7%、海外の円建て13.0%(円安を含む)。ハードル:JGB10Y 2.84%(2026-11-12)· 日経225(価格、配当除く)年9.0%(FY2019〜2024)。JGB10Yの実質(物価連動国債の利回り、財務省公表)は0.84% — 市場ベースでプラスである。IFRSの国内損保の保険収益 FY2025 +3.6%。

⚠ 규율: 보험료 '증가율'과 국채 '수익률'·주가 '변화율'은 성격이 다른 숫자입니다 — 사용자 허들 틀을 그대로 옮긴 비교. 닛케이225 는 증권사 HTS 의 가격지수라 배당이 빠져 총수익(TR)보다 낮게 나옵니다. 일본 실현 CPI 는 Raw Data 에 없어 실현 기준 실질금리는 계산하지 않았습니다(BEI 는 기대치). 일본은행 물가 전망치도 Raw Data 밖. 국내손보 보험료는 국내손보 MD&A 표(세그먼트 간 제거 전), FY2024 이후는 IFRS 라 이 표가 없습니다.

⚠ Discipline: Premium 'growth', bond 'yields' and equity 'returns' are different kinds of numbers — the comparison carries over the user's hurdle frame as is. The Nikkei 225 here is the brokerage HTS price index, so dividends are missing and it comes out below total return (TR). Japan's realised CPI is not in the Raw Data, so no realised real rate was calculated (BEI is an expectation). The Bank of Japan's inflation forecasts are also outside the Raw Data. Domestic P&C premiums come from the domestic P&C MD&A table (before inter-segment elimination); after FY2024 the accounts are IFRS and this table does not exist.

⚠ 規律:保険料の「伸び率」と国債の「利回り」・株価の「変化率」は性質の異なる数字 — 利用者のハードルの枠組みをそのまま移した比較。日経225は証券会社HTSの価格指数のため配当が抜け、トータルリターン(TR)より低く出る。日本の実績CPIはRaw Dataにないため実績ベースの実質金利は計算していない(BEIは期待値)。日本銀行の物価見通しもRaw Data外。国内損保の保険料は国内損保のMD&Aの表(セグメント間消去前)で、FY2024以降はIFRSのためこの表はない。

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).
Source: brokerage HTS export (Nikkei 225).
Limitations: 보험료 증가율과 금리·주가 수익률은 성격이 다른 숫자 · 닛케이225 는 가격지수(배당 제외) · 일본 실현 CPI 는 Raw Data 에 없어 BEI(기대치)로 · 국내손보 보험료 = MD&A 표(세그먼트 간 제거 전). Definitions: navy/red = Tokio Marine premiums FY2018–FY2024; other bars = hurdles: JGB 10Y and BEI/real latest, Nikkei 225 (price, excl. dividends) and US CPI over the same fiscal years.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).
Source: brokerage HTS export (Nikkei 225).
Limitations: Premium growth and bond yields or equity returns are different kinds of numbers · the Nikkei 225 is a price index (dividends excluded) · Japan's realised CPI is not in the Raw Data, so BEI (an expectation) is used · domestic P&C premiums = MD&A table (before inter-segment elimination). Definitions: navy/red = Tokio Marine premiums FY2018–FY2024; other bars = hurdles: JGB 10Y and BEI/real latest, Nikkei 225 (price, excl. dividends) and US CPI over the same fiscal years.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).
Source: brokerage HTS export (Nikkei 225).
Limitations: 保険料の伸び率と金利・株価のリターンは性質の異なる数字 · 日経225は価格指数(配当除く)· 日本の実績CPIはRaw DataにないためBEI(期待値)を使う · 国内損保の保険料 = MD&Aの表(セグメント間消去前)。 Definitions: navy/red = Tokio Marine premiums FY2018–FY2024; other bars = hurdles: JGB 10Y and BEI/real latest, Nikkei 225 (price, excl. dividends) and US CPI over the same fiscal years.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Q15 BEIJapan 10-year break-even inflation at each inflation-indexed JGB auctionJapan 10-year break-even inflation at each inflation-indexed JGB auction物価連動国債の入札ごとの日本10年ブレーク・イーブン・インフレ率

Q15 — Japan 10Y break-even inflation at inflation-indexed JGB auctionspercent · Data as of 2026-08-12 · Created 2026-11-13-2%-1%0%1%2%3%4%13-1015-0116-0417-0818-1120-0221-0522-0823-1125-0226-08%Nominal JGB, same maturityReal yield (auction)Break-even (nominal − real)+2.8%+1.9%+0.9%

입찰 기준 BEI: 2026-08-12 1.94% (실질 0.86% · 같은 잔존 9.6년 명목 2.80%). 재무성 공표 BEI(유통시장, 2026-09-17 현재): 2.089% = 명목 2.925% − 실질 0.836%. 2013-10 이후 입찰 기준 BEI 범위 -0.12~1.94%.

Auction-based BEI: 2026-08-12 1.94% (real 0.86% · nominal 2.80% at the same remaining 9.6 years). MOF-published BEI (secondary market, as of 2026-09-17): 2.089% = nominal 2.925% − real 0.836%. Range of auction-based BEI since 2013-10: -0.12–1.94%.

入札ベースのBEI:2026-08-12 1.94%(実質0.86% · 同じ残存9.6年の名目2.80%)。財務省公表のBEI(流通市場、2026-09-17時点):2.089% = 名目2.925% − 実質0.836%。2013年10月以降の入札ベースBEIの範囲は-0.12〜1.94%。

⚠ 규율: 입찰 실질수익률은 최저가격 기준 단리, 커브는 재무성 국채금리(복리) — 산식 차이 몇 bp. 물가연동국채는 잔액이 작고(재무성 원문 주석: 「物価連動国債は、元本が物価に連動して増減する国債。8月末時点の発行残高は約10.2兆円。」) 원금 보장(플로어)이 붙어 BEI 가 순수한 기대 인플레이션과 다를 수 있습니다. 재무성 공표 BEI 는 그림 PDF 의 최신값만 읽어 2026-10-02 부터 매일 쌓습니다(과거 일별 선은 Raw Data 에 없음). 원문 출처 주석: 일본상호증권 제공 금리 정보로 재무성 계산.

⚠ Discipline: The auction real yield is a simple yield at the lowest accepted price, while the curve is MOF's JGB yields (compound) — a formula gap of a few bp. Inflation-indexed JGBs have a small outstanding amount (MOF note, original: 「物価連動国債は、元本が物価に連動して増減する国債。8月末時点の発行残高は約10.2兆円。」) and a principal floor, so BEI can differ from pure expected inflation. The MOF-published BEI is read only as the latest value in the chart PDF and has been accumulated daily since 2026-10-02 (no past daily line in the Raw Data). Original source note: calculated by the Ministry of Finance from interest-rate information provided by Japan Bond Trading.

⚠ 規律:入札の実質利回りは最低価格ベースの単利、カーブは財務省の国債金利(複利)— 算式の差で数bp。物価連動国債は残高が小さく(財務省原文の注:「物価連動国債は、元本が物価に連動して増減する国債。8月末時点の発行残高は約10.2兆円。」)元本保証(フロア)が付くため、BEIが純粋な期待インフレ率と異なりうる。財務省公表のBEIは図のPDFの最新値だけを読み、2026年10月2日から毎日蓄積している(過去の日次の線はRaw Dataにない)。原文の出所注:日本相互証券提供の金利情報を基に財務省にて計算。

出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Limitations: 입찰 실질수익률(단리)과 커브(복리)는 산식이 달라 몇 bp 어긋난다 · 명목은 같은 잔존으로 직선 보간(우리 계산) · 물가연동채는 잔액이 작고 원금 보장이 붙는다. Definitions: x = auction dates since 2013-10 (about quarterly); nominal interpolated on the MOF curve at the bond's remaining maturity.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Limitations: The auction real yield (simple) and the curve (compound) use different formulas and differ by a few bp · the nominal yield is linearly interpolated to the same remaining maturity (our calculation) · inflation-indexed JGBs have a small outstanding amount and a principal floor. Definitions: x = auction dates since 2013-10 (about quarterly); nominal interpolated on the MOF curve at the bond's remaining maturity.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工)
Limitations: 入札の実質利回り(単利)とカーブ(複利)は算式が異なり数bpずれる · 名目は同じ残存期間に直線補間(当サイト計算)· 物価連動国債は残高が小さく元本保証が付く。 Definitions: x = auction dates since 2013-10 (about quarterly); nominal interpolated on the MOF curve at the bond's remaining maturity.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

16

Raw Data 상태Raw Data statusRaw Dataの状態

검증Checks検証Ledger statusLedger statusRaw Dataの状態

삼성화재: 보고서 31건 · 패널 PASS1 OK · 유가증권표 31 · 지급여력 31 · 배당 9년 · 현대해상: 보고서 31건 · 패널 PASS1 OK · 유가증권표 29 · 지급여력 31 · 배당 7년 · DB손보: 보고서 31건 · 패널 PASS1 OK · 유가증권표 31 · 지급여력 30 · 배당 9년 · 도쿄해상: 보고서 25건 · 검증 369건(원문 자체 불일치 0, 빈 값 1).

Samsung F&M: reports 31 · panel PASS1 OK · securities tables 31 · solvency 31 · dividends 9 years · Hyundai M&F: reports 31 · panel PASS1 OK · securities tables 29 · solvency 31 · dividends 7 years · DB Insurance: reports 31 · panel PASS1 OK · securities tables 31 · solvency 30 · dividends 9 years · Tokio Marine: reports 25 · checks 369 (source-internal inconsistencies 0, blank values 1).

Samsung F&M:報告書31件 · パネルPASS1 OK · 有価証券表31 · 支払余力31 · 配当9年 · Hyundai M&F:報告書31件 · パネルPASS1 OK · 有価証券表29 · 支払余力31 · 配当7年 · DB Insurance:報告書31件 · パネルPASS1 OK · 有価証券表31 · 支払余力30 · 配当9年 · Tokio Marine:報告書25件 · 検証369件(原文自体の不一致0、空の値1)。

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Raw Data 상태 요약(차트 아님).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Summary of the Raw Data status (not a chart).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Raw Dataの状態の要約(チャートではない)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

∞

천장 — 이 페이지가 말할 수 없는 것Ceilings — what this page cannot say限界 — このページが言えないこと

  • 도쿄해상 주가는 시세 Raw Data 가 아닙니다. 有報의 EPS×PER 로 3월말 주가를 역산(세 경로 1% 안 일치) — 연말·현재 수익률은 시세를 붙여야 합니다.
  • 도쿄해상 회계기준이 바뀝니다. FY2025 부터 IFRS(비교 FY2024 포함 두 해). FY2025 일본기준 값은 미감사 참고치. 2024-04 부터 1Q·3Q 보고서가 없어 분기 Raw Data 는 FY2023 3Q 에서 끊깁니다.
  • 정책보유 공시는 최대 보유회사(東京海上日動) 기준이고, 수정순이익은 회사 KPI(비GAAP, FY2021 정의 변경, FY2026 부터 IFRS 정의)입니다.
  • 시대가 둘이다. IFRS 4(~2022)와 17(2023~)의 손익 줄은 이어 붙이지 않았다. 시대를 넘는 건 수입보험료(업무보고서)·순이익·배당·운용자산뿐.
  • 배당수익률은 회사 기재값. 기준가 = 배당기준일 전 1주일 평균 종가. 이익수익률은 그걸로 역산한 주가에 EPS — 배당 없는 해는 못 낸다.
  • 주석 다음 단계: 신용등급별·잔존만기별 채권, 관계기업·지분증권(삼성전자 지분 등), 특수관계자 거래, 전 회사 CSM 잔액·상각.
  • 시세 Raw Data 없음. P/B·시총·총주주환원율(자사주 매입 포함)은 시세를 붙여야 한다.
  • TOPIX 값은 싣지 않는다. JPX 지수 라이선스 원문(홈페이지 게재도 라이선스료 대상일 수 있음)을 확인할 수 없어 외부 불가로 본다 — 有報 TSR 표의 TOPIX 칸도 뺐다. 일본 주가 기준선은 닛케이225(증권사 HTS 내보내기, 가격지수·배당 제외).
  • Tokio Marine's share price is not from market-price Raw Data. The March-end price is backed out from EPS × PER in the annual securities report (three routes agree within 1%) — year-end or current yields need market prices attached.
  • Tokio Marine changes accounting standards. IFRS from FY2025 (two years including the FY2024 comparative). FY2025 J-GAAP figures are unaudited reference values. Q1 and Q3 reports stopped from 2024-04, so the quarterly Raw Data ends at FY2023 Q3.
  • Policy-holding disclosures are for the largest holding company (Tokio Marine & Nichido), and adjusted net income is a company KPI (non-GAAP; definition revised in FY2021; IFRS definition from FY2026).
  • Two accounting eras. Profit-and-loss lines under IFRS 4 (to 2022) and IFRS 17 (from 2023) are not joined. Only premium income (business reports), net income, dividends and invested assets cross the break.
  • Dividend yields are as reported by the companies. Reference price = average close over the week before the dividend record date. Earnings yield = EPS over the price backed out from it — not available for years without a dividend.
  • Notes, next step: bonds by credit rating and residual maturity, associates and equity securities (e.g. the Samsung Electronics stake), related-party transactions, CSM balances and release for every company.
  • No market-price Raw Data. P/B, market capitalisation and total shareholder yield (incl. buybacks) need market prices attached.
  • No TOPIX values. The JPX index licence terms could not be confirmed (even posting on a website may carry a licence fee), so TOPIX is treated as not for external use — the TOPIX column of the annual-report TSR table is dropped as well. The Japanese equity benchmark is the Nikkei 225 (brokerage HTS export, price index, dividends excluded).
  • Tokio Marineの株価は株価のRaw Dataではない。有報のEPS×PERから3月末株価を逆算(3経路が1%以内で一致)— 年末・現在の利回りは株価を付ける必要がある。
  • Tokio Marineの会計基準が変わる。FY2025からIFRS(比較のFY2024を含む2年)。FY2025の日本基準の値は未監査の参考値。2024年4月から第1・第3四半期報告書がなく、四半期のRaw DataはFY2023第3四半期で途切れる。
  • 政策保有の開示は最大保有会社(東京海上日動)ベースで、修正純利益は会社KPI(非GAAP、FY2021に定義変更、FY2026からIFRS定義)である。
  • 会計の時代が二つある。IFRS 4(〜2022)とIFRS 17(2023〜)の損益項目はつなげていない。時代をまたぐのは収入保険料(業務報告書)・純利益・配当・運用資産のみ。
  • 配当利回りは会社開示値。基準株価 = 配当基準日前1週間の平均終値。益回りはそこから逆算した株価に対するEPS — 配当のない年は出せない。
  • 注記の次の段階:信用格付別・残存期間別の債券、関連会社・持分証券(Samsung Electronics株式など)、特別関係者との取引、全社のCSM残高・償却。
  • 株価のRaw Dataはない。PBR・時価総額・総還元利回り(自己株式取得を含む)は株価を付ける必要がある。
  • TOPIXの値は載せない。JPXの指数ライセンス原文(ホームページ掲載もライセンス料の対象となりうる)を確認できず、外部利用不可とみなす — 有報TSR表のTOPIX欄も除いた。日本株の基準線は日経225(証券会社HTSのエクスポート、価格指数・配当除く)。

Source: DART, Financial Supervisory Service. 출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13 Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates). Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index). 出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工) 出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工) 出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。 Source: brokerage HTS export (Nikkei 225).